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Abstract 
This thesis evaluates the in vitro pro-apoptotic and anti-migratory effects of Marantodes 
pumilum Blume Kuntze and Ficus deltoidea L. plants on prostate cancer cells, 
characterising both their mechanism of actions on some of the main Hallmarks of 
Cancer, and their chemistry with a view to contribute to future chemopreventive 
strategies. Plant materials of M. pumilum (MP) F. deltoidea var. angustifolia (FD1) and 
F. deltoidea var. deltoidea (FD2) were obtained from dedicated farms in Southern 
Malaysia. The crude methanolic extract was partitioned into n-hexane (MPh, FD1h, 
FD2h) chloroform (MPc, FD1c, FD2c) and aqueous extracts (MPa, FD1a, FD2a). Active 
fractions (GI50<30 μg/mL) based on prostate cancer cell line, PC3, Sulforhodamine B 
staining were further fractionated. Active compound/s were identified using 
spectroscopic methods. In vitro mechanistic studies on PC3 cells were conducted to 
investigate the mode of death of PC3 cells and effects of the active extracts on PC3 
cells migration and invasion. MPc, FD1c and FD2c extracts induced cell death via 
apoptosis as evidenced by nuclear DNA fragmentation, accompanied by a significant 
increase in MMP depolarization (P<0.05), activation of caspases 3 and 7 (MPc P<0.01; 
FD1c and FD2c P<0.05) in both PC3 and LNCaP cell lines. All active plant extracts up-
regulated Bax and Smac/DIABLO and down-regulated Bcl-2 (P<0.05). Only MPc 
inhibited the expression of ALOX-5 mRNA gene expression (P<0.001). None resulted 
cytotoxic against normal human fibroblast cells (HDFa) at the tested concentrations. All 
active plant extracts inhibited both migration and invasion of PC3 cells (MPc; P<0.01, 
FD1c and FD2c; P<0.05), achieved by down-regulation of both VEGF and CXCL-12 
gene expressions (P<0.001). A monounsaturated 5-alkyl resorcinol was isolated as the 
active compound present in the MPc extract. LC-MS dereplication identified isovitexin in 
FD1c; and oleanolic acid, moretenol, betulin, lupenone and lupeol in FD2c. In 
conclusion, evidence gathered in this study suggests a role for interaction of MPc, FD1c 
and FD2c in three of the Hallmarks of Cancer in PC3 cells: (1) apoptosis by activating 
of the intrinsic pathway, (2) inhibition of both migration and invasion by modulating the 
CXCL12-CXCR4 axis, and (3) inhibiting angiogenesis by modulating VEGF-A 
expression. The compounds identified and dereplicated in this study will be further 
characterized and used for the standardization of the active extracts in the future. 
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CHARACTERISTICS OF APOPTOSIS SUCH AS THE FORMATION OF APOPTOTIC 
BODIES (AB), MEMBRANE BLEBBING (MB) AND NUCLEAR COMPACTION (NC).	 163	
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MAGNIFICATION) AFTER 72 HOURS OF TREATMENT WITH THE GI50 
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MAGNIFICATION) AFTER 72 HOURS OF TREATMENT WITH THE GI50 
CONCENTRATION OF PACLITAXEL (B), FD1 (CHLOROFORM) (C), AND FD2 
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PC3 CELLS). THE CELLS SHOWED CHARACTERISTICS OF APOPTOSIS SUCH AS 
THE FORMATION OF APOPTOTIC BODIES (AB), MEMBRANE BLEBBING (MB) AND 
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FIGURE 4.23.  FLUORESCENCE IMAGE OF PC3 CELLS STAINED WITH DAPI AFTER 72 
HOURS INCUBATION WITH THE ACTIVE EXTRACTS OF MARANTODES PUMILUM 
AND PACLITAXEL (POSITIVE CONTROL). APOPTOTIC CELLS WERE REPRESENTED 
BY THE BLUE FLUORESCENCE COLOUR SEEN IN THE IMAGES. MORE APOPTOTIC 
CELLS CAN BE SEEN IN THE CELLS TREATED WITH PACLITAXEL AND THE ACTIVE 
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FIGURE 4.24.  FLUORESCENCE IMAGE OF LNCAP CELLS STAINED WITH DAPI AFTER 72 
HOURS INCUBATION WITH THE ACTIVE EXTRACTS OF MARANTODES PUMILUM 
AND PACLITAXEL (POSITIVE CONTROL). APOPTOTIC CELLS WERE REPRESENTED 
BY THE BLUE FLUORESCENCE COLOUR SEEN IN THE IMAGES. MORE APOPTOTIC 
CELLS CAN BE SEEN IN THE CELLS TREATED WITH PACLITAXEL AND THE ACTIVE 
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FIGURE 4.26.  FLUORESCENCE IMAGE OF LNCAP CELLS STAINED WITH DAPI AFTER 72 
HOURS INCUBATION WITH THE ACTIVE EXTRACTS OF FICUS DELTOIDEA AND 
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THE BLUE FLUORESCENCE COLOUR SEEN IN THE IMAGES. MORE APOPTOTIC 
CELLS CAN BE SEEN IN THE CELLS TREATED WITH PACLITAXEL AND THE ACTIVE 
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FIGURE 4.27.  THE DOT PLOTS OF LNCAP CELLS AFTER 6 HOURS TREATMENT WITH 
THE ACTIVE EXTRACTS OF MARANTODES PUMILUM AS DETERMINED BY ANNEXIN 
V-FITC AND PI STAINING. THE CELLS WERE TREATED WITH DIFFERENT ACTIVE 
EXTRACTS FOR 6 HOURS. RESULTS SHOWN ARE REPRESENTATIVE OF THREE 
INDEPENDENT EXPERIMENTS.	 174	
FIGURE 4.28.  THE PERCENTAGE (%) OF CELL DISTRIBUTION OF LNCAP CELLS AFTER 6 
HOURS TREATMENT WITH THE ACTIVE EXTRACTS OF MARANTODES PUMILUM AS 
DETERMINED BY ANNEXIN V-FITC AND PI STAINING. THE CELLS WERE TREATED 
WITH DIFFERENT ACTIVE EXTRACTS FOR 6 HOURS. * P< 0.05 AS COMPARED TO 
THE UNTREATED CELLS. RESULTS SHOWN ARE REPRESENTATIVE OF THREE 
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FIGURE 4.30.  THE PERCENTAGE (%) OF CELL DISTRIBUTION OF PC3 CELLS AFTER 6 
HOURS TREATMENT WITH THE ACTIVE EXTRACTS OF MARANTODES PUMILUM AS 
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WITH DIFFERENT ACTIVE EXTRACTS FOR 6 HOURS. * P< 0.05 AS COMPARED TO 
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THE UNTREATED CELLS. RESULTS SHOWN ARE REPRESENTATIVE OF THREE 
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FIGURE 4.31.  THE DOT PLOTS OF LNCAP CELLS AFTER 6 HOURS TREATMENT WITH 
THE ACTIVE EXTRACTS OF FICUS DELTOIDEA AS DETERMINED BY ANNEXIN V-
FITC AND PI STAINING. THE CELLS WERE TREATED WITH DIFFERENT ACTIVE 
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FIGURE 4.32.  THE PERCENTAGE (%) OF CELL DISTRIBUTION OF LNCAP CELLS AFTER 6 
HOURS TREATMENT WITH THE ACTIVE EXTRACTS OF FICUS DELTOIDEA AS 
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FIGURE 4.35.  CASPASE 3/7 ACTIVITY IN LNCAP CELLS TREATED WITH THE ACTIVE 
EXTRACTS OF MARANTODES PUMILUM FOR 72 HOURS. THE Y-AXIS SHOWS THE 
LUMINESCENT SIGNAL SUBTRACTED FROM A BLANK, WHICH IS PROPORTIONAL 
TO THE CASPASE ACTIVITY. THE ERROR BARS DISPLAY THE STANDARD ERROR 
OF MEAN (SEM) OBTAINED FROM 3 INDEPENDENT EXPERIMENTS. SIGNIFICANCE 
COMPARED TO CONTROL, *(P<0.05),**(P<0.01) AS DETERMINED BY UN-PAIRED T-
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FIGURE 4.36.  CASPASE 3/7 ACTIVITY IN PC3 CELLS TREATED WITH THE ACTIVE 
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FIGURE 4.37.  CASPASE 3/7 ACTIVITY IN LNCAP CELLS TREATED WITH THE ACTIVE 
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FIGURE 4.38.  CASPASE 3/7 ACTIVITY IN PC3 CELLS TREATED WITH THE ACTIVE 
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FIGURE 4.39.  REPRESENTATIVE MMP PROFILES OF FLOW CYTOMETRY FOR ACTIVE 
PLANT EXTRACTS-TREATED PC3 CELLS. DEPOLARIZATION OF MITOCHONDRIAL 
MEMBRANE POTENTIAL (MMP) OF PC3 PROSTATE CANCER CELL LINES WAS 
INDUCED BY THE ACTIVE EXTRACTS OF MARANTODES PUMILUM .PC3 CELL LINES 
WERE TREATED WITH THE GI50 OF THE PLANT EXTRACTS FOR 6 HOURS. 
RESULTS SHOWN ARE REPRESENTATIVE OF THREE INDEPENDENT 
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TREATED WITH MNTC OF THE ACTIVE PLANT EXTRACTS OF MARANTODES 
PUMILUM AND FICUS DELTOIDEA AFTER 96 HOURS. THE GENES EXPRESSIONS 
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FIGURE 4.51.  MIGRATION OF PC3 CELLS TREATED WITH THE MNTC OF PACLITAXEL 
FOR 24, 48, AND 72 HOURS VIEWED UNDER THE EVOS® FL IMAGING SYSTEM. 
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1 Introduction 
 
1.1 Research Background 
 Cancer is a broad group of various diseases characterized by unregulated 
cell growth (Ochwang’i, Kimwele et al. 2014). In cancerous cells, growth and 
division are uncontrollable that could result in the formation of tumours which 
can become malignant by metastasizing other parts of the body. Current 
treatment regimes for cancer include chemotherapy, radiotherapy and surgery 
(Vickers 2004). However, toxic effects on other non-target tissues often limit the 
effectiveness of these treatments such as chemotherapy. It is usual that cancer 
patients resort to the use of complementary and alternative therapies to palliate 
these toxic effects or to extend their chances of survival. In the last decade, the 
population has become more ‘health conscious’ and an expanding range of 
complementary and alternative medicines (CAMs) is now globally available 
leading to a dramatic increase in the use of such approaches in recent years.  
 
 Since ancient times, almost all cultures and communities have considered 
plants as a valuable source of bioactive compounds for treating many diseases, 
including cancer (Mohan, Bustamam et al. 2011). History shows that the use of 
herbal drug preparations for medicinal purposes evolved for thousands of years 
and reached its peak hundreds of years ago. The 19th century brought about 
the application of modern chemistry to therapy; facilitating the isolation and 
characterization of plant compounds which in turn have been the building blocks 
of modern drug discovery and development.  
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 In the last 30 years of the 20th century, the scientific community embarked 
into a giant quest for anticancer drugs with a focus on plants. This sparked a 
wider global research applying modern methods in a scale never seen before. 
As a result, it is believed that up to 70,000 species of plants have been screened 
for their medicinal use, most of them were selected based on their 
ethnopharmacological uses (Veeresham 2012). According to Newman and 
Cragg (2012), about 50% of the approved drugs during the last 30 years (1981-
2010) are derived either directly or indirectly from natural products. In the field of 
cancer treatment, over the time frame from around 1940s to date, 85 from the 
175 drugs used are being directly or indirectly derived from natural products. 
This clearly shows the importance of natural products in drug discovery and they 
will continue to do so in many years ahead. 
 
 Prostate cancer is one of the most common types of cancer worldwide, 
especially in Western societies. In the last 5 to 10 years, the incidence of 
prostate cancer is significantly increasing in Asian countries including Malaysia. 
Initially, this phenomenon was linked to the influx of Western food restaurants 
and franchises in most of the Asian continent that have led to the change of the 
normal dietary pattern of Asians. However, numerous studies made clear that 
even though diet could be one of the risk factors for prostate cancer, it only has 
a weak association with the disease. Direct risk factors such as age, ethnicity, 
family history and genetic conditions are reported to play major role in the onset 
of prostate cancer.  
 
Traditional herbal medicines are still very important for Malaysians both 
from a nutritional and a medicinal point of view. Malay traditional medicine is 
largely driven to gender-related groups of preparations: women’s health (Jamu 
and/or Meroyan remedies) and men’s health (tonics or makjun) which work by 
“cleansing the blood” and improving virility (Zakaria and Mohd 2010). In the 
45 
same way that daily administration of phytoestrogens has been put forward as a 
potential chemopreventive approach for prostate cancer, (Morrissey and G 
Watson 2003) plants traditionally used for women’s health may be a source of 
such compounds for prostate cancer therapy.  
The use of plant-derived products in prevention and/or treatment of cancer 
may take two different pathways, in the one hand the identification and 
characterization of active extracts for use as food supplements (nutraceuticals) 
with the purpose of ‘contributing to a healthy bodily function’ which is in fact a 
hidden chemopreventive claim and in the other hand the isolation and 
identification of active molecules as lead compounds to develop drugs for future 
chemotherapy. Each option has extremely different regulatory frameworks, 
which lead to different research and development processes as explained in 
more details in section 2.3. The sponsor of this project retains that the first 
option is more realistic in the context of current market trends, nevertheless they 
did not want to compromise on the quality; therefore they decided to gather 
preclinical data even if this is not strictly necessary for this class of final product. 
 With this in mind, the main aims of this research are to investigate both 
the mechanisms of cytotoxic effect and the chemistry of the active plant extracts 
from two Malaysian plant species, predominantly used by the women namely 
Marantodes pumilum (Blume) Kuntze (synonym Labisia pumila var pumila) and 
Ficus deltoidea L. This study will inform the development of herbal preparations 
for prostate health standardized in the identified/dereplicated phytochemicals by 
Universiti Teknologi of Malaysia. 
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1.2 Problem Statement 
Prostate cancer is the fourth most common type of cancer worldwide, and 
the second most common cancer in men. Prostate cancer is the fifth leading 
cause of death from cancer in men. The metastatic type of prostate cancer, 
which is often lethal, has no effective therapeutic management to date. 
Therefore, the finding of any new lead compounds from other sources including 
plants is important to improve the current management available for this 
condition. 
 
1.3 Hypothesis 
The active extracts of Marantodes pumilum (Blume) Kuntze (synonym 
Labisia pumila var pumila) and Ficus deltoidea L. plants induce prostate cancer 
cell death and inhibit both prostate cancer cell migration and invasion. 
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1.4 Objectives of study 
This project aims to investigate the effect of Marantodes pumilum (Blume) 
Kuntze (synonym Labisia pumila var pumila) and Ficus deltoidea L. plant 
extracts on prostate cancer cells, characterize the phytochemistry and anti-
cancer mechanism of actions based on the main Hallmarks of Cancer with a 
view to develop chemopreventive therapies. This aim will be achieved by 
following an array of different strategies including: 
Ø Characterizing the prostate cancer cells mode of death by using In vitro 
mechanistic studies 
Ø Characterizing the molecular pathways involved in the inhibition of both 
prostate cancer cells migration and invasion induced by the cytotoxic 
fractions or principles of the plants 
Ø Bioguided isolation and identification of bioactive compounds from the 
plants with a view to future standardisation of the extracts  
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2 Literature Review 
 
2.1 Prostate Cancer 
 Prostate cancer is also known as the carcinoma of the prostate. It occurs 
when cancerous cells develop in the prostate which is a gland in the male 
reproductive system. 
 
	
Figure 2.1  Posterior view of the Prostate gland. Adapted from Ballacchino (2015) 
 
 Prostate cancer is classified as adenocarcinoma or glandular cancer. It 
begins when some normal cells of the semen-secreting prostate glands mutate 
into cancerous cells. Prostate cancers are usually slow growing tumour cells, 
however in rare cases some prostate cancer cells can grow relatively fast. 
Adenocarcinoma cells are commonly found in the peripheral zone of the 
prostate gland where they initially form small clumps of cancer cells that remain 
confined to otherwise normal prostate glands. This condition is known as 
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carcinoma in situ or prostatic intraepithelial neoplasia (PIN). As mentioned 
earlier, most prostate carcinomas are slow growing tumours, therefore it will take 
time for these cancer cells to begin multiplying and spreading to the surrounding 
prostate tissue (the stroma) in order to form a full blown tumour. Eventually, the 
tumour has the ability to grow large enough to invade nearby organs such as the 
seminal vesicles or the rectum. Apart from that, given suitable conditions, the 
tumour cells could also develop the ability to travel in the bloodstream and 
lymphatic system. Therefore, because of these abilities, prostate cancer is 
considered as a malignant tumour, which is able to metastasize to other parts of 
the human body. The most common parts where prostate cancer metastasizes 
include the bones, lymph nodes, and local organs such as bladder and lower 
ureters (Roodman 2012). The tumour cells can spread to the bones using a 
specialized route known as the prostatic venous plexus, which connect directly 
to the vertebral veins (Casimiro, Guise et al. 2009). 
 
2.1.1 Incidence 
Prostate cancer is the fourth most common type of cancer worldwide, and 
the second most common cancer in men. In 2012, an estimated 1.1 million men 
worldwide were diagnosed with prostate cancer, which account for almost 15% 
of the cancers diagnosed in men. 70% of these cases occurred in more 
developed nations and this could be due to the practice of prostate specific 
antigen (PSA) testing and subsequent biopsy that has become widespread in 
this part of the world. 307,000 estimated deaths were reported in 2012 which 
make prostate cancer as the fifth leading cause of death from cancer in men 
(6.6% of the total men deaths) (Ferlay, Soerjomataram et al. 2013). In the 
United Kingdom, prostate cancer contributed to the 46,690 (13%) new cases 
and 11,287 deaths annually. 54% of prostate cancer cases in the UK are 
diagnosed in males aged 70 and over every year (Cancer Research UK 2016). 
According to the statistics provided by the National Cancer Registry (2011) of 
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Malaysia, prostate cancer ranked ninth overall and is the fourth most frequent 
cancer (7.3% of all cancers) diagnosed in men. Although the incidence of 
prostate cancer is more prevalent in the western countries, the number of 
prostate cancer cases has also grown rapidly in Asian countries such as Japan, 
and Hong Kong (Figure 2.2) (Wynder, Fujita et al. 1991, Liu 1993). These 
statistical data show that prostate cancer has no geographical boundaries and 
may be found in different parts of the world. 
 
 
Figure 2.2  Worldwide incidence and mortality rate of prostate cancer. Adapted from 
Ferlay, Soerjomataram et al. (2013) 
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2.1.2 Risk Factors 
 Many studies have been conducted to determine the risk factors that are 
related to the onset of prostate cancer. However, a complete understanding of 
the cause of prostate cancer remains elusive. No modifiable and preventable 
factors have been conclusively linked with prostate cancer risk due to the 
complexity in interpreting the epidemiological evidence around prostate cancer 
(Giovannucci, Liu et al. 2007, Cogliano, Baan et al. 2011).  The International 
Agency for Research on Cancer (IARC) (2014) together with the American 
Institute for Cancer Research (AICR) (2014) have underlined several risk factors 
for prostate cancer.  
 
One of the risk factors include age and ethnicity which are strongly 
related to prostate cancer. The highest incidence of prostate cancer cases occur 
in older men. In the UK between 2009 and 2011, an average of 36% of cases 
were diagnosed in men aged 70 years and over while only 1% were diagnosed 
in the under-50s (Northern Ireland Cancer Registry , Welsh Cancer Intelligence 
and Surveillance Unit) and this number has increased steadily over time as 54% 
of prostate cancer cases were diagnosed in the UK between the period of 2012 
to 2014 in men aged 70 and over (Cancer Research UK 2016). Ethnicity also 
play an important role in prostate cancer incidence as age-standardised rates for 
White males with prostate cancer range from 96.0 to 99.9 per 100,000. Rates for 
Asian males are significantly lower, ranging from 28.7 to 60.6 per 100,000 
whereas the rates for Black males are significantly higher, ranging from 120.8 to 
247.9 per 100,000 (National Cancer Intelligence and Cancer Research UK). In 
Malaysia, the overall age standardized incidence is 12 per 100,000 populations, 
with the highest incidence of prostate cancer reported among Chinese (15.8 per 
100,000) followed by Indians (14.8 per 100,000) and the lowest in Malays (7.7 
per 100,000). 
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 Apart from that, family history and genetic conditions also play important 
roles in prostate cancer, for example men whose father has/had the disease has 
2.1-2.4 times higher risked in developing prostate cancer (Johns and Houlston 
2003, Watkins Bruner, Moore et al. 2003, Kicinski, Vangronsveld et al. 2011) 
and Men whose brother has/had prostate cancer in the family has 2.9-3.3 times 
higher risk of developing the disease (Johns and Houlston 2003, Watkins 
Bruner, Moore et al. 2003, Kicinski, Vangronsveld et al. 2011). However, 
prostate cancer is not associated with a breast cancer in a sister (Hemminki and 
Chen 2005, Chen, Page et al. 2008). Prostate cancer risk is not associated with 
prostate cancer in adoptive parents or adoptive family (Zöller, Li et al.); this has 
further supported the family history and genetic link hypothesis. Men with 
BRCA2 mutation has up to 5 times higher risk in developing prostate cancer 
when compared to the general population and this risk could increase to 7 times 
higher in men aged under 65 (The Breast Cancer Linkage Consortium, 1999). 
BRCA1 mutation in men could also increase prostate cancer risk but the 
evidence remains unclear (Thompson, Easton et al. 2002, Fachal, Gómez-
Caamaño et al. 2011). Lynch syndrome which is an autosomal dominant genetic 
condition could also increase the risk of prostate cancer by 2.1-4.9 times higher 
when compared to the general population as shown by a meta-analysis and a 
cohort study (Haraldsdottir, Hampel et al. 2014, Ryan, Jenkins et al. 2014) Apart 
from that, endogenous hormone such as insulin-like growth factor-1 (IGF-1) has 
been reported to increase prostate cancer risk by 38-39% higher in men with 
highest level of IGF-1 (Renehan, Zwahlen et al. , Roddam, Allen et al. 2008). 
However, studies have shown that prostate cancer risk is not associated with 
both insulin-like growth factor-2 (IGF-2) and insulin-like growth factor binding 
protein (IGFBP) (Roddam, Allen et al. 2008, Rowlands, Gunnell et al. 2009), but 
the risk may vary between IGFBPs. These are the main risk factors associated 
with prostate cancer, other risk factors with weaker association include diet, 
occupational exposures, exposure to ionizing radiation and obesity.  
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2.1.3 Stages 
 Cancer staging is very important as it will help to determine the extent to 
which a cancer has developed by spreading. There are a few different staging 
system used for prostate cancer. Two of the most commonly used systems are 
the ‘TNM’ staging system and the ‘number staging’ system. TNM is an 
abbreviation for tumour (T), node (N), and metastasis (M). TNM system shows 
how far the cancer has spread in and around the prostate, it also shows how far 
the cancer has spread to the nearby lymph nodes and evaluate whether the 
cancer has already spread to other parts of the body such as the bones. The 
‘number staging’ for prostate cancer is divided into 4 stages (I,II,III and IV) 
(Figure 2.3). Primary prostate cancer is under stages I and II. In these two 
stages the cancer cells are still localised in the prostate. Stage II prostate cancer 
means that the cancer cells are at an advanced stage compared to stage I but 
are still localised in the prostate. Patients with stage I and stage II prostate 
cancer has low or intermediate risk of having a metastasis. Stage III and stage 
IV prostate cancer cells are characterized by the spreading of the cells to other 
bodily parts. In stage III prostate cancer, the cells have spread beyond the outer 
layer of prostate and may have spread to the seminal vesicles whereas in stage 
IV, the cancer cells have spread beyond the seminal vesicles to nearby tissues 
or organs such as the rectum, bladder or pelvic wall and also to distant parts of 
the body. Therefore stage IV represents the worst stage of prostate cancer and 
patients at this stage only have 28% of 5-year relative survival rate according to 
the American Cancer Society (2016). 
		 55 
 
Figure 2.3  Stages of prostate cancer. Adapted from Healthfavo (2014) 
 
2.1.4 Pathophysiology of Prostate Cancer 
 Many abnormalities at cellular, molecular and genetics levels have been 
associated with the occurrence of prostate cancer. These include chromosomal 
abnormalities, the presence of oncogenes and overexpression of certain 
proteins.  
 
2.1.4.1 Chromosomal abnormalities and oncogenes 
Chromosomal abnormalities associated with prostate cancer includes the 
deletion of 8p,10q, 13q, and 16q as well as the gains of 7p,7q,8q and Xq 
chromosomes. These allelic abnormalities has been reported by Nupponen and 
Visakorpi (1999), Hughes, Murphy et al. (2005) and Shi, Sun et al. (2013). Apart 
from that other allelic loss has been reported by Rubin and Rubin (1998), Shen 
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and Abate-Shen (2010) and Fraser, Sabelnykova et al. (2017) which include the 
loss of 6q,7q,17p and 18q.  
 
 The MYC is a well-known oncogene which plays an important role in the 
regulation of cellular proliferation, differentiation and apoptosis. This oncogene is 
located at 8q24 and also at other amplified region of 8q (Visakorpi, Kallioniemi et 
al. 1995, Cher, Bova et al. 1996, Nupponen, Kakkola et al. 1998, Taylor, Schultz 
et al. 2010). The overexpression and amplification of this oncogene have been 
detected in prostate cancer cells especially in the metastatic stage (Bubendorf, 
Kononen et al. 1999, Taylor, Schultz et al. 2010, Rickman, Beltran et al. 2017). 
Besides MYC, the RAS family oncogenes are the most common oncogenes in 
human cancer. However, in prostate tumours, mutations in the ras genes 
(HRAS, KRAS and NRAS) are relatively uncommon (Min, Zaslavsky et al. 2010, 
Zeng, Hu et al. 2014), except in the rare ductal form of the disease. Morote, de 
Torres et al. (1999), has reported that overexpression of ERBB2 gene is a 
frequent event in prostate cancer. The ERBB2 gene, commonly referred to as 
Her-2/neu belongs to a family of genes that provide instructions for producing 
growth factors receptors. These growth factors are important in stimulating cell 
growth and division. ERBB2 gene amplification will result in the overproduction 
of ErbB2 protein and this can cause cells to grow and divide continuously 
leading to uncontrolled cell division, which is one of the hallmarks of cancerous 
tumour progression (Pignon, Koopmansch et al. 2009, Yan, Parker et al. 2014). 
Another oncogene that plays a very important role in the progression of prostate 
cancer is Bcl-2. Several authors have reported the overexpression of Bcl-2 
especially in recurrent tumours (McDonnell, Troncoso et al. 1992, Colombel, 
Symmans et al. 1993, Krajewska, Krajewski et al. 1996, Pienta and Bradley 
2006, Delbridge, Grabow et al. 2016), however, this event did not seem to 
happen due to the amplification of the genes (Nupponen and Visakorpi 1999, 
Pienta and Bradley 2006). Bcl-2 inhibits apoptosis of the prostate cancer cells 
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subjected to androgen deprivation therefore allowing the cancerous cells to 
survive even without the presence of required hormone.  
 
2.1.4.2 Androgen receptor 
 Androgen receptor (AR) is a type of nuclear receptor that is encoded by a 
single copy gene located on the X-chromosome (Xq11.2-q12), which consists of 
919 amino acids in length, but this can vary depending on the poly-glutamine, 
poly-glycine, and poly-proline repeats of variable lengths (Velcheti, Karnik et al. 
2008). AR signalling is very important as it plays critical role not only for prostate 
function and differentiation but also for the growth and progression of prostate 
cancer (Velcheti, Karnik et al. 2008, Yuan, Cai et al. 2014). AR activity is 
regulated by two major ligands, testosterone and dihydrotestosterone (DHT). 
DHT, which has 10 times higher binding affinity to AR is the primary androgen 
bound to AR. The binding of DHT to AR promotes the recruitment of proteins 
kinases, which lead to the phosphorylation of several serine residues. This 
process is very important as it serves many functions such as protection from 
proteolytic degradation, stabilization, and transcriptional activation (Edwards and 
Bartlett 2005). The transactivation of AR is vital as it regulates specific gene 
targets that are involved in cells growth and survival (Chmelar, Buchanan et al. 
2007). The rate of cells proliferation and the rate of cells apoptosis are balanced 
in normal prostate epithelium, however, the balance is lost in prostate cancer 
that leads to the formation of tumour cells (Denmeade, Lin et al. 1996). Since 
prostate cancer growth is highly dependent on androgen, androgen-ablation 
therapy has always been the most effective treatment for prostate cancer at an 
early stage. However, this therapy only manages to delay tumour progression by 
18-24 months followed by the development of a lethal drug-resistant stage 
known as castration-resistant prostate cancer (CRPC). Visakorpi, Kallioniemi et 
al. (1995), has reported that in CRPC patients, the frequent amplification of 
chromosome Xq in recurrent tumours has led to the overexpression of AR after 
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androgen deprivation therapy. This type of chromosomal amplification is rarely 
seen in the primary tumours.  The overexpression of AR overcomes the 
decreased levels of circulating androgens in hormone-independent prostate 
cancer thus allowing the cancer cells to continue growing even in very low level 
of androgen left in serum after castration (Visakorpi, Kallioniemi et al. 1995, Tan, 
Li et al. 2015). The overexpression of AR also produce a receptor that is more 
sensitive to a low androgen levels or that can be activated by other types of 
steroids such as adrenal androgens, estrogens, progestins, as well as anti-
androgens that used in the management of the disease (Scher and Sawyers 
2005). 
 
2.1.4.3 Metastasis 
Metastasis is defined as the spread of tumour cells from their primary site 
to distant organs and their ability to grow and survive at the new sites remains 
the most fearsome aspect of cancer. Metastasis has been the subject of study 
for more than 100 years. However, only until recently that researchers have 
gained important insight into the mechanism by which metastatic cells arise from 
primary tumour and the reasons why certain tumours tend to spread or 
metastasize to specific organs (Fidler 2003). Back in 1889, an English surgeon 
proposed the ‘seeds and soil’ hypothesis that says metastasis depends on 
cross-talk between selected cancer cells (the ‘seeds’) and the specific 
microenvironments (the ‘soils’) surrounding them (Paget 1889). Although this 
hypothesis still holds forth today, it is now understood that the ability of tumour 
cells to metastasize depend on several elements including its interactions with 
the homeostatic factors that promote tumour-cell growth, angiogenesis, survival, 
invasion and metastasis (Fidler 2003). Figure 2.4 shows the general process of 
cancer metastasis, which consists of a long series of sequential and inter-related 
steps. Each of these steps can be rate-limiting, therefore a failure or 
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insufficiency at any steps could lead to the collapse of the whole process (Poste 
1980, Fidler 2002).  
Figure 2.4  The process of cancer metastasis. Adapted from “The pathogenesis of cancer 
metastasis: the 'seed and soil' hypothesis revisited” by I. J. Fidler, 2003. a. Growth of 
primary tumours require nutrient that is initially supplied by simple diffusion. b. The 
growth of tumour mass exceeding 1-2 mm in diameter requires extensive vascularization. 
c. Lymphatic channels, which are characterized by their thin-walled venules, act as the
most common route for tumour-cell entry into the circulation. d. Tumour cells that
survived the circulation become trapped in the capillary bed of distant organs by
adhering either to exposed capillary endothelial cells or subendothelial basement
membrane. e. Extravasation occurs. f. Proliferation of the tumour cells at distant organ
accompanied by micrometastasis. Nature Reviews Cancer 3, 453-458. Copyright 2003 by
Nature Publishing Group. Adapted with permission.
		 60 
Prostate cancer is one of the most malignant types of cancer in men. It 
has the ability to spread to other distant sites including bones, lymph nodes, 
lungs, liver and brain. However, prostate cancer frequently metastasizes to the 
bone marrow.(Roudier, Morrissey et al. 2008) This is evident as almost 90% of 
advanced prostate cancer patient suffer from pathologic fractures, spinal cord 
compression, and pain due in part of deregulated cycles of osteoblastic and 
osteolytic resorption/formation driven by the growing tumour mass (Rubens 
1998, Fizazi, Carducci et al. 2011). Although the mechanisms that account for 
the tendency of prostate cancer cells to metastasize to bone have not yet been 
elucidated but it may include direct vascular pathway, highly permeable 
sinusoids, chemotactic factors produced by bone marrow stromal cells and the 
synthesis of growth factors important to support cells survival, and proliferation 
of ‘seeded’ cancer cells (Diel 1994, Geldof 1996). Taichman, Cooper et al. 
(2002) hypothesize that metastatic prostate carcinomas may use the 
hematopoietic model to localize to the bone barrow. In this model, chemokines, 
which are a group of molecules known to play significant roles as activators and 
chemoattractants, including CXC chemokine such as CXCL12 and its receptor 
CXCR4 appear to be critical molecular determinants for the events in this model 
(Aiuti, Tavian et al. 1999, Kim and Broxmeyer 1999). In their study, Taichman, 
Cooper et al. (2002) showed that the CXCL12/CXCR4 chemokine axis was 
activated in prostate cancer metastasis to the bone. They also confirmed that 
CXCR4 expression is related to increasing tumour grade, as well as showing 
that CXCL12 signalling through CXCR4 triggers the adhesion of prostate cancer 
cells to bone marrow endothelial cells (Sun, Wang et al. 2003). Similar studies 
conducted by other researchers also suggest that CXCL12/CXCR4 axis play 
parallel roles in other tumours that also metastasize to the marrow. Müller, 
Homey et al. (2001) reported that CXCL12/CXCR4 axis play central roles in 
regulating metastasis by showing that normal breast tissues express little 
CXCR4 receptors compared to breast neoplasms, which express high levels of 
CXCR4. Furthermore, this study also shows that the use of antibody that could 
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block CXCR4 receptor was able to prevent the spread of tumours cells to lungs 
and lymph nodes. 
 
Apart from that, the metastatic progression of prostate cancer is also 
closely associated with two genes namely E-cadherin (CDH1) and KAI1 genes. 
The expressions of both genes are significantly reduced in metastatic prostate 
cancer cells (Umbas, Schalken et al. 1992, Morton, Ewing et al. 1993). 
However, this was not caused by allelic loss but rather by post-transcriptional 
events regulated by p53. Therefore loss of p53 function in the late stages of 
tumour progression could cause down-regulation of these two genes with 
subsequent metastasis (Mashimo, Watabe et al. 1998). 
 
2.1.4.4 Arachidonic acid metabolism  
Besides the abnormalities in chromosomes, as well as the presence of 
oncogenes and the overexpression of specific receptors, malignant cancer cells 
commonly overexpress key enzymes of the arachidonic acid metabolism (mainly 
COX-2 and 5-LOX). The COX-2 is overexpressed in practically every 
premalignant and malignant condition involving the colon, liver, pancreas, 
breast, lung, bladder, skin, stomach, head, neck and oesophagus (Eberhart, 
Coffey et al. 1994, Hida, Yatabe et al. 1998, Hwang, Byrne et al. 1998, Koga, 
Sakisaka et al. 1999, Mohammed, Knapp et al. 1999, Tucker, Dannenberg et al. 
1999, Aggarwal and Shishodia 2006, Wolfesberger, Walter et al. 2006). 
Interestingly, human prostate cancer cells are known to generate 5-
lipoxygenase (5-LOX) instead. 5-LOX is a type of enzyme in human encoded by 
the ALOX-5 gene. Ghosh and Myers (1997) reported that chemical constituents 
such as arachidonic acid, an omega-6, polyunsaturated fatty acid was found to 
stimulate prostate cancer cell growth via the 5-LOX pathway. This has been 
recently corroborated by Yang, Cartwright et al. (2012),who also point towards 
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12-LOX. The expression of 5-LOX is normally restricted to specified immune
cells such as neutrophils, eosinophils basophils and macrophages whereas the
vast majority of non-immune body cells do not express 5-LOX unless at the
onset of certain diseases such as asthma, arthritis, psoriasis and cancer
(Fürstenberger, Krieg et al. 2006, Werz and Steinhilber 2006, Rådmark, Werz et
al. 2007, Ghosh 2008). 5-LOX plays a very important role in chemotaxis in these
cells (Werz and Steinhilber 2006). Ghosh and Myers (1997), reported that the
inhibition of 5-LOX would block the production of 5-LOX metabolites and triggers
apoptosis in prostate cancer cells. The expression of 5-LOX in normal prostate
glands is almost undetectable, however 5-LOX is heavily expressed in prostate
tumour tissues. Therefore, this finding is very important for the development of
future therapeutic approaches for prostate cancer as 5-LOX plays a critical role
in the survival of prostate cancer cells. This leads to the concept that 5-LOX may
play a major role in the development and progression of prostate cancer and
could be used as a promising target in prostate cancer therapy. Other
abnormalities including the amplification and overexpression of certain genes
mentioned earlier could also be used as potential target in future prostate cancer
therapy.
2.1.4.5 Angiogenesis 
Tumour normally consists of cancer cells and stromal cells. These 
stromal cells face a very hostile metabolic environment characterized by 
acidosis and hypoxia. Tumour development requires the supply of oxygen and 
nutrition, this is usually provided by the nearby blood vessels (Holmgren, 
O'Reilly et al. 1995). With this, the tumour growth is only limited to 1-2 mm in 
diameter (avascular phase) (Carmeliet 2003). Therefore in order for the tumour 
to exceed the size limit, the tumour needs an increased blood supply. This is 
mainly provided by the formation of new blood vessels from pre-existing 
capillaries and venules. This process is called angiogenesis (Carmeliet 2003). 
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The classical angiogenesis process is shown in Figure 2.5. Prostate tumours 
like other type of tumour cells overexpress vascular endothelial growth factor 
(VEGF) (Li, Younes et al. 2004). VEGF is a homodimeric glycoprotein that 
belongs to the first group of pro-angiogenic factors (Ferrara, Gerber et al. 2003). 
Other important pro-angiogenic factors include fibroblast growth factor (FGF) 
(Friesel and Maciag 1995), platelet-derived growth factor B (PDGF-B) (Battegay, 
Rupp et al. 1994), angiopoietins (Battegay, Rupp et al. 1994, Friesel and Maciag 
1995), growth-related oncogenes (Wang, Hendricks et al. 2006), tumour growth 
factor β (TGFβ) (Sankar, Mahooti-Brooks et al. 1996), and matrix 
metalloproteases (MMPs) (Egeblad and Werb 2002). 
 
The overexpression of VEGF in prostate tumours will promote the 
development of tumour neovascularization and this overexpression also 
correlate with increasing grade, vascularity and tumorigenicity. Besides that, the 
receptor for VEGF, VEGFRs and α5β integrin were expressed by prostate 
cancer cells in-vitro and and prostate tumours in-vivo and their expression was 
elevated at sites of bones metastasis compared to original prostate tumour. He, 
Kozaki et al. (2002) reported that the angiogenic effect of VEGF in prostate 
tumour could be blocked by the inactivation of its receptor, VEGFR. Without 
VEGF or VEGFR, the prostate tumour cells would not be a able to form 
sprouting capillaries. Therefore, this could be a potential target to stop the 
development and progression of prostate cancer. 
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Figure 2.5  The classical angiogenic process. Adapted from “Circulating endothelial cells 
as biomarkers of prostate cancer” by H. D. Georgiou, B. Namdarian, N. M. Corcoran, A. J. 
Costello, and C. M. Hovens, 2008, Nature Clinical Practice Urology (2008) 5, 445-454. 
Copyright 2008 by Nature Publishing Group. Adapted with permission. 
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2.1.5 Treatment 
 
2.1.5.1 Chemoprevention of Prostate cancer 
The idea of chemoprevention was initially introduced in the mid 1970s 
(Sporn and Newton 1979, Brawley 2002). It is defined as the administration of 
agents or substances such as drugs or vitamins to try and reduce the risk or 
delay the development or recurrence of cancer. Carcinogenesis in cancer 
development is a complex process that normally requires a long period of time; 
therefore chemoprevention could play a major role in inhibition or slowing of this 
process before cancer growth becomes clinically significant (Kelloff, Lieberman 
et al. 1999). Chemoprevention is a type of preventive medicine and can be 
divided into primary, secondary and tertiary prevention. Primary prevention 
deals with the incidence of disease in an otherwise healthy individual. 
Secondary prevention aims to stop the progression of a disease to a clinically 
significant stage by focusing on the treatment given to an individual already with 
a premalignant condition. Tertiary prevention focuses on the prevention of 
recurrence or progression of disease in an individual previously treated with 
malignancy (Sandhu, Nepple et al. 2013). In the case of prostate cancer, 
chemoprevention is essentially aimed at primary and secondary prevention 
(Sandhu, Nepple et al. 2013). 
 
 There are many reasons that support the use of chemoprevention as part 
of prostate therapy. As mentioned earlier in this section, carcinogenesis in 
cancer development occurs over time and this is also the case for prostate 
cancer. In fact, carcinogenesis in prostate cancer is thought to consist of a 
protracted multistep molecular processes affecting numerous pathways 
(Gonzalgo and Isaacs 2003).  This molecular pathogenesis could lead to the 
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development of pre-cancerous characteristics such as atypical small acinar 
proliferation (ASAP) and high grade intraepithelial neoplasia (HGPIN) (Epstein 
and Herawi 2006). Both ASAP and HGPIN can be detected many years before 
the formation of the actual cancer mass in the prostate gland itself. These 
characteristics make prostate cancer as an ideal target for primary 
chemopreventation. Apart from that, prostate cancer also has a prolonged latent 
disease state. This simply means there is a long period between the 
development of the cancerous cells and their eventual manifestations by 
symptoms. Therefore increasing the incidence of prostate cancer in elderly men 
aged between 60-79 years old (Stamatiou, Alevizos et al. 2006). This specific 
characteristic of prostate cancer makes it suitable as a target for secondary 
chemoprevention. 
 
 In chemoprevention, it is vital to use agents or substances with low 
toxicity as it involves the treatment of healthy individual (Hong and Lippman 
1994). In prostate cancer, chemoprevention can be used to prevent the 
transformation of normal cells or precursor lesions to cancerous cells 
(secondary prevention) as well as stopping the growth of the existing tumour 
cells (Walsh 2010). 5 Alpha-reductase inhibitors are one of the 
chemopreventives used in prostate cancer therapy. Inhibition of 5-α-reductase 
will decrease the amount of dihydrotestosterone (DHT) in prostate cancer 
tissues, thus lowering the androgenic stimulation to the prostate (Brawley 2002). 
Several studies showed that the inhibition of 5-α-reductase in prostate cancer 
tumours grafted into animal has significantly impeded tumour implantation and 
growth (Tsukamoto, Akaza et al. 1998, Roehrborn, Boyle et al. 1999). 
Finasteride is a type of 5-α-reductase inhibitor, which lowers intraprostatic DHT 
levels while causing testosterone level to increase slightly (Stoner 1994). It was 
the first 5-α-reductase inhibitor to enter human trial. Another 5-α-reductase 
inhibitor that is used for prostate cancer chemoprevention is dutasteride. Unlike 
finasteride, dutasteride is thought to have better efficacy in chemoprevention as 
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it can inhibit both isoforms of 5-α-reductase (Bramson, Hermann et al. 1997). 
Recent study conducted by Andriole, Bostwick et al. (2010) showed that 
dutasteride reduced the risk of prostate cancers and precursor lesions among 
men at increased risk of prostate cancer and for benign prostatic hyperplasia 
(BPH) while improving many outcomes related to BPH. Other agents such as 
vitamin C, vitamin B1, vitamin B2, vitamin B3, calcium, zinc, protein and 
selenium have been used in the hope of preventing the growth of prostate 
cancer, however no clear association exists between these common dietary 
factors and prostate cancer (Brawley 2002). In this study, characterization of the 
active extracts could lead to their use in prostate cancer chemoprevention in the 
future. 
 
2.1.5.2 Management of Prostate cancer 
Treatments and prostate cancer management depends on several factors 
such as the stage of the disease, age, general health, and a person’s view about 
potential treatments and their possible side effects. Due to the aggresiveness 
and the annoying side effects (erectile and urinary dysfunction) of most 
treatment options, treatment discussion often focus on balancing the goals of 
therapy with the risk of lifestyle alterations. A combinations of treatment options 
is highly recommended for managing the disease (Lu-Yao, Albertsen et al. 2009, 
Mongiat-Artus, Peyromaure et al. 2009, Picard, Golshayan et al. 2012). The 
management of prostate cancer can be divided into three categories; 1) 
management of localised prostate cancer, 2) management of locally advanced 
prostate cancer, 3) management of metastatic prostate cancer. 
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Most patients diagnosed with localised prostate cancer will have an 
excellent prognosis. This is achieved by radical prostatectomy and/or radiation 
therapy. One-fifth of the patients opt out surgery and will undergo ‘watchful 
waiting’. However, 20%-40% of the patients who went through primary therapy 
will experience biochemical relapse, with 30%-70% of those developing 
metastatic disease within 10 years after the introduction of local therapy (Pound 
and Pound 1999, D'Amico, Cote et al. 2002, Antonarakis, Trock et al. 2009, 
Uchio and Uchio 2010). Metastatic stage of prostate cancer is normally 
managed by the use of androgen-deprivation therapy or also known as hormone 
ablation therapy. A luteinizing hormone-releasing hormone (LHRH) agonist will 
improve the symptoms but tumours invariably become hormone independent 
(castration-resistant) and evolve to the progressive stage. Before 1990s, 
patients with castration-resistant prostate cancer (CRPC) were generally treated 
with palliative approaches, as no other life-prolonging options were available. As 
prostate cancer is often associated with elderly men with limited bone marrow 
reserve and concurrent medical conditions, the use of chemotherapy at this time 
was not recommended as it can further deteriorate the quality of life (Paller and 
Antonarakis 2011). 
 
 Tannock, Osoba et al. (1996) has reported that mitoxantrone (with 
prednisone) has the ability to improve quality of life and reduce bone pain 
besides lowering serum PSA level in men with CRPC. This important discovery 
has led to the use of intercalating agent mitoxantrone as the initial standard of 
care for such patients. The cytotoxic Docetaxel has replaced the use of 
mitoxantrone as the first line standard of care in 2004 after the Soutwest 
Oncology Group reported that docetaxel (with estramustine) significantly 
extended progression-free and overall survival for CRPC patients when 
compared to mitoxantrone (with prednisone) (Petrylak, Petrylak et al. 2004). 
However, up until 2010, physicians have no other life-prolonging second-line 
options after the failure of docetaxel. On June 17 the same year, the US Food 
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and Drug Administration (FDA) approved the use of cabazitaxel for CRPC 
patients previously treated with a docetaxel-containing regime (US Food and 
Drug Administration) thus changing from stabilisation of microtubule to inhibition 
of the assembly as the underlying mechanism of therapeutic action. Until 
recently, other therapies including Enzalutamide (Xtandi®), Abiraterone 
(Zytiga®) and Radium-233 (Xofigo®) have been used for the management of 
CRPC patients. Both Enzalutamide and Abiraterone are a new type of hormone 
therapy for men with prostate cancer that is no longer responding to hormone 
therapy or chemotherapy. Enzalutamide works by blocking the hormone 
testosterone from reaching the prostate cancer cells whereas Abiraterone works 
by stopping the production of testosterone in the body. Without the availability of 
this hormone, prostate cancer cells will cease to grow wherever they are in the 
body. 
 
2.2 Possible therapeutic targets for Prostate Cancer based on the 
major hallmarks of cancer 
Figure 2.6 shows the 6 main hallmarks of cancer originally proposed by 
Hanahan and Weinberg (2000) which include sustaining proliferative signaling, 
evading growth suppressors, resisting cell deaths, activating invasion and 
metastasis, inducing angiogenesis and enabling replicative immortality. The 
same authors later extended this list after considering the new progresses made 
in the past decade by adding two new hallmarks comprising the reprogramming 
of energy metabolism and the evasion of immune destruction (Hanahan and 
Weinberg 2011). These are the biological capabilities acquired by the tumor 
cells during their multistep development that enable them to become 
tumorigenic and ultimately malignant. The understanding of these hallmarks is 
very important in order to find suitable therapeutic targets that can be used more 
effectively in cancer treatment. Blandin, Renner et al. (2015) has reported that 
ß1 integrins which is a type of matricellular receptors (extracellular matrix 
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component), plays important role in the modulation of these cancer hallmarks. 
Therefore, it can be used as one of the suitable therapeutic targets for cancer 
therapy. This study aims to find bioactive compound/s from plants that could 
modulate some of the cancer hallmarks namely resisting cell death or evading 
apoptosis, activating invasion and metastasis and inducing angiogenesis. These 
are the three main hallmarks of cancer that would be the focus of this study. The 
discovery of bioactive compound/s with the ability to modulate these 3 important 
hallmarks would be vital for the future of prostate cancer therapy. 
 
 
 
Figure 2.6  The Hallmarks of Cancer. Adapted from “Hallmarks of Cancer: The Next 
Generation” by D. Hanahan, and R. A. Weinberg, 2011, Cell (2011) 144 (5), 646-674. 
Copyright 2011 by Elsevier Inc. Adapted with permission. 
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2.2.1 Resisting cell death: Role of Smac/DIABLO in cancer progression 
The ability of tumor cells to expand in numbers depends not only on the 
rate of cells proliferation but also on the rate of cells death, which occur normally 
through apoptosis. In normal cells, this process is tightly regulated in order to 
maintain cells population and immune system development (Vaux and 
Korsmeyer 1999). However, disruptions and deregulations of the process lead to 
uncontrolled cell growth, which is a characteristic of tumor cells. Therefore, 
inducing cancer cells apoptosis is important in any type of cancer therapy and in 
this case prostate cancer therapy. 
 
Apoptosis can be activated through two distinct pathways (Figure 2.7): 
The extrinsic pathway, which is mediated by death receptors (CD95 and TRAIL) 
or the intrinsic pathway, which is mediated by the mitochondria (Martinez-Ruiz, 
Maldonado et al. 2008). Stimulation of death receptors such as CD95 or TNF-
related apoptosis-inducing ligand (TRAIL) located on the plasma membrane 
result in the activation of the initiator caspase-8 which can cause direct cleavage 
of downstream effector caspases such as caspase-3 (Walczak and Krammer 
2000). Effector caspases such as caspase-3 will cause irreversible damage to 
the nuclear lamina, cleave the proteins that normally hold a DNA degrading 
enzyme (DNAse) in an inactive form, freeing the DNAse to cut the DNA in the 
cell nucleus and ultimately causing the dismantling of the cells in a quick and 
neat way (Fulda and Debatin 2006). 
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Figure 2.7  The Extrinsic and Intrinsic Apoptosis. Adapted from “Extrinsic versus intrinsic 
apoptosis pathways in anticancer chemotherapy” by S. Fulda and K-M. Debatin, 2006. 
Apoptosis signalling pathways. Apoptosis pathways can be initiated through two main 
entry sites, at the plasma membrane by death receptor pathway or at the mitochondria by 
the mitochondrial-driven pathway. Stimulation of the death receptor pathway (Extrinsic 
Apoptosis) involves ligation to the tumor necrosis factor (TNF) receptor superfamily such 
as CD95 or TNF-related apoptosis-inducing ligand (TRAIL) receptors. Activation of the 
death receptors results in recruitment of the adaptor molecule Fas-associated death 
domain (FADD) and caspase-8. Upon recruitment, caspase-8 becomes activated and 
initiates apoptosis by cleaving and activating downstream effector caspases. The 
mitochondrial-driven pathway (Intrinsic Apoptosis) is initiated by stress signals through 
the release apoptogenic factors such as cytochrome c, apoptosis inducing factor (AIF), or 
Smac/DIABLO from the mitochondrial intermembrane space. Cytochrome c forms an 
aggregate called apoptosome complex with apoptotic protease activating factor 1 (Apaf-
1) and caspase-9. The formation of this complex will activate caspase-3 and other 
downstream effector caspases. Smac/DIABLO promotes caspase activation by 
neutralizing the inhibitory effects of IAPs, whereas IAF cause DNA condensation. 
Oncogene (2006) 25, 4798–4811. Copyright 2006 by Nature Publishing Group. Adapted 
with permission. 
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 The mitochondrial-driven (intrinsic) pathway is initiated with the 
permeabilization of the outer mitochondrial membrane by pro-apoptotic 
members of the Bcl-2 family such as Bax and Bak (Green and Kroemer 2004). 
This process is regulated by proteins from the Bcl-2 family (e.g. Bcl-2, Bcl-xL, 
Bcl-w, Bax, Bak and Bok), mitochondrial lipids, proteins that regulate 
bioenergetics metabolic flux and components of the permeability transition pore 
(Green and Kroemer 2004). After the disruption of the outer mitochondrial 
membrane, apoptogenic factors such as cytochrome c, apoptosis-inducing 
factor (AIF), TG (Smac/DIABLO), Omi/HtrA2 or endonuclease G are released 
into the cytosol from the mitochondrial intermembrane space (Candé, Cecconi et 
al. 2002, Saelens, Festjens et al. 2004). The release of cytochrome c activates 
caspase-3 and eventually leads to the dismantling of the cells in a neat and 
quick way without causing any harm to the neighboring cells.  
 
 Smac/DIABLO is a novel mitochondria-derived pro-apoptotic protein that 
plays an important role in sensitizing tumor cells to die by apoptosis (Figure 2.8) 
(Du, Fang et al. 2000, Verhagen, Ekert et al. 2000). It has a pro-apoptotic effect 
that is mediated by its interaction with inhibitor of apoptosis proteins (IAPs) and 
the release of effector caspases from them. The IAP protein family that includes 
XIAP, c-IAP1 and c-IAP2 blocks both intrinsic and extrinsic apoptotic pathways 
by binding to and inhibiting active caspases, thus stopping the caspase cascade 
(Jia, Patwari et al. 2003). XIAP is the most potent among the IAPs due to the 
presence of three domains known as baculoviral IAP repeat (BIR) domains. BIR 
domains are very important in inhibiting the activity of active caspases 
(Deveraux, Roy et al. 1998). Smac/DIABLO functions by neutralizing the 
caspase-inhibitory properties of XIAP (Ekert, Silke et al. 2001). This is achieved 
by the displacement of XIAP from caspase 9 by Smac/DIABLO, thus 
overcoming the ability of XIAP to repress the activity of effector caspase, 
caspase-9, within the apoptosome complex (Srinivasula, Hegde et al. 2001). 
Several studies have shown that Smac/DIABLO is required for mitochondrial-
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driven apoptosis in human multiple myeloma and prostate cancer cells (Carson, 
Behnam et al. 2002). Smac peptide was also reported to enhance apoptosis 
induced chemo or immunotherapeutic agents in the leukaemic Jurkat cell line 
(Guo, Nimmanapalli et al. 2002) and in malignant glioma cells in vivo (Fulda, 
Wick et al. 2002). These findings prompted scientists to develop peptides 
derived from NH2-terminal of Smac/DIABLO and small molecules that mimic the 
funtions of Smac/DIABLO as therapeutic agents to induce cancer cells death or 
increase the apoptotic effects of the chemotherapeutic agents (Martinez-Ruiz, 
Maldonado et al. 2008). Currently small molecules such as AT-406, LCL-161 
and Birinapant are all being in preclinical phase for their anticancer properties in 
combination with more specific chemotherapy drugs such as TRAIL and BRAF 
inhibitors (Perimenis, Galaris et al. 2016). In this study, we are interested to find 
bioactive compound/s from several species of Malaysian plant that could 
increase the expression of Smac/DIABLO protein, thus increasing the apoptotic 
effect. 
 
Figure 2.8  Role of Smac/DIABLO in apoptosis. Adapted from “Role of Smac/DIABLO in 
cancer progression” by G. M. Ruiz, V. Maldonado, G. Ceballos-Cancino, J. P. R. Grajeda, 
J. Melendez-Zajgla, 2008, Journal of Experimental & Clinical Cancer Research (2008) 
27(1): 48. Open-access. 
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2.2.2 Activation of invasion and metastasis: Role of CXCL12/CXCR4 axis 
in cancer metastasis 
Even though prostate cancer could spread to other distant sites including 
lymph nodes, lung, liver and brain, the spread to the bone marrow prove to be 
the most frequent as almost 90% of advanced prostate cancer patient suffer 
from pathologic fractures, spinal cord compression, and pain due in part of 
deregulated cycles of osteoblastic and osteolytic resorption/formation driven by 
the growing tumour mass (Rubens 1998). Several reports have shown that 
CXCL12/CXCR4 axis is involved in breast (Müller, Homey et al. 2001) and 
prostate (Taichman, Cooper et al. 2002, Chinni, Sivalogan et al. 2006) cancer 
cells metastasis to bone, where high expression of CXCR4, receptor for the 
CXCL12 chemokine, is detected (Conley-LaComb, Saliganan et al. 2013, 
Singareddy, Semaan et al. 2013).  
 
Chemokines are a superfamily of cytokine-like proteins that activate 
chemokine receptors by binding to them (Sun, Cheng et al. 2010). To date, over 
50 chemokines have been identified, and they are divided into 4 distinct families 
namely CXC, CX3C, CC and C. These divisions are made based on the 
positions of 4 conserved cysteine residues (Vindrieux, Escobar et al. 2009). 
Previously, chemokines are associated with their inflammatory responses 
achieved through the stimulation of leukocytes chemotaxis during inflammation 
(Thelen 2001), however new evidences suggest that they are major regulators 
of cells trafficking and adhesion (Kyriakou, Rabin et al. 2008, Gillette, Larochelle 
et al. 2009). CXCL12 or stromal-derived factor 1 (SDF-1), is a CXC chemokine, 
and its receptor CXCR4 are reported to play critical role in the spread of prostate 
cancer cells to the bone.  
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The binding of CXCL12 to CXCR4 is said to initiate divergent signalling 
pathways that lead to multiple responses including the phosphorylation of 
MEK/ERK signalling cascade and the activation of NF-κB, which is important for 
tumor cells survival (Figure 2.9) (Sun, Cheng et al. 2010). Morever, Sun, 
Schneider et al. (2005) has reported that the levels of CXCL12 in human and 
mouse tissues were higher at the preferable sites of metastasis for prostate 
cancer cells such as bone, liver and kidney when compared with tissues rarely 
affected by the tumor cells including lung, tongue and eye. Higher expression of 
CXCL12 leads to the increased adhesion of prostate cancer cells to an 
endothelial cell monolayer and to immobilized fibronectin, laminin, collagen 
(Engl, Relja et al. 2006), and to osteosarcoma cells (Taichman, Cooper et al. 
2002) due to the up-regulation of α5 and β3 integrins.  
 
Apart from that, overexpression of CXCR4 gene was documented in 
aggressive phenotypes of prostate tumor tissues and prostate cancer patient 
with this phenotypic characteristic often has poor survival rate (Lee, Kang et al. 
2014). Sun, Schneider et al. (2005) has reported that in an in vivo study, the 
extent of bone metastasis in prostate cancer was limited by using neutralizing 
antibody against CXCR4. These data clearly show that CXCL12/CXCR4 axis 
plays a major role in prostate cancer cells progression. In our study, we 
investigate the potential of bioactive compound/s from plants to modulate this 
axis in order to reduce or prevent prostate cancer cells migration and invasion. 
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Figure 2.9  The role of CXCL12/CXCR4 axis and its microenvironment in tumor cells 
progression. Adapted from “CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer 
progression” by X. Sun, G. Cheng, M. Hao, J. Zheng, R. S. Taichman, K. J. Pienta, and J. 
Wang, 2010, Cancer and Metastasis Reviews (2010) 29 (4), 709-722. Copyright 2010 by 
Springer Science+Business Media, LLC. Adapted with permission. 
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2.2.3 Induction of Angiogenesis: Role of VEGF in angiogenesis 
One of the most important phenotypic traits of malignant tumors is their 
ability to have sustained angiogenesis. Angiogenesis is a crucial process as it 
ensures continues supply of oxygen, nutrients, growth factors and hormones, 
and proteolytic enzymes (Folkman 1990). Without angiogenesis, the progression 
of malignant tumors to distant site will not be possible. Although, a report has 
been made a century ago regarding the observation that tumor growth can be 
accompanied by increased vascularity (Ferrara, Hillan et al. 2004), it was not 
until 1939 that the first postulate about the existence of a tumor-derived-blood-
vessel-growth stimulating factor that serve to aid the formation of new blood 
supply to the tumor, was made by Ide and colleagues (Ide, Baker et al. 1939). 6 
years later, Algire, Chalkley et al. (1945) made a proposal saying that the rapid 
growth of tumor transplant is dependent on the development of a rich vascular 
supply. This proposal was made based on the observation that tumor growth 
started after an increased in blood-vessel density using a transparent chamber 
technique to the mouse. (Algire 1943, Algire, Chalkley et al. 1945). In 1971, 
Folkman has proposed that finding an anti-angiogenesis factor could be an 
effective anticancer strategy (Folkman 1971), and this pioneering hypothesis 
has led to the understanding of several important angiogenic factors such as 
epidermal growth factor (EGF), transforming growth factor (TGF)-α, TGF-ß, 
tumour-necrosis factor-α (TNF-α) and angiogenin (Folkman and Klagsbrun 
1987). However, most of the research efforts initially put for these angiogenic 
factors were then discontinued as they were only shown to promote 
angiogenesis in bioassay models but not physiologically (Klagsbrun and 
D'Amore 1991).  
 
Vascular Endothelial Growth Factor (VEGF), which is now known to be 
the main regulators of angiogenesis was first described by Senger, Galli et al. 
(1983) and then was successfully isolated and identified by Ferrara and 
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colleagues in 1989 (Ferrara and Henzel 1989). VEGF is a homodimeric 
glycoprotein with an approximate molecular weight of 45 kDa. It belongs to a 
family of structurally related mitogen known as platelet-derived growth factor 
(PDGF) (Carmeliet 2005). The VEGF family consists of six secreted 
glycoproteins known as VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and 
placenta growth factor (PlGF-1 and PlGF-2) all of which are derived from distinct 
genes (Hicklin and Ellis 2005).  
 
VEGF-A has been indicated to play the most critical role in the regulation 
of angiogenesis (Ferrara, Carver-Moore et al. 1996) whereas the vascular effect 
of the other VEGF in the family members remain to be fully characterized 
(Ferrara and Davis-Smyth 1997, Ferrara 1999, Ferrara 2001). Initially, two 
VEGF receptors were identified on endothelial cells and characterized as the 
specific tyrosine kinase receptors VEGFR-1 and VEGFR-2 (Shibuya, 
Yamaguchi et al. 1990, Terman, Dougher-Vermazen et al. 1992), and several 
years after that another tyrosine kinase receptors known as VEGFR-3 was 
identified and has been found to play major role in lymphangiogenesis 
(Kaipainen, Korhonen et al. 1995, Paavonen, Puolakkainen et al. 2000). All 
VEGF family members have different binding affinity towards these receptors, 
and this characteristic has helped to elucidate their specific functions. All of the 
isoforms of VEGF-A can bind to both VEGFR-1 and VEGFR-2, while the 
naturally occurring heterodimers of VEGF-A has been shown to have higher 
binding affinity towards VEGFR-2 (DiSalvo, Bayne et al. 1995, Cao, Chen et al. 
1996).  
 
Since VEGF-A has the ability to bind to both VEGFR-1 and VEGFR-2 
receptors, questions has been asked about which receptor activation could lead 
to direct effect on tumor cells angiogenesis. A consensus has been reached on 
this matter as studies show that VEGFR-2 is the major mediator of angiogenesis 
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process (Ferrara 2004). Even though VEGFR-1 is said not to have direct effect 
on mitogenesis and angiogenesis, but it might act as a decoy receptor that 
sequesters VEGF and prevents its interaction with VEGFR-2 (Park, Chen et al. 
1994).  
 
Angiogenesis or also known as neovascularization, is very important in 
human cancers and it has been specifically linked to increased tumor growth 
and metastatic potential (Ferrara 2002). Figure 2.10 summarizes the role played 
by VEGF/VEGFR in tumor cells angiogenesis. Overexpression of VEGF mRNA 
has been observed in various human tumors including lung, breast, prostate, 
gastrointestinal tract, renal, and ovarian carcinomas through in situ hybridization 
studies (Yoshiji, Gomez et al. 1996, Ferrer, Miller et al. 1997, Sowter, Corps et 
al. 1997, Volm, Koomägi et al. 1997, Ellis, Takahashi et al. 1998, Tomisawa, 
Tokunaga et al. 1999). The expression of VEGF ligands in tumor cells supported 
the hypothesis that claimed that VEGF supports the growth of tumor cells not 
only by inducing angiogenesis but also through their direct action on VEGFRs 
that created a VEGF/VEGFR autocrine loop, which induces tumor growth arrest 
and apoptosis when disrupted (Hicklin and Ellis 2005). Studies conducted by 
Warren, Yuan et al. (1995) has demonstrated that in an in vivo mouse colon 
cancer model of liver metastasis, a significant decrease in the size of tumor was 
achieved after the treatment with anti-VEGF monoclonal antibodies. Another 
studies also show that a significant decreased in tumor size and prolonged 
survival were achieved in mice bearing human leukaemias xenograft after 
treatment with antibodies that function by blocking the VEGFR-2 receptor (Dias, 
Hattori et al. 2001). Therefore, the results from all these studies clearly 
demonstrate that angiogenesis is VEGF-dependent and finding bioactive 
compound/s that could block VEGFs and its receptors or both could reduce or 
prevent tumor cell angiogenesis. 
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Figure 2.10  Role of VEGF/VEGFR in tumor cells angiogenesis. The expression of VEGF 
ligands on tumor cells or host stromal cells stimulate the VEGFR1 and VEGFR2 on 
endothelial cells and lead to the activation of tumor cells proliferation, migration, survival 
and vascular permeability. Adapted from “Role of the Vascular Endothelial Growth Factor 
Pathway in Tumor Growth and Angiogenesis” by D. J. Hicklin and L. M. Ellis, 2005, 
Journal of Clinical Oncology (2005) 23 (5), 1011-1027. Copyright 2005 by American 
Society of Clinical Oncology. Adapted with permission. 
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2.3 Modern trends in the use of natural products in cancer 
prevention and treatment 
Chemical substances derived from natural products including plants, 
animals and microbes have played a vital role in cancer chemotheraphy for the 
past 30 years (Mann 2002). Plants have been used by almost all cultures and 
communities in the world due to their continous role as important source of 
bioactive compounds not just for cancer therapy but other diseases as well 
(Challand and Willcox 2009). Harwell (1982) has produced an extensive review 
that listed almost 3000 plants species that have been reported to be used in the 
treatment of cancer. However, in many instances, the term ‘cancer’ is undefined 
or reference is made to conditions such as abcesses, ‘hard-swelling’, calluses, 
wart, polyps or tumors. But many of the claims for efficacy should be viewed 
with extreme skepticisim because cancer as a disease is likely to be poorly 
defined in terms of folklore and traditional medicine (Cragg and Newman 2005).  
 
For example, the roots of mayapple, Podophyllum peltatum for example, 
have been used by the American Indians to treat skin cancer and venereal 
warts. The main chemical constituent in this plant is known as podophyllotoxin. 
This chemical belongs to the anticancer agent group known as podophyllins 
which includes other bioactive compounds such as etoposide and teniposide 
(Mann 2002). Similarly, a plant known as Catharanthus roseus has been used 
as hypoglycaemic agent in many parts of Asia, but it was not until 1958 that its 
two main constituents known as vinblastine and vincristine were discovered to 
have potent cytotoxic activities against cancer cells (Roussi, Guéritte et al. 
2012). These discoveries encouraged the National Cancer Institute (NCI) to 
launch a large-scale screening programme to look for antitumor agents (Zubrod 
1984). 35,000 plant samples were evaluated primarily against the mouse 
leukaemia cell line, L1210 and P388, between 1960 and 1982 in this large-scale 
study. The most significant drug produced from this huge study was Taxol, 
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which was obtained from the bark of the Pacific yew Taxus brevifolia. (Kingston 
2005). Positive outcomes from this massive screening programme have 
encouraged the National Cancer Institute to start a new programme in 1985 in 
which extracts from plants, animals and microorganisms were screened against 
a panel of 60 human cancer cells line including prostate, breast, lung, colon, 
kidney, skin, ovary and brain cancer. Due to this giant quest to find new 
anticancer drugs, almost 50% of the approved drugs during the last 30 years 
(1981-2010) are derived either directly or indirectly from natural products 
(Newman and Cragg 2012). 
 
The above examples, although compelling for the case of natural products 
as effective sources of anticancer therapies; represent extremely expensive 
approaches. It also yields non-readily available therapies for much of the world 
populations. This makes equally compelling the case for high quality extracts 
standardized on proven anticancer phytochemicals, which may be put in the 
market at a reduced price with chemopreventives indications, thus making the 
final products more accessible to the public even in developing countries. 
 
Saw palmetto berry is a perfect example for this as it is widely used for the 
treatment of benign prostatic hyperplasia (BPH), often as an alternative to 
pharmaceutical agents. Although pathologically, BPH is not considered as a 
precursor for prostate cancer, approximately 83% of prostate cancer incidence 
occur in men with BPH (Bostwick, Cooner et al. 1992, Chokkalingam, Nyrén et 
al. 2003) and both conditions share common risk factors and respond to anti-
androgen therapy. Saw palmetto is a palm plant that is commonly found along 
the Atlantic and Gulf coast of the USA. The large berries produced by the plant 
are highly enriched in fatty acids, phytosterols, and flavonoids (Schantz, Bedner 
et al. 2008). Numerous clinical trials had been conducted to evaluate the 
effectiveness of the extract of the fruits in treating BPH (Bent and Ko 2004, 
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Gerber and Fitzpatrick 2004, Bonnar-Pizzorno, Littman et al. 2006), and based 
on the positive results of these clinical trials, saw palmetto was developed as a 
whole extract with no single active ingredient unlike any other conventional drug. 
It has been marketed as a dietary supplement to treat enlarged prostate. In 
continental Europe, saw palmetto is available as a Full Licensed Medicine 
(Permixon®) but also available as a Traditional Medicine (THMP) (Prostasan®) 
as well as food supplement without explicit indications but obviously transporting 
onto the health conscious consumer the hidden message of prostate health. 
Outside Europe, the market drastically splits into Food or Drug leaving Saw 
Palmetto manufacturers and consumers with the food supplement pathway as 
the sole way to bring this obviously efficacious natural product to the public  
 
Approximately 2.5 millions adult in the United States were reported to use 
saw palmetto in a National Survey conducted in 2002 (Barnes, Powell-Griner et 
al. 2004). It is also very popular in Europe as half of German urologist prefers 
prescribing plant-based extracts to synthetic drugs (Lowe and Ku 1996, Bent , 
Kane  et al. 2006). Saw palmetto is available in the market as encapsulated 
capsule, powdered berries and gel capsules containing liquid extract. This 
extract is thought to treat BPH by inhibiting the 5-α-reductase enzyme (Bayne, 
Donnelly et al. 1999, Habib, Ross et al. 2005), which is similar to finasteride, a 
popular chemopreventive used in prostate cancer therapy, as explained in 
section 2.1.5.1. Several studies were conducted to investigate whether saw 
palmetto is active against prostate cancer and these studies showed that the 
lipidosterolic extract of saw palmetto appears to inhibit LNCaP, PC3, 267B-1, 
and BRFF-41T prostate cancer cell line in-vitro when treated with physiologically 
plausible doses (Goldmann, Sharma et al. 2001, Iguchi, Okumura et al. 2001, 
Hill and Kyprianou 2004). The inhibition of the prostate cancer cell lines occurs 
through several different mechanism including apoptosis, necrosis, and growth 
inhibition (Goldmann, Sharma et al. 2001, Iguchi, Okumura et al. 2001). 
However, no studies have been conducted to examine the activity of saw 
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palmetto in any animal models. The development of saw palmetto as an agent 
to promote prostate health could be a good example on how the active extracts 
of both Marantodes pumilum and Ficus deltoidea plants can be introduced into 
the market in the near future.  
 
2.3.1 R & D of Anticancer drugs from natural products 
The process of developing a new drug is complex, time consuming and 
very expensive. Normally it takes around 12 years from the discovery of a new 
drug in laboratory settings to its application in human diseases. It also involves 
more than 1 billion USD of investment in today’s context in order to develop a 
new drug from laboratories to clinics (Katiyar, Gupta et al. 2012). Drug 
development process in current pharmaceutical settings can be divided into 7 
phases namely: 1) Preclinical research, 2) Investigational New Drug (IND) 
application, 3) Phase 1 trials, 4) Phase 2 trials, 5) Phase 3 trials, 6) New Drug 
Application (NDA), and 7) Approval.  
 
In the case of natural products, drug discovery process started with 
rigorous screening procedures using different species of plants on a panel of 
different cancer cell lines (Monks, Scudiero et al. 1991). Different approaches 
can be used for screening of plants to be tested against cancer cell lines. These 
approaches include random approach, ethnopharmacology approach (Ganesan 
2008), traditional system of medicine approach and zoo-pharmacognosy 
approach (Katiyar, Gupta et al. 2012). Once the task of screening potential 
candidates is over, the next steps include; 1) screening of biological activity 
using selective assays, 2) Bioguided fractionation of the identified plant, 3) 
Isolation and structure elucidation of the active compounds, 4) Evaluation of 
chemical do-ability, druggability, and patentability, 5) Decisions based on safety 
and biological activity screening(Katiyar, Gupta et al. 2012). This process is 
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considered as the preclinical research phase mentioned earlier. Once this phase 
is completed, the potential drug needs to go through 6 remaining phases for 
drug development before it can reach clinics for human application.  
 
However, due to low succes rate of finding new chemical entities (NCE) by 
following this conventional approach, maybe now is the right time for large-scale 
pharmaceutical organizations to open up the developmental strategies and 
adopt nutraceuticals approach (Section 2.3.2). This approach that allows the 
development of herbal extracts hitting multiple targets as new drugs should be 
given serious consideration. This strategy will not only reduce developmental 
cost, but would also enhance the chances of success in terms of providing 
effective and safe drugs as well as minimizing the risk of post-marketing 
withdrawal. In this study, the active extracts of the plants will be characterized 
and the bioactive compounds responsible for the inhibition of prostate cancer 
cells growth will be used as markers for future standardization of the extract. 
However, before the standardized active extracts could reach the market for 
human consumption, additional studies are required to be carried out to 
investigate the efficacy of the standardized extract on relevant animal models as 
well as following the regulations set for nutraceuticals development in the 
targeted market.  
 
2.3.2 R & D of nutraceuticals for prostate health 
The term ‘nutraceuticals’ was first introduced in 1989 by the founder and 
chairman of the Foundation for Innovation in Medicine (FIM), Dr Stephen 
DeFlice. It is a term derived from ‘nutrition’ and ‘pharmaceuticals’ and is defined 
as any substance that is food or part of a food that provide medical or health 
benefits, including prevention and/or treatment of a disease. Recently, the use of 
nutraceuticals in prostate disease is becoming more popular. Approximately 
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30% of men diagnosed with prostate disease in North America were reported to 
use some complementary and alternative medical (CAM) therapy or 
nutraceuticals products (Lee, Chang et al. 2002, Chan, Elkin et al. 2005). 
Prostate cancer develops over a long period of time thus making it suitable for 
primary, secondary and tertiary prevention strategies (Trottier, Bostrom et al. 
2010). This is one of the reasons why CAM and nutraceuticals are becoming 
very popular to promote prostate health. Besides that, nutraceuticals are not 
regulated in the same way as drugs are, as they are classified according to 
different food categories. The regulations for nutraceuticals also vary from one 
country to another and not as stringent as medicines. This lowers their cost of 
production and development, so the population can use them in appreciable 
amounts to prevent diseases. Consequently, the global use and trade of 
nutraceuticals has boomed in recent years and investment in this sector is very 
attractive to pharmaceuticals companies, for example Glaxosmithkline (GSK) 
has Benecol® for lowering cholesterol and Bayer markets Iberogast® for 
functional dyspepsia. 
 
 The most popular dietary approaches to promote healthy prostate include 
popular nutraceuticals such as saw palmetto (Section 2.3), Pygeum africanum, 
phytosterols, rye pollen extract (eg, Cernilton®, Graminex LLC, Saginaw) and 
vitamins and minerals, such as vitamin E and selenium (Curtis Nickel, Shoskes 
et al. 2008). Despite the lack of stringent regulations associated with the 
production and development of nutraceuticals, sound research practices are 
required in order to provide high quality products backed by scientific evidence. 
Therefore, it is very common to see scientists involved in pre-clinical research as 
part of the development of nutraceuticals. Following this step, some might 
choose to continue testing the efficacy of the nutraceuticals on relevant animal 
models while the others could directly release the product into the market 
providing that the regulations for nutraceuticals development in that specific 
country or region are strictly followed. For example, in the US, nutraceuticals are 
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monitored as ‘dietary supplements’ according to the Dietary Supplement, Health 
and Education Act (DSHEA) of 1994 (Coppens, Da Silva et al. 2006). The 
DSHEA establishes that manufacturers are responsible for the safety evaluation 
of the product and if a new ingredient was to be introduced into the product, they 
must inform FDA that the new ingredient ‘can reasonably be expected to be 
safe’ at least 75 days before going to the market. In the European Union (EU), a 
specific law regulating nutraceuticals does not exist, however if a claim was 
made that implies medicinal benefit for a nutraceutical product, the product 
needs to comply with the regulatory requirements for medicinal products in 
respect of safety, efficacy, quality testing and marketing authorization 
procedures (Coppens, Da Silva et al. 2006). EU regulations also state that the 
beneficial effects of nutraceuticals can only be ‘health claim’ and not ‘medicinal 
claim’. In Malaysia, no specific law on nutraceuticals exists, however they are 
monitored under the Malaysia’s Food Act 1983 and the Food Regulations of 
1985, which govern food safety and quality control, including food standards, 
hygiene, import and export activities, advertisement and accreditation of 
laboratories (Arora, Sharma et al. 2013). This law is enforced by the Food 
Safety and Quality Division (FSQD) of the Ministry of Health (MOH).  
 
 Despite the lack of stringent regulations for nutraceuticals development, 
this should not be an excuse for scientists and manufacturers to ignore good 
research practice to ensure production of high quality nutraceuticals backed by 
scientific evidence. 
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2.3.3 Development of Natural Anticancer Products from Malay 
Biodiversity 
With the global resurgence of interest for natural remedies as a 
commodity, Malaysia is looking towards capitalizing on its megabiodiversity, 
which includes the oldest rain forest in the world and an estimated 1,200 
medicinal plants. To harness this potential, a “Herbal Development Office” has 
been formed under the Ministry of Agriculture (MoA). It outlines the strategic 
direction, policies and regulation of research and development (R&D) clusters 
focusing on the discovery, crop production and agronomy, standardization and 
product development, toxicology/pre-clinical and clinical studies, and processing 
technology. Preference has been given to a subset of 11 traditional plant 
species with high economic potential. This list includes the two plants selected 
for this project namely Marantodes pumilum (Blume) Kuntze (synonym Labisia 
pumila var pumila) and Ficus deltoidea L. Given that Malaysia is mostly an 
agricultural country, sufficient supply of raw materials for research and 
development (R&D) is ensured. Moreover, its multi-ethnic population facilitates 
clinical trials which results can be extrapolated to many other markets. With this 
in mind, and to promote and protect the growth of a local herbal industry, 
endemic species and varieties of these medicinal plants are under active study 
to derive high value herbal supplements and remedies (Malaysian Ministry of 
Agriculture, 2011). 
Phytochemical research previously conducted on both of the selected plant 
species showed that they contain phytochemicals linked to cancer prevention: 
flavonols such as epigallocatechins, phenolic acids such as gallic acids and 
phytoestrogens among others. Therefore, this project aims to investigate the 
effect of these phytochemicals on prostate cancer cells, isolate and identify the 
bioactive compound/s providing maximum efficacy and characterize the 
mechanism of actions that lead to prostate cancer cells growth inhibition. 
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2.4 Marantodes pumilum (Blume) Kuntze 
 
2.4.1 Traditional Use  
 Marantodes pumilum (Blume) Kuntze (Figure 2.11 and Figure 2.12) 
(synonym Labisia pumila var pumila) belongs to Myrsinaceae family, locally 
known as Kacip Fatimah, is a herb that has been widely used in South East 
Asian communities for a variety of illnesses and also as health supplements 
(Jamal, Houghton et al. 2003). It is an indigenous medicinal herb of Malaysia 
and sometimes also referred locally as Akar Fatimah, Selusoh Fatimah, Tadah 
Matahari, Rumput Siti Fatimah, Bunga Belangkas Hutan and Pokok Pinggang 
There are three varieties of Marantodes pumilum, i.e. Marantodes pumilum var. 
alata, Marantodes pumilum var. pumila and Marantodes pumilum var. 
lanceolata. Each variety has their respective use and local healers tend to use 
var alata and var pumila traditionally (Ibrahim and Jaafar 2011). This herb’s 
extract is prepared by boiling the roots, leaves or the whole plant with water and 
the extract is taken orally (Jamal, Houghton et al. 2003, Ibrahim and Jaafar 
2011).  The decoction of the roots is also given to pregnant women between one 
or two months before delivery, as this is believed to induce and expedite labour. 
It has also been widely used with a long history by women in Malaysia to treat 
post-partum illnesses, to assist contraction of the birth channel, shrink the 
uterus, improve menstrual cycle, and weight loss (Jamal, Houghton et al. 2003). 
It was also reported that Marantodes pumilum can be used for delaying fertility 
and to regain body strength; while some other folkloric uses include treatment of 
flatulence, dysentery, dysmenorrhoea, gonorrhoea and “sickness in the bones”. 
Due to its various applications, hence Marantodes pumilum is known as “queen 
of plants” of all Malaysian herbs. 
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Figure 2.11  Marantodes pumilum (Blume) Kuntze plant 
Figure 2.12  The farming of Marantodes pumilum (Blume) Kuntze plant in Malaysia 
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2.4.2 Anticancer Phytochemicals 
 Al-Mekhlafi, Shaari et al. (2012), described the anti-proliferative 
properties of Marantodes pumilum extracts against different types of cancer 
cells. In this study, 4 compounds isolated from the leaves of Marantodes 
pumilum namely 1-O-methyl-6-acetoxy-5-(pentadec-10Z-enyl)resorcinol (1), 
labisiaquinone A (2) , labisiaquinone B (3), and 1-O-methyl-6-acetoxy-5-
pentadecylresorcinol (4) (Figure 2.13) showed strong cytotoxicity activity against 
3 different cancer cell lines, PC3 (prostate), HCT116 (colon) and MCF-7 (breast) 
with very low IC50 value (<10 µM). These 4 compounds also exhibited strong 
selectivity for PC3 and HCT116 relative to MCF-7. Moreover, the presence of 
certain phytochemicals such as favonols (catechin and epigallocatechin), 
phenolic acids (gallic acid, coumaric acid), flavanols (quercetin, myricetin) 
(Figure 2.14) and phytoestrogens indicate that the use of this plant could be 
expanded for other pharmacological applications (Chua, Lee et al. 2012). Other 
studies using plants containing similar phytochemical compounds have clearly 
demonstrated their anticancer properties by addressing some of the hallmarks of 
cancer. Gallic acid is identified as the major anticancer compound in T. sinesis 
leaf extract. Studies conducted using this extract have shown that gallic acid is 
cytotoxic against DU145 prostate cancer cells through generation of reactive 
oxygen species (ROS). It is also capable of blocking the growth of DU145 cells 
at G2/M phases by activating Chk1 and Chk2 and inhibiting Cdc25C and Cdc2 
(Huei et al., 2009). 
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Figure 2.13  The chemical structure of the known phytochemicals in Marantodes pumilum 
with anticancer activity 
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(5)                                                            (6) 
                     
(7)                                                        (8) 
                     
(9)                                                    (10) 
Figure 2.14  The chemical structure of the known phytochemicals in Marantodes 
pumilum. (5) Catechin, (6) Epigallocatechin, (7) Gallic Acid, (8) Coumaric Acid, (9) 
Quercetin and (10) Myricetin 
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 Another phytochemical compound available in Marantodes pumilum, 
epigallocatechin, has been shown to have anticancer properties on another 
prostate cancer cell line PC-3. This study has indicated that epigallocatechin 
was able to inhibit PC-3 prostate cancer cell proliferation via MEK-independent 
ERK1/2 activation (Albrecht, Clubbs et al. 2008).  
 
The regulation of estrogen receptor alpha (ERalpha) and estrogen receptor 
beta (ERbeta) is very important in prostate cancer prevention (Pravettoni, 
Mornati et al. 2007). One of the phytochemical compounds that can mimic the 
action of estrogen in inhibiting the growth of prostate cancer cell line is 
phytoestrogens. Research has shown that one of the most important 
phytochemical compounds in Marantodes pumilum extract is the phytoestrogen 
(Adlercreutz 2002). Early biological studies on the activity of the phytoestrogen 
in soy (isoflavones) have demonstrated that phytoestrogen has the ability to 
upregulate estrogen receptor beta (ERbeta) and downregulate estrogen 
receptor alpha (ERalpha), which then lead to the inhibition of prostate cancer 
cell proliferation (Hussain, Banerjee et al. 2003). Therefore, it is believed that, 
the phytoestrogen content in Marantodes pumilum plant extract could also 
cause similar action, which might lead to the death of the cancer cells. With that 
in mind, this study aims to investigate the potential of Marantodes pumilum 
(Blume) Kuntze extract in prostate cancer prevention and characterize the 
mechanism involved in inhibiting prostate cancer cell proliferation leading to 
cancer cell death. 
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2.5 Ficus deltoidea L. 
 
2.5.1 Traditional Use  
 Ficus deltoidea is a native shrub, which belongs to the family of Moracea 
(Figure 2.15). The plant is characterized by the evergreen small tree or shrub 
and in the wild the plant can reach around 5-7 meters tall. This species of plant 
can normally be found in south-east Asian countries including Malaysia, 
Indonesia and southern Phillipines. It is commonly known as “Mas Cotek” in the 
peninsular Malaysia and people in east Malaysia normally refer to this plant as 
“sempit-sempit” and “agolaran” (Berg 2003). This plant plays a vital role in 
traditional medicine, where different parts of the plant is used for the treatment 
of several ailments such as the relief of headache (fruit part), toothache (fruit 
part), and sores and wound (roots and leaves). Women consume the decoction 
of boiled leaves of Ficus deltoidea as an after-birth treatment to contract the 
uterus and vaginal muscles besides treating the disorders of the menstrual cycle 
and leucorrhoea (Burkill and Haniff 1930).  Even though, the plant has a lot of 
important applications traditionally, only few studies have been conducted to 
explore its potential pharmacological properties. Abdullah, Karsani et al. (2008), 
reported that the fruit extract of Ficus deltoidea showed inhibitory effects against 
Angiotensin-I converting enzyme (ACE) enzyme. This finding suggested that the 
fruit extract has antihypertensive properties. Moreover, tea prepared from Ficus 
deltoidea showed high potential in reducing total cholesterol level, LDL-
cholesterol and the risk of cardiovascular disease by lowering the antherogenic 
index (LDL/HDL ratio) and increasing the percentage of HDL/total cholesterol 
ratio (Hadijah, Normah et al. 2007). This study also finds no sign of cytotoxicity 
in rats based on a sub-acute toxicity study. 
 
		 97 
 
Figure 2.15  Ficus deltoidea  plant 
 
2.5.2 Anticancer Phytochemicals 
 Flavonoids is one of the phytochemical compounds that can be found in 
abundance in Ficus deltoidea which includes gallocatechin, epigallocatechin, 
catechin, luteolin-8-C-glucoside, 4-p-coumaroylquinic acid, orientin, vitexin, 
isovitexin, rutin, quercetin and naringenin (Figure 2.16 and Figure 2.17) 
(Bunawan, Amin et al. 2014). The presence of these phytochemicals gives its 
yellow pigmentation, and many studies confirmed that any herbs containing 
flavonoids could have the ability to acts as anti inflammatory, anti allergy, anti 
cancer and anti microbial agents, so this explain how the plant is able to protect 
itself from insects and microorganism (Abdullah, Hussain et al. 2009, Uyub, 
Nwachukwu et al. 2010, Akhir, Chua et al. 2011, Zakaria, Hussain et al. 2012). 
As mentioned earlier flavonoids such as epigallocatechin has the ability to inhibit 
PC3 prostate cancer cell line. Zhou, Liu et al. (2009) has reported that vitexin 
showed cytotoxic effect on breast, ovarian and prostate cancer cells by inducing 
apoptosis with the cleavage of PARP protein, up-regulation of Bax and 
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downregulation of Bcl-2. Rutin, quercetin and orientin have been reported to 
have anticancer properties by inducing apoptosis in murine leukemia WEHI-3 
cells (rutin) (Lin, Yang et al. 2012), human lung cancer cell line A-549 
(quercetin) (Zheng, Li et al. 2012), and human cervical carcinoma cells, HeLa 
(orientin) (Guo, Tian et al. 2014). Ficus species containing 
phenanthroindolizidine alkaloids and a series of triterpenoids with C-28 
carboxylic acid functional groups are reported to be very strong cytotoxic 
compounds. Triterpenoids, isolated from the aerial roots of Ficus microcarpa 
demonstrated cytotoxicity in three human cancer cell lines with IC50 values from 
4.0 to 9.4 µM, including HONE-1 nasopharyngeal carcinoma cells, KB oral 
epidermoid carcinoma cells, and HT29 colorectal carcinoma cells (Chiang and 
Kuo 2002, Chiang, Chang et al. 2005). In a study by Akhir, Chua et al. (2011), 
they found that both aqueous and ethanolic extracts of Ficus deltoidea extracts 
gave IC50 value of 224.39 + 6.24 µg/ml and 143.03 ± 20.21 µg/ml respectively. 
The aqueous extract caused the detachment of the cancer cell as observed by 
cell viability assay. While DNA fragmentation was not detectable after treatment 
with the aqueous extract, but at 1000 µg/ml of the ethanolic extract DNA 
fragmentation occurred around 200 Kbp (Akhir, Chua et al. 2011). Therefore, 
this study aims to investigate the anticancer properties of Ficus deltoidea plant 
extracts and three other varieties of the plants on human prostate cancer cell 
lines. 
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(11)                                                            (12) 
                     
(13)                                                          (14) 
 
(15) 
Figure 2.16  The chemical structure of the known phytochemicals in Ficus deltoidea (11) 
Gallocatechin, (12) Epigallocatechin, (13) Catechin, (14) Naringenin and (15) Quercetin. 
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(16)                                                                (17) 
 
                     
(18)                                                                (19) 
 
 
(20) 
 
Figure 2.17  Chemical structure of known phytochemical in Ficus deltoidea (16) Vitexin, 
(17) 4-p-coumaroylquinic acid, (18) Orientin, (19) Rutin and (20) Isovitexin 
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3 Materials and Methods 
3.1 Plant Material 
Plant materials used in this research were acquired by the Institute of 
Bioproduct Development (IBD), Universiti Teknologi Malaysia (UTM), from a 
local farm (Johor, Malaysia) over the period of September 2013 to February 
2014 (Table 3.1). A Pharmacognosist at Universiti Putra Malaysia (UPM), 
Malaysia, identified the plant materials and Vouchers were deposited at IBD. 
Table 3.1  Plant Species, Voucher Number and Local names 
Voucher 
Number 
Code Family 
Name 
Scientific Name Local Name Parts 
SK 
2308/13 
MP Primulaceae Marantodes 
pumilum  (Blume) 
Kuntze (synonym 
Labisia pumila var. 
pumila) 
Kacip 
Fatimah 
Aerial 
SK 
2309/13 
FD1 Moraceae Ficus deltoidea var. 
angustifolia (Miq.) 
Corner 
Mas Cotek Aerial 
SK 
2310/13 
FD2 Moraceae Ficus deltoidea 
Jack var. deltoidea 
Mas Cotek Aerial 
SK 
2311/13 
FD3 Moraceae Ficus deltoidea 
Jack var. deltoidea 
Mas Cotek Roots 
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3.1.1 Plant Extraction 
Samples were processed using a laboratory scale mill until fine powder 
was produced at IBD. The air-dried and powdered parts of different amount of 
plants (± 50 g) were extracted at the UCL School of Pharmacy with methanol for 
72 hours via a maceration process. The crude extracts were obtained after the 
evaporation of the methanol to complete dryness under reduced pressure at 
40°C. The crude methanol extracts was re-dissolved in 90% methanol and 
subjected to liquid-liquid partition with n-hexane for three times (100 ml each 
time) to yield the n-hexane extracts (MPh, FD1h, FD2h). The aqueous phase 
was further partitioned with chloroform and ethyl acetate to give the chloroform 
(MPc, FD1c, FD2c) and aqueous extracts (MPa, FD1a, FD2a). This procedure 
was repeated three times. The n-hexane and chloroform extracts were collected 
and concentrated by using rotary evaporator under reduced pressure at 40°C. 
Water in the aqueous extracts was removed by freeze-drying overnight to 
produce dried extracts. These dried extracts were then stored at -20°C until 
required for further testing.  
 
3.1.2 Fractionation of plant extracts 
A sample (500 mg) of the crude chloroform extract was suspended in 2 mL 
of absolute methanol and applied onto a chromatographic column (2.3 x 40 cm) 
packed with Sephadex LH-20 (GE Healthcare, UK) and equilibrated with 
absolute methanol. The column was exhaustively washed with absolute 
methanol. The sample was eluted with absolute methanol at a flow rate of 4 
mL/min and 6 mL fractions were collected using a Retriever ® II fraction collector 
in soda glass test tubes. 140 fractions were collected for each plant extract.  
Eluates were then pooled into major fractions based on the TLC profiles. After 
evaporation of methanol, the samples were left to air-dried and residues 
weighed. 
		 104 
3.1.3 Thin Layer Chromatography (TLC) 
All fractions were examined by a thin layer chromatography (TLC) 
methodology on silica gel plates (TLC Silica gel 60 F254, Merck KGaG, 64271 
Darmstadt) using (a) Chloroform-Methanol (80:20, v/v) as mobile phase. The 
bands were visualized at white light, 254 nm and 366 nm wavelengths before 
and after derivatization with anisaldehyde using CAMAG TLC Visualizer.  
 
3.1.4 Preparation of stock solution of extracts and fractions 
Stock solutions for each plant extracts and fractions were prepared by 
dissolving them in Dimethyl sulfoxide (DMSO) Cell culture grade (Sigma-
Aldrich©, UK) at a concentration of 50 mg/ml. All plant extracts and fractions 
were cold sterilized using a syringe-driven filter (pore size: 0.2 µm) (Millex ®) in 
a laminar flow cabinet before being used for cell-based assays. 
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3.2 Cell Lines 
 The following tumour cell lines were used: the PC3 cell line (ATCC 
Number: CRL-1435™) was kindly provided by Dr Cyrill Bussy (Centre for Drug 
Delivery Research, UCL School of Pharmacy, UK), the DU145 cell line (ATCC 
Number: HTB-81™) was purchased from Sigma Aldrich UK, and was obtained 
from the American Type Culture Collection (ATCC) and the LNCaP clone FGC 
cell line (ATCC Number: CRL-1740™) was purchased from Sigma Aldrich UK, 
and was obtained from the American Type Culture Collection (ATCC). Human 
Dermal Fibroblasts, adult (HDFa) catalogue number C-013-5C was kindly 
provided by Dr George Pasparakis (Department of Pharmaceutics, UCL School 
of Pharmacy), this cell line has been used for specificity study as it is not a 
tumour cell line. All tumour cell lines were used for the cytotoxicity, and PC3 cell 
line was used for mechanistic studies including apoptosis, cell cycle analyses, 
migration and invasion studies. All cell lines are adherent cells that tend to grow 
as monolayer and are classified as Biosafety Level 1. Three cell lines were used 
because of the different characteristics of each cell lines, which are important in 
order to achieve the objectives and aims of this study. LNCaP cells have 
androgen receptors that are functional enabling them to be androgen sensitive 
and these cells also secrete prostate-specific antigen (PSA). Both PC3 and 
DU145 cells are androgen independent but PC3 cells are highly invasive with 
strong metastatic potential as compared to DU145 cells. 
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3.3 Cell Culture Protocols 
 
3.3.1 Sub-culture and Routine Maintenance  
 Both PC3 and LNCaP cell lines were grown in a cell culture flask (Nunc), 
surface area 75 cm2 and maintained in RPMI-1640 (Roswell Park Memorial 
Institute medium) (Lonza, BE12-702F) containing L-glutamine. The media was 
supplemented with 10% of heat-inactivated fetal bovine serum (FBS) (Gibco®, 
10500-064) and 1% penicillin-streptomycin antibiotics containing 10000 Units/ml 
of penicillin and 10000 µg/ml streptomycin (Gibco®, 15140-122) to prevent 
bacterial growth. DU145 cell line was grown in a cell culture flask (Nunc), 
surface area 75 cm2 and maintained in EMEM (Eagle’s Minimum Essential 
Medium) (Sigma, M4655) containing Earle’s salt, L-glutamine and Sodium 
bicarbonate. The media was supplemented with 10% of heat-inactivated fetal 
bovine serum (FBS) (Gibco®, 10500-064) and 1% penicillin-streptomycin 
antibiotics containing 10000 Units/ml of penicillin and 10000 µg/ml streptomycin 
(Gibco®, 15140-122) to prevent bacterial growth. HDFa cell line was grown in a 
cell culture flask (Nunc), surface area 75 cm2 and maintained in DMEM 
(Dulbecco’s Modified Eagle Medium) containing L-Glutamine and high glucose 
(Gibco® 11965092). The media was supplemented with 10% of heat-inactivated 
fetal bovine serum (FBS) (Gibco®, 10500-064), 1% 100X NEAA (non-essential 
amino acids, Gibco® 11140035), and 0.1% of both 10 mg/mL Gentamicin 
solution 1000X (Gibco® 15710049) and 250 ug/mL Amphotericin B solution 
1000X (Gibco® 15290018) to prevent bacterial growth. All cells were maintained 
at 37ºC in a humidified atmosphere of 5% CO2. The prepared media was used 
to grow and seed the cells in a 96-well plate (Nunclon™) for cellular based 
assays and for plant extracts as well as fractions dilution. 
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3.3.2 Cell passaging/sub-culturing 
The growth media was changed every 2-3 days and all cell lines were 
sub-cultured every 3-4 days when the monolayer culture of the cells has 
reached almost 70-80% confluency. The cells were split into ratios of 1:3, 1:4 or 
1:8. The media used in this monolayer culture was aspirated before the flasks 
were rinsed gently with 10 ml Phosphate buffered saline (PBS) pH 7.4 (Gibco, 
10010-056). This procedure was done in order to remove traces of serum, which 
could cause inhibition to the action of tyrpsin. After that, the wash solution was 
removed and 1 ml of 0.25% trypsin EDTA (Gibco, 25200-056) was added. The 
0.25% trypsin EDTA will act as a dissociation agent. The flask containing the cell 
lines was incubated for 5 minutes at 37ºC in 5% CO2. When the cells were 
ready, the cells began to change and transform into rounded shapes and 
detached from the surface of the flasks. These changes were observed by using 
an inverted microscope. After cell detachment, the proteolytic activity of trypsin 
was inhibited by the addition of 3 ml of growth media. A suitable amount of cell 
suspension, depending on the split ratio was transferred to a flask containing 
20ml of pre-warmed media. The flask containing the cells was labelled with the 
cell name, passage number and date and was then carefully placed in an 
incubator (NuAire™ Autoflow CO2 Air-Jacketed Incubator, NuAir Inc.) with 
humidified air of 5% CO2 and atmosphere at 37ºC (Wang 2006). 
 
3.3.3 Cell Counting and Cell Viability 
 The dye exclusion test is normally used in cell culture to determine the 
number of viable cells present in a cell suspension. This method is based on the 
principle that live cells possess intact cell membrane, which will exclude certain 
dyes whereas dead cells do not. In this study, Trypan blue exclusion test using 
Neubauer improved bright-line haemocytometer (FORTUNA®, Germany) (Figure 
3.1) was used for cell counting. Trypan blue (Gibco, 15250-061) is excluded by 
live cells but accumulates in dead cells. A clear coverslip was placed on a 
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haemocytometer slide. 50 µL of cell suspension was mixed with 50 µL trypan 
blue. The cell suspension mixture was carefully transferred to the edge of the 
coverslip. The number of stained (non-viable) cells and non-stained (viable) cells 
were counted under an inverted microscope. Concentration of viable cells and 
the percentage of viable cells are calculated using the following formula: 
Cells/ml = the average count per square x dilution factor x 10 4 
Total cells = cell/ml x original volume from which sample is removed 
The percentage viability is calculated as shown below: 
Percentage viability = Number of unstained cells×100 Total number of stained and unstained  
 This test was used to count cells for experimental setup and also for the 
proliferation analysis of all cell lines in 75 cm2 T- flask (Wang 2006). 
 
Figure 3.1  Haemocytometer (improved Neubauer), magnified view of the total area of the 
grid showing viable cells as unstained and clear, with a refractile ring around them and 
non-viable cells are dark and have no refractile ring (Freshney 2005). 
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3.3.4 Cell Cryopreservation 
 Healthy PC3, DU145, LNCaP, and HDFa cells at log phase (exponential 
phase) were used for the freezing procedure. The healthy cells needed to be 
trypsinized and centrifuged at 1000 rpm (Biofuge primo®) before the addition of 
the freeze medium. The freezing medium was prepared manually and contained 
90% FBS and 10% DMSO or 90% complete media and 10% DMSO. The 
freezing medium was slowly added to the cell suspension containing 
approximately 106–107 cells/ml of cells concentration. Cells were then aliqouted 
at 1 ml and transferred into cryogenic vials. The cryogenic vials were labelled 
with the name of the cell lines, passage number and date. Before putting the 
cryogenic vials containing the cells into a liquid nitrogen tank, the vials were kept 
inside a freezing container (Nalgene Cryo™) containing 250 ml isopropanol to 
achieve a -1ºC/min cooling rate and stored at -80ºC overnight. On the next day 
the vials were then transferred into a liquid nitrogen Dewar with the temperature 
of -200ºC and stored until needed (Wang 2006).  
 
3.3.5 Cell Recovery 
 The cryopreserved cells are fragile and the thawing procedure is stressful 
to them, so careful handling is required to ensure a high proportion of cell 
survival. The cryogenic vial containing the cells was slowly and carefully 
removed from the liquid nitrogen storage. The cells were then thawed by gently 
agitating the vial in a water bath set at 37ºC temperature until it was completely 
thawed. After thawing the content of the vials, the cells were transferred into a 
pre-warmed media and centrifuged at 1000 rpm. After that, the supernatant was 
discarded from the centrifuge tube leaving a cell pellet. The cell pellet was 
suspended in a culture flask containing 20 ml of growth media previously 
equilibrated at 37ºC in 5% CO2 and the flask was labelled with the cell name, 
split ratio, passage number, and date. The flask was placed back in an incubator 
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at 37ºC in a humidified atmosphere with 5% CO2 then the cell lines were sub-
cultured as described earlier in section 2.4.2 (Wang 2006). 
 
3.4 Proliferation and viability analysis 
 To measure the viability and/or proliferation of cultured cells, the 
Sulforhodamine B (SRB) and the (3-(4,5-dimethylthiazolyl-2)-2,5-
diphenyltetrazolium bromide (MTT) assays were chosen, respectively. Two 
different assays were chosen as both assays utilize different mechanisms in 
assessing cells proliferation and viability. The SRB assay determines cell’s 
proliferation by staining the cellular protein contents whereas the MTT assay 
determine cell’s viability by measuring the mitochondrial activity based on the 
conversion of MTT into formazan crystals by living cells. The total mitochondrial 
activity is related to the number of viable cells. Therefore, the use of these two 
assays was important for results validation. 
 
 PC3, DU145, LNCaP, and HDFa cells were seeded in 96-well flat-bottom 
microtiter plate at a density of 2 x 104 cells/well for proliferation and viability 
assays. The number of cells seeded in the 96-well flat-bottom microtiter plate for 
each cell lines were determined using an optimization procedure. This specific 
cells seeding was used because it will result in 80% of the space in each well to 
be occupied by each cancer cell lines. Therefore, it allows the cells especially in 
the negative control (untreated cells) to grow within the 72 hours incubation 
period without running out of space for growth. Lack of growing space will cause 
the cells to die either via apoptosis or necrosis thus influencing the results of the 
experiment. 72 hours of incubation time after the treatment with the active 
extracts or active fractions of the plants was chosen because at this period, the 
cells are at the exponential phase of growth for the specific cell lines used in this 
study (PC3, DU145 and LNCaP). Figure 3.2 shows the growth curve for cells, 
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which consist of lag phase, exponential phase, stationary phase and death 
phase. A complete understanding on the growth profile for each cell lines used 
in any scientific studies is important in order to produce reliable data. The plates 
were then incubated at 37ºC in 5% CO2 in order to allow the cells to grow and 
reach confluency. After 24 hours of incubation, the cells were treated with 
different concentration of extracts or fractions, vehicle control (DMSO) (Sigma, 
D2650), and Paclitaxel as positive control (Sigma, T7402-5MG). All the 
preparation was done in the culture media within a laminar flow cabinet. 
 
 
Figure 3.2  Phases of Cells growth (Freshney 2005) 
 
3.4.1 Proliferation assay (SRB) 
 The sulforhodamine B assay (SRB) is a colorimetric assay characterized 
by simplicity with a high level of reproducibility (McCaffrey, Agarwal et al. 1988, 
Vichai and Kirtikara 2006). In this study, the SRB assay was performed 
according to a previously described method by Skehan, Storeng et al. (1990). In 
this method, cell number is estimated by the determination of cell density based 
on the staining of proteins with SRB. Under mild acidic condition (trichloroacetic 
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acid, TCA), the SRB has the ability to bind to the protein compounds of fixated 
cells providing a sensitive index of cellular protein content. As the binding is 
stoichiometric, an increase or decrease in the number of cells (total biomass) 
results in a corresponding change in the amount of dye extracted from stained 
cells (Skehan, Storeng et al. 1990, Vichai and Kirtikara 2006). 
 
 The cells were seeded in 96 well plates and plant extracts or fractions 
were added. After the incubation period of 24, 48, and 72 hours, 50 µL of cold 
40% w/v trichloroacetic acid (TCA) solution (Sigma, T6399-500G) in deionised 
water was added to the cell culture supernatant for cell fixation. The plates were 
incubated at 4ºC for 1 hour and then rinsed four times with distilled water. The 
TCA-fixed cells were stained by adding 100 µL of SRB solution (0.4% SRB 
(Sigma, S1402-5G0 in 0.1% acetic acid) and left at room temperature for 1 hour. 
After that, the plates were quickly rinsed four times with 1% acetic acid and 
flicked to remove unbound dye and then left to air-dry overnight. 
 
 After drying completely, 100 µL of 10 mM Tris buffer solution (Sigma, 
T1503-25G) was added to each wells and the plates agitated in an orbital 
shaker for 5 minutes, to allow for the solubilisation of the SRB-protein complex. 
The optical density (OD) was measured at 510 nm by using a microtiter plate 
reader (Tecan Infinite® M200). The percentage of change in cell growth was 
calculated as follows: 
 
% Of viable cells = [OD (sample) - OD (Blank)] / [OD (Control) – 
OD(Blank)]*100. 
This assay was performed independently in triplicate. 
113 
3.4.2 Mitochondrial viability Assay (MTT) 
MTT is a colorimetric assay that can be used to measure cell viability. 
This assay assesses cell viability by measuring the activity of NAD(P)H-
dependent cellular oxidoreductase enzymes which reflect the number of viable 
cells present. The yellow tetrazolium dye, MTT (3-(4,5-dimethylthiazolyl-2)-2,5-
diphenyltetrazolium bromide) (Sigma, M5655-100MG) is reduced by 
metabolically active cells, in part by the action of mitochondrial dehydrogenase 
enzymes, to generate reducing equivalents such as NADH and NADPH. The 
resulting intracellular purple formazan can be dissolved in acidified isopropanol 
and quantified by spectrophotometric means (microtiter plate reader). The 
amount of formazan formed is directly proportional to the number of 
metabolically active cells. 
Normally, the MTT assay is used for cytotoxicity studies of a drug or a 
plant extract on certain types of cell and in this case, the PC3, DU145 and 
LNCaP cell lines. The cells were seeded in microplates and extracts were added 
as detailed earlier (section 3.1). The MTT assay was performed according to the 
original method (Mosmann 1983) with slight modifications. 
After the 24, 48, and 72 hours incubation period, 10µL of the MTT 
solution (5 mg/ml dissolved in PBS) was added into all wells and incubated 
again for 4 hours in a humidified atmosphere at 37°C. After 4 hours, both the 
cell media and the MTT solution were removed from the wells and 200 µl of 
DMSO was added in each well in order to allow dissolution of the purple MTT-
formazan crystals. 
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 The absorbancy (optical density, OD) was measured at wavelength of 
570 nm and reference wavelength 630 nm with a microplate reader (Tecan 
Infinite® M200) within one hour after adding MTT solvent. The relative 
difference to control was determined by; 
Relative difference to control = OD (sample)  −  OD (Blank)OD (Control) –  OD(Blank  
The assay was performed independently in triplicate. 
 
3.4.3 Cells morphology 
PC3 and LNCaP cells were seeded in 12 well plates and left to attach 
and proliferate for 48 hours of incubation time. Then the plant extracts were 
added, the morphology and the population of the cells were monitored using an 
EVOS® FL Imaging System at 24, 48 and 72 hours. 
 
3.5 Apoptosis detection 
The number of cells in a multicellular organism is highly regulated. This 
process does not only involve controlling the rate of cells division but also by 
controlling the rate of cell death. When cells are no longer needed or become a 
threat to the organism, these cells could be destroyed by a tightly regulated cell 
suicide process known as programmed cell death or apoptosis (Alberts, 
Johnson et al. 2002). Apoptosis is a complex process and proceed through at 
least two main pathways namely extrinsic and intrinsic (Elmore 2007). Both 
pathways are mediated by an intracellular proteolytic cascade involving a family 
of cysteine proteases known as Caspases (Alberts, Johnson et al. 2002). 
Apoptosis can be described by its morphological characteristics, which include 
cells shrinkage, membrane blebbing, nuclear fragmentation, chromatin 
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condensation, and global mRNA decay (Kerr, Winterford et al. 1994). In cancer 
study, the discovery of bioactive compound/s that could induce cancer cells 
death via apoptosis is more favorable than necrosis. Necrotic cell death leads to 
a spill of cells content all over their neighbors causing a potentially damaging 
inflammatory response whereas apoptotic cells shrink and condense to form a 
structure called apoptotic bodies which can be rapidly phygocytosed by 
macrophages preventing any leakage of the cells contents (Kerr, Winterford et 
al. 1994). Figure 3.3 shows the flowchart for the screening cascade used in 
determining prostate cancer cell death via apoptosis. 
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Figure 3.3  Screening cascade for Apoptosis 
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3.5.1.1 4’-6-Diamidino-2-phenylindole (DAPI) staining 
This method was used to determine the presence of apoptotic cells. 1 x 
105 cells/well of PC3 and LNCaP cells were seeded in 12 wells plates. After 48 
hours, the cells were treated with plant extracts and positive control for 72 hours.  
After 72 hours the cells were rinsed with 1 mL of 1X PBS and fixed with 4% 
formaldehyde for 10 minutes. After 10 minutes, the cells were treated with 0.1% 
Triton X-100 in PBS for 10 minutes at room temperature. After washing with 
PBS, the cells were stained with DAPI (1 µg/mL) and incubated in the dark for 
30 minutes. The cells were then viewed and photographed using the EVOS® FL 
Imaging System. 
 
3.5.1.2 Annexin V-FITC and Propidium Iodide staining 
PC3 and LNCaP cells were seeded in 12 well plates and incubated for 48 
hours. After incubation, plant extracts and Paclitaxel (positive control) were 
added and further incubated for 6 hours at 37 °C in a 5% CO2 atmosphere. The 
cells were then washed with PBS and detached with 0.25% Trypsin-EDTA 
solution. The cells were then re-suspended in 100 µL of 1X binding buffer and 
10 µL of Annexin V-FITC were added. The mixture was mixed carefully and 
incubated for 15 minutes in the dark at room temperature. After 15 minutes, the 
cells were washed again with 1mL of 1X binding buffer and centrifuged at 300xg 
for 10 minutes. Subsequently the cells were re-suspended in 500 µL of 1X 
binding buffer and Propidium Iodide (PI) solution were added prior to 
flowcytometry (MACSQuant® Analyzer 10) analysis. 
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3.5.1.3 Caspases 3/7 activity 
 In this study, the apoptosis induced by plant extracts was determined by 
measuring the activity of Caspases 3 and 7 using an apoptosis detection kit 
(Promega, G8091). The Caspase-Glo® 3/7 assay was performed according to 
the manufacturer’s protocol. PC-3, DU145 and LNCaP cells were seeded in 96 
well plate at 2.5 x 103 cells/well. The cells were left for 24 hours to allow cells 
attachment. After 24 hours the cells were treated with extracts, fractions, vehicle 
control (DMSO), Paclitaxel and a blank (cell-free medium) for 48 hours. 100 µl of 
Caspase-Glo® 3/7 reagent was added to each wells after 48 hours incubation 
period and mixed gently for 30 seconds. Then, the plate was incubated for 1 
hour at room temperature. After the completion of the incubation period, the 
luminescence of each plant extracts was measured using a plate-reading 
luminometer (Tecan Infinite® M200). The assay was performed independently 
in triplicate and the results were calculated using the following equation: 
 
RLU = Luminescence (samples) – Luminescence (blank) 
 
3.5.1.4 Determination of Mitochondrial Membrane potential (MMP) 
The change in mitochondrial transmembrane potential (Δψm) induced by 
the active extracts of the plants in prostate cancer cell line (PC3) was 
determined by using flowcytometry technique with the appropriate fluorescent 
probe known as JC-1 (Isenberg and Klaunig 2000). 1 x 106 cells/ml of PC3 was 
seeded into 6 well plate and incubated for 48 hours. After incubation, plant 
extracts and Paclitaxel (positive control) were added and further incubated for 6 
hours at 37 °C in a 5% CO2 atmosphere. The treated cells were then labeled 
with 2 µM of JC-1 for 15 minutes at 37 °C and washed with warm phosphate-
buffered saline (PBS). The cells were analyzed on a flowcytometer 
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(MACSQuant® Analyzer 10) with 488 nm with 530- and 585 nm pass emission 
filters. CCCP-treated cells (10 µM) were taken as positive controls. 
 
3.5.1.5 Terminal deoxynucleotidyl transferase-mediated biotin dUTP Nick 
End Labeling assay 
To detect apoptotic cells, in situ end labelling of the 3′OH end of the DNA 
fragments generated by apoptosis-associated endonucleases was performed 
using the Dead End apoptosis detection kit (dUTP Nick End Labeling, TUNEL 
assay) from Promega (Madison, USA). Briefly, the cells were grown in LabTek II 
chamber slide and treated with plant extracts for 72 hours. The cells were 
washed in phosphate-buffered saline and fixed by immersing the slides in 4% 
paraformaldehyde for 25 min. All the steps were performed at room 
temperature, unless otherwise specified. They were then washed twice by 
immersing in fresh phosphate-buffered saline for 5 min. Cells were 
permeabilised with 0.1% Triton X-100 solution in phosphate-buffered saline for 5 
min, washed twice in phosphate-buffered saline, and then covered with 100µL of 
equilibration buffer and kept for 5–10 min. The equilibrated areas were blotted 
around with tissue paper, and 50 µL of terminal deoxynucleotidyl transferase 
(TdT) reaction mix was added to the sections on the slide and were then 
incubated at 37 °C for 60 minutes inside a humidified chamber for the end-
labelling reaction to occur. Immersing the slides in 2X sodium chloride–sodium 
citrate buffer for 15 minutes terminated the reactions. The slides were washed 
three times by immersing them in fresh phosphate-buffered saline for 5 minutes 
to remove unincorporated biotinylated nucleotides. The slides were then 
immersed in a freshly prepared 1 µg/mL propidium iodide solution for 15 
minutes at room temperature in the dark. The washing procedure was repeated 
after 15 minutes and then the slides were immediately analyze under a 
fluorescence microscope (EVOS® FL Imaging System) using a standard 
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fluorescein filter set to view the green fluorescein at 520 ± 20 nm and the red 
fluorescence of propidium iodide at 620 nm. 
 
3.6 Cell migration and Invasion study 
The ability of cells to move or migrate is important for the development and 
maintenance of multicellular organisms. Processes including embryonic 
development, wound healing and immune responses require the orchestrated 
movement of cells in particular directions to specific locations. Cells migration is 
defined as the directed movement of cells within the body, which allow cells to 
change their position within tissues or different organs (Kramer, Walzl et al. 
2013). Cells migration only occurs on 2D surfaces such as basal membranes, 
extracellular matrix (ECM) fibers or plastic plates without any obstructive fiber 
network (Kramer, Walzl et al. 2013). Cells invasion, which is defined as the 
ability of cells to penetrate through tissue barriers such as the basement 
membranes and the underlying interstitial tissues, occurs via a 3D matrix that 
requires restructuring and remodeling of the ECM (Friedl and Wolf 2010).  Some 
malignant cancer cells have the ability to metastasize to other organs within the 
human body including advanced prostate cancer cells. Metastasis is a process, 
which involves infiltrative growth through the ECM, cells migration through blood 
and lymph vessels and rise of distant colonies (Gupta and Massagué 2006). 
Therefore, finding new strategies to control or inhibit cancer cells migration and 
invasion are important in cancer studies. 
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3.6.1  In Vitro cell migration assay 
 
3.6.1.1 Oris™96-well 2D cell migration assay 
The In Vitro cell migration was determined by using the Oris™ 96-well cell 
migration assay kit (Platypus Technologies) (Figure 3.4) following the 
manufacturer’s instruction. 5 x 104 of PC3 cells were seeded in each well and 
left for 24 hours. The stoppers that were used to create the migration zone were 
removed after 24 hours and the cells were washed with PBS to remove any 
unattached cells. 100 µL of fresh media with or without the plant extracts were 
added to each well. The cells were allowed to migrate into the migration zone for 
72 hours. Cells were fluorescently stained with CellTracker™ Green (Life 
Technologies). The seeded plate was incubated in a humidified chamber for 72 
hours and at various time points (24h, 48h, 72h), the fluorescent signals in the 
detection zone were measured using a microplate reader (Synergy™ HT, 
BioTek) with 492 nm excitation and 517 nm emission filters. 
 
 
Figure 3.4  The schematic of Oris cell migration assay 
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3.6.1.2 Boyden chamber 3D migration assay 
The cell migration study was also performed using the CytoSelect Cell 
Migration Assay kit (Catalogue number CBA-100-C purchased from Cell Biolab 
Inc.) (Ridley, Schwartz et al. 2003) (Figure 3.5). This kit contains polycarbonate 
membrane inserts (8µm pore size) in a 24 well plate. The membrane serves as 
a barrier to discriminate migratory cells from non-migratory cells. Migratory cells 
are able to extend protrusions towards chemoattractants (via actin cytoskeleton 
reorganization) and ultimately pass through the pores of the polycarbonate 
membrane. These migratory cells are then dissociated from the membrane and 
subsequently detected by a microtiter plate reader. 
 
Under sterile conditions, the 24 well migration plate was allowed to warm 
up to room temperature for 10 min. Cell suspension containing 1.0 × 106 cells/ml 
in serum-free media was prepared. Fresh media (control) and media with 
respected plant extracts, were added directly to individual microwell inserts (8 
µm pore size) (Transwell©, Corning®, UK) with the cell suspension. Overnight 
serum starvation had been performed prior to running the assay. 500 µL of 
media containing 10% fetal bovine serum was added to the lower well of the 
migration plate and 300 µL of the cell suspension solution was added to the 
inside of each insert and then incubated for 24 hours in a cell culture incubator. 
After 24 hours incubation, the media were carefully aspirated from the inside of 
the microwell insert. The interior part of the inserts was washed with wet cotton 
swab in order to remove non-migratory cells. The inserts were transferred to a 
clean well containing 400 µL of Cell Stain Solution (Crystal Violet dye) and 
incubated for 10 min at room temperature. Then, the inserts were gently washed 
in a beaker of water and left to air dry. Each inserts were transferred into wells 
containing 200 µL of Extraction Solution (10% Acetic Acid), incubated for 10 
minutes at room temperature on an orbital shaker. 100 µL of each sample was 
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transferred to a 96 well plate and was measured at 560 nm by using a microtiter 
plate reader (Tecan Infinite® M200). 
 
 
Figure 3.5  The schematic of Modified Boyden chamber 3D migration assay 
 
3.6.2 In Vitro 3D cell invasion assay 
The cell invasion was measured using a Cytoselect 24-well cell invasion 
assay kit (Catalogue number CBA-100-C purchased from Cell Biolabs, Inc.) 
(Figure 3.6). This kit included polycarbonate membrane inserts (8 µm pore size). 
The upper surface of the insert membrane was coated with a protein matrix 
isolated from Engelbreth-Holm-Swarm tumor cells. Basement membranes of 
Boyden chambers were rehydrated with 300 µL serum-free media, and 1× 106 
cells were then seeded into the upper area of the chamber in serum-free media 
(control) with or without the plant extracts. Overnight serum starvation had been 
performed prior to running the assay. 500 µL of media containing 10% fetal 
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bovine serum was added to the lower well of the migration plate. After 
incubation for 48 hours, the non-invading cells on the upper surface of the 
inserts were removed with a cotton swab and invading cells on the lower surface 
were stained with crystal violet Cell Stain Solution and incubated for 10 minutes 
at room temperature. Then, the inserts were gently washed in a beaker of water 
and left to air dry. Each inserts were transferred into wells containing 200 µL of 
Extraction Solution (10% Acetic Acid), incubated for 10 minutes at room 
temperature on an orbital shaker. 100 µL of each sample was transferred to a 
96-well plate and was measured at 560 nm by using a microtiter plate reader 
(Tecan Infinite® M200). 
 
 
Figure 3.6 The schematic of Modified Boyden chamber 3D invasion assay 
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3.7 Cell cycle distribution study 
PC3 and LNCaP cells were seeded in 6 well plates and incubated for 48 
hours. Plant extracts and Paclitaxel (positive control) were added after 48 hours, 
and the cells were further incubated for 48 hours at 37 °C in a 5% CO2 
atmosphere. The cells were then washed and trypsinized with 0.25% Trypsin-
EDTA solution for cells detachment.  Cell pellet were re-suspended in 1 mL PBS 
and washed twice by adding 10 mL PBS. After that the cells were centrifuged at 
300xg for 10 minutes at 4°C. Once the supernatant was removed, 1 mL of ice-
cold 70% ethanol was slowly added drop by drop to the cell pellet. The cells 
were allowed to fix in ethanol for 18 hours. After 18 hours, the cells were 
centrifuged at 500xg for 10 minutes at 4°C. The supernatant was removed and 1 
mL of staining solution containing 1 mg/mL Propidium Iodide and 100 Kunitz 
units/mL of RNase A were added to the cells and incubated for 30 minutes 
before being analysed using flowcytometry (MACSQuant® Analyzer 10). 
 
3.8 Real-Time RT-qPCR Analysis 
 
3.8.1 mRNA Extraction and cDNA Synthesis 
After exposing PC3 cells (5 x 105 cells/well) to plant extracts, fractions and 
DMSO 1% for 96 hours, total RNA was extracted using RNeasy® Plus Mini 
(Qiagen) according to the manufacturer’s protocol. Samples were treated with 
gDNA eliminator spin column (Qiagen) to avoid genomic DNA contamination. 
The quantity and quality of RNA was determined by differential readings at 260 
and 280 nm wavelength using Nanodrop 2000 (Thermo Scientific). The integrity 
of total RNA from PC3 cells was assessed by visual inspection of the two rRNAs 
28 and 18 s on agarose gels. cDNA was synthesized from 1 µg of total RNA by 
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using Omniscript® Reverse Transcription kit (Qiagen) as per the manufacturer’s 
instructions in a final volume of 20 µL. 
 
3.8.2 RT-qPCR Conditions and Analysis 
Sequence for the primers used in this study are listed in Table 3.2. All 
primers used in this study were designed and obtained from Primerdesign®. 
The RT-qPCR was carried out in 96-well plates using a PikoReal™ Real-Time 
PCR detection System (Thermo Fisher Scientific). Each well contained a final 
reaction volume of 20 µL (10 µL of PrecisionFAST™ MasterMix with SYBR 
Green, 5 µL of cDNA template diluted appropriately, 1 µL of resuspended primer 
mix at a final concentration of 300nM and 4 µL of RNase/DNase free distilled 
water). PCR reaction was performed using the following conditions: initial 
denaturation at 95ºC for 2 minutes, then 40 cycles of denaturation at 95ºC for 15 
seconds, corresponding annealing temperature of each genes as listed in table 
1 for 30 seconds and extension at 72ºC for 30 seconds. At the end of the run, 
heating the amplicon from 60 to 95ºC in order to confirm the specificity of the 
amplification for each primer pair generated a melting curve. All RT-qPCR were 
run in quadruplicates. Standard curves were produced to check the PCR 
efficiency using a fivefold dilution series of cDNA. Efficiency (E) of primer pairs 
was obtained from the slope of the calibration curve generated. The relative 
expression was calculated on the basis of ‘delta delta Ct’ (∆∆Ct) values. 
Normalization of the target genes was achieved by using GAPDH as a reference 
gene. 
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Table 3.2  Sequence of primers used in RT-qPCR analysis 
Gene Primer Sequences Annealing 
temperature 
(ºC) 
GAPDH Sense         : 5’-ATGCTGGCGCTGAGTACGTC-3’ 
Anti-sense  : 5’-GGGCAGAGAGATGATGACCCTT-3’ 
55 
BAX Sense         : 5’-ATGGAGCTGCAGAGGATGAT-3’ 
Anti-sense  : 5’-CAGTTGAAGTTGCCGTCAGA-3’ 
56.5 
BCL-2 Sense         : 5’-GAGGTCACGGGGGCTAATT-3’ 
Anti-sense  : 5’-GAGGCTGGGCACATTTACTG-3’ 
56.8 
ALOX5 Sense         : 5’-AAGCGATGGAGAACCTGTTCA-3’ 
Anti-sense  : 5’-GTCTTCCTGCCAGTGATTCATG-3’ 
56.8 
VEGFA Sense         : 5’-TGCTCTACTTCCCCAAATCACT-3’ 
Anti-sense  : 5’-CTCTCTGACCCCGTCTCTCT-3’ 
57.6 
Smac 
DIABLO 
Sense         : 5’-GCACAGAAATCAGAGCCTCATT-3’ 
Anti-sense  : 5’-TTCAATCAACGCATATGTGGTCT-3’ 
56.4 
CXCR4 Sense: 5’-CCAAAGAAGGATATAATGAAGTCACT-3’ 
Anti-sense  : 5’-GGGCTAAGGGCACAAGAGA-3’ 
56.4 
CXCL12 Sense         : 5’-CTCCTCTTTCAACCTCAGTGATT-3’ 
Anti-sense :5’-GAGAAGCAGAAGCAAGATTAAGC-3’ 
56.8 
 
 
 
		 128 
3.9 HPLC-DAD (High Performance liquid chromatography-diode 
array detector) 
 HPLC-DAD chromatograms were obtained on an Agilent 1200 series 
HPLC system (Agilent, USA). Fingerprint analysis of plant extracts was 
conducted as described by Springfield, Eagles et al. (2005). All samples were 
dissolved in methanol (≥99.9% for HPLC, Sigma-Aldrich) and mixed properly 
using an ultrasonic bath. The concentration of each extract was equivalent to 1 
mg/mL. A volume of 5 mL of each sample was filtered through a 0.45µm filter 
before analysis. The rest were evaporated to dry and stored in a freezer. The 
filtered samples (10 µL) were injected for HPLC analysis. The stationary phase 
was Agilent C18 column (250mm x 4.6mm id, 5µm). Samples were eluted with a 
mobile phase consisted of formic acid solution (A, 0.1 % v/v) and acetonitrile (B, 
≥99.9% for HPLC, Fisher Scientific) using a linear gradient program (5% B in 0–
5 min, 5–15% B in 5–20 min, 15–20% B in 20–35 min, 20–35% B in 35–45 min, 
35–100% B in 45–60 min). The flow rate was 1.0 mL/min and the chromatogram 
was detected at wavelengths of 210nm, 269 nm, 280nm, 365 nm. The data was 
collected and processed with the Agilent Chemstation© Edition software 
(Agilent). 
 
3.10 Nuclear Magnetic Resonance (NMR) 
Samples for NMR characterization were prepared by dissolving in 0.8 ml 
of appropriate deuterated solvents. All NMR spectra were obtained using Bruker 
Avance 500 MHz NMR spectrometer equipped with broadband and triple 
resonance (1H, 13C and 15N) inverse probe in order to identify the correlation 
between protons and protons as well as protons and carbons. 2D experiments 
carried out include (i) COSY (Correlation Spectroscopy) that analyses direct 
correlation between a proton and its coupled partner, (ii) HMQC (Heteronuclear 
Multiple-Bond Correlation), shows correlation between carbons and protons, (iii) 
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HMBC (Heteronuclear Multiple-Bond Correlation), shows the present of long-
range couplings between protons and carbons in the distance of two or three 
bonds, and (iv) NOESY (Nuclear Overhauser Effect Spectroscopy), which 
shows correlations between protons, through bonds and spaces. 
 
3.11 Mass spectrometry 
The mass spectrometric analyses were performed by the Research 
Services Unit of the UCL School of Pharmacy. The molecular weight of the 
isolated compounds was determined by electrospray ionisation mass 
spectrometry (ESI-MS), using both positive and negative mode on a LCQ Duo 
Ion-Trap mass spectrometer (Thermo Finnigan).  The samples were run in either 
50% methanol in water or a solvent it is best soluble in, as a mobile phase under 
the following conditions; sheath gas flow rate (20-100 units), auxiliary gas flow 
rate (0 - 60 units), ion spray voltage (1-8 KV), spray current (0.34uA), capillary 
temperature (100-220oC), capillary Voltage (38-100 V) and tube lens offset (0- 
40V).  
 
3.12 Fourier Transformed Infrared spectroscopy (FT-IR) 
The FT-IR spectra of the compounds were recorded on a Perkin Elmer 
precise spectrum 100 FT-IR spectrometer as a thin film. 
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3.13 Ultra High Performance Liquid Chromatography (UHPLC) Mass 
Spectrometry (MS) 
This study was done in collaboration with Prof Jean-Luc Wolfender and 
funded by a Plants for Health Award (Appendix 1). The active fractions of FD1c 
and FD2c were dried and sent to Phytochimie et Produits Naturels Bioactifs, 
Université de Genève for analysis. The samples were analysed according to 
standard protocols previously published with slight modifications (Yang, Liang et 
al. 2014). 
 
3.14 Statistical Analysis 
 Data collected and reported in this study is expressed as a mean ± 
standard deviation. Statistical analysis of the data was carried out using the 
GraphPad software (GraphPad Software Inc, La Jolla, CA, USA). The values of 
p < 0.05 were considered to be statistically significant. All experiments were 
conducted three times independently in triplicate. 
 
 The Growth Inhibitory concentration 50 (GI50) values were taken from the 
minimal experimental concentration showing 50% cell death and calculated 
using GraphPad Prism 5. Each plant extracts was compared to the control group 
with GraphPad by using the student’s t-test to determine any significant effect of 
the extract. Other statistical calculations (averages, standard deviation, etc.) in 
this study were calculated using Microsoft Excel (Microsoft, Redmont, USA) 
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4 Results and Discussion 
 These experiments were conducted to study the in vitro effects of the 
plant extracts on three prostate cancer cell lines, LNCaP, DU145 and PC3. 
These cell lines represent two different stages of prostate cancer, LNCaP (Stage 
1, hormone-dependent prostate cancer), DU145 and PC3 (Stage 2, hormone-
independent prostate cancer). The cytotoxicity of the n-hexane, chloroform and 
aqueous extracts against LNCaP, DU145 and PC3 cell lines were measured by 
performing SRB and MTT assay after 72 hours of exposure to each respective 
extracts. Extracts exhibiting potential activity based on the results of the 
cytotoxicity assays were subjected to further mechanistic studies. 
 
4.1 Results 
 
4.1.1 Plant extractions  
All plant materials were subjected to a solvent-solvent partitioning 
process with n-hexane, chloroform and ethyl acetate as described in the 
previous section (3.1.1). The yields of each fraction are presented in Table 4.1. 
 
 
 
 
 
		 133 
Table 4.1  The yields of Marantodes pumilum, Ficus deltoidea 1 (FD1), Ficus deltoidea 2 
(FD2), and Ficus deltoidea 3 (FD3) 
Plant Extract Plant Sample (g) Yield (%) 
Marantodes 
pumilum   
Hexane 50 0.11 
Chloroform 50 0.42 
Aqueous 50 3.44 
Ethyl Acetate 50 0.49 
Ficus deltoidea 1 
(FD1) 
Hexane 50 0.27 
Chloroform 50 0.96 
Aqueous 50 13.18 
Ficus deltoidea 2 
(FD2) 
 
Hexane 50 0.22 
Chloroform 50 0.65 
Aqueous 50 13.10 
Ethyl Acetate 50 1.95 
Ficus deltoidea 3 
(FD3) 
Hexane 50 0.24 
Chloroform 50 0.25 
Aqueous 50 6.92 
Ethyl Acetate 50 1.79 
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4.1.2 HPLC Fingerprint 
 
4.1.2.1 HPLC Fingerprint analysis of Marantodes pumilum and Ficus spp.  
 The establishment of a standard fingerprint for various plant extracts is 
very important due to the high chemical complexity of the plant extracts. The 
fingerprint accounts for the variability in the chemistry of the plants depending on 
the variety, climates, and places. Chang, Ding et al. (2008) reported that 
chromatographic fingerprint is a powerful tool for the analysis of multi-
component of herbal medicines and plant extracts. The Chinese State Food and 
Drug Administration (SFDA) and the World Health Organization (WHO) have 
accepted chromatographic fingerprint as an identification and quality evaluation 
technique for herbal medicines (Chang, Ding et al. 2008). The chromatographic 
fingerprints of the different plant extracts (hexane, chloroform and aqueous) are 
shown in Figure 4.1 to Figure 4.12. The acetonitrile: 0.1% formic acid solution 
was used as the solvent, and the peak distributions of various extracts were 
detected by using a reverse-phase column with ultraviolet (UV) detection at 
different wavelengths (210nm, 254nm, 269nm, 280nm and 365nm). Table 4.2 
summarizes the distribution of the most characteristic peaks for Marantodes 
pumilum (MP) and three different varieties of Ficus deltoidea plant extracts as 
analysed by High Performance Liquid Chromatography (HPLC). 
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Table 4.2  The distribution of most characteristics peaks for Marantodes pumilum (MP) and three different varieties of Ficus deltoidea 
plant extracts as analysed by High Performance Liquid Chromatography (HPLC). Results shown are representative of three independent 
experiments. 
 
Sample Extract Peak Region 
tR 0 to tR 10 tR 11 to tR 20 tR 21 to tR 30 tR 31 to tR 40 tR 41 to tR 50 tR 51 to tR 60 
Marantodes 
pumilum 
(MP) 
n-Hexane  tR 19 tR 29 tR 34, tR 36,  
tR 38 
 tR 54, tR 56 
Chloroform tR 10 tR 16, tR 19 tR 22, tR 27  tR 47, tR 50 tR 54, tR 56 
Aqueous tR 2, tR 3 tR 14, tR 15     
Ficus 
deltoidea 1 
(FD1) 
n-Hexane tR 10 tR 16 tR 30    
Chloroform  tR 11, tR 16     
Aqueous tR 10 tR 16     
Ficus 
deltoidea 2 
n-Hexane  tR 13, tR 14, 
tR 16, tR 19 
tR 27, tR 30 tR 32, tR 35,  
tR 37 
 tR 56 
		 136 
(FD2) Chloroform  tR 11, tR 16 tR 22, tR 24, 
tR 27 
  tR 52, tR 56 
Aqueous tR 12, tR 16,   
tR 17 
     
Ficus 
deltoidea 3 
(FD3) 
n-Hexane   tR 30, tR 32, tR 35  tR 59 
Chloroform  tR 11 tR 21, tR 22    
Aqueous  tR 15, tR 16     
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Figure 4.1  HPLC fingerprint of Ficus deltoidea 1 hexane extract. 
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Figure 4.2  HPLC fingerprint of Ficus deltoidea 1 chloroform extract. 
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Figure 4.3  HPLC fingerprint of Ficus deltoidea 1 aqueous extract. 
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Figure 4.4  HPLC fingerprint of Ficus deltoidea 2 hexane extract. 
141 
Figure 4.5  HPLC fingerprint of Ficus deltoidea 2 chloroform extract. 
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Figure 4.6  HPLC fingerprint of Ficus deltoidea 2 aqueous extract. 
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Figure 4.7  HPLC fingerprint of Ficus deltoidea 3 hexane extract. 
144 
Figure 4.8  HPLC fingerprint of Ficus deltoidea 3 chloroform extract. 
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Figure 4.9  HPLC fingerprint of Ficus deltoidea 3 aqueous extract 
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Figure 4.10  HPLC fingerprint of Marantodes pumilum hexane extract 
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Figure 4.11  HPLC fingerprint of Marantodes pumilum chloroform extract 
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Figure 4.12  HPLC fingerprint of Marantodes pumilum aqueous extra 
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 Chromatographic fingerprinting using HPLC mainly utilizes the ultraviolet 
(UV) detection system; therefore, different compounds had their maximum 
absorptions at specific wavelengths, which can affect the peak areas of the 
same compounds. More than one wavelength was used in this study as different 
compounds will be detected at different wavelengths and this will help in building 
the full fingerprints of the plant. Chua, Lee et al. (2012) and Bunawan, Amin et 
al. (2014) reported that the UV absorption for flavonoids and phenolic 
compounds vary greatly according to their structures. Kumar and Pandey (2013) 
and Barreca, Bellocco et al. (2012) have further supported this finding by 
reporting that most flavones and flavonols exhibit two strong absorption bands; 
Band I (320-385nm) which is attributed to the styrene-type π-system 
represented the B ring absorption, while Band II (250-285nm) which is mostly 
attributed by the dihydroxybenzoyl portion of the conjugated π-system of ring A 
absorption. Apart from that, isoflavonoids also lack the structural presence of the 
styrene-type π-system (B ring) thus causing a significant difference in the UV-
Vis absorption spectra when compared to flavones and flavonols. Therefore, by 
comparing chromatograms recorded simultaneously at various wavelengths, it 
will enable us to determine the proper wavelength for some analytes such as 
flavonoids and terpenes as well as building a full fingerprint of the plant.  
 
 From the chromatographs, we can see that different varieties of Ficus 
deltoidea extracts showed different phytochemical profiles at the same 
wavelength. This indicates extreme variability of chemistry in these extracts 
even though they are from the same species. Normally, we would expect plants 
from the same species to have close or similar phytochemical profiles. However, 
this is not the case for the 2 different varieties of Ficus deltoidea plants used in 
this study (FD1 and FD2). The chromatographs also showed that, different parts 
of Ficus deltoidea plant, aerial and roots, from the same species and variety 
(FD2 and FD3) have different phytochemical constituents. Figure 4.1 to Figure 
4.9 showed that in FD1 most of the peaks could only be detected at the more 
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polar phase between retention times - tR, 10 minute to 20 minute - and there 
was nearly no peaks detected in the last 30 minutes of the chromatographs in all 
three different extracts of FD1. However, FD2 showed different distribution of 
phytochemical constituents according to the chromatographs as more peaks are 
detected in both the polar phase and the non-polar phase in all three extracts of 
FD2. This could suggest that FD2 has more phytochemical constituents when 
compared to FD1. Figure 4.4 to Figure 4.6 also indicate that the distribution of 
peaks varies greatly depending on the type of extract being analysed. More 
peaks are detected between tR =20 to tR =40 in FD2 n-hexane extract, whereas 
more peaks were detected after tR =40 in FD2 chloroform extracts. The FD2 
aqueous extract only showed peaks in the first 20 minutes of the retention time 
at which, more polar phytochemical constituents are normally detected. These 
results demonstrate that different extracts in different solvents could greatly 
influence the distribution of phytochemicals compounds in a plant. The 
chromatographs for FD3 (Figure 4.7 to Figure 4.9) also showed extreme 
variability in terms of the distribution of the phytochemical compounds 
depending on the type of extracts being analysed. More peaks were detected 
after tR =20 for the n-hexane extract of FD3, whereas for both aqueous and 
chloroform extracts of FD3, peaks were only detected during the first 30 minutes 
of the retention time with FD3 chloroform extracts showing more peak variability 
in this region. 
 
 Figure 4.10 to Figure 4.12 show the distribution of phytochemical 
constituents in Marantodes pumilum plant extracts. Similar to both FD2 and 
FD3, MP plant extracts also demonstrate great variability in phytochemical 
compound distribution, depending on the type of extracts being analysed. In MP 
n-hexane extract, even though several peaks were seen between tR =20 to tR 
=30, most peaks were detected after tR =30. Whereas peak distribution for MP 
chloroform extract could be detected in two separate regions - the first is 
between tR =10 to tR =30; and the second region is after tR =40. In the aqueous 
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extract of MP, peaks were only detected in the first 20 minutes of the retention 
time. Once again, these results demonstrate that the distribution of the 
phytochemical constituents in a plant could be influenced by the type of solvents 
used for extraction as different solvents have different polarity - therefore 
attracting phytochemical compounds based on their polarity. The HPLC 
chromatographs suggested that different varieties of a plant that belong in the 
same species may contain different chemical constituents, making HPLC 
fingerprinting to be one of the most important and acceptable approaches for 
quality evaluation of herbal preparation (Liang, Jin et al. 2009) 
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4.1.3 In vitro cytotoxic effects of plant extracts on different human 
Prostate Cancer cell lines 
 
4.1.3.1 Effects of plant extracts on cells proliferation using 
sulfhorhodamine staining assay (SRB) 
 In this study, SRB assay was used to determine the effect of the plant 
extracts on the proliferation of three prostate cancer cell lines, namely PC3, 
DU145 and LNCaP cells. All cell lines were treated with n-hexane, chloroform 
and aqueous extracts over a range of concentrations for 72 hours. The cytotoxic 
effects of all plant extracts were investigated and the GI50 values were 
determined. 
 
From table 4.3, we can see that the most cytotoxic extract against all 
three prostate cancer cell lines (PC3, DU145 and LNCaP) was the chloroform 
extract of Marantodes pumilum with a GI50 value of less than 15 µg/mL. Both 
chloroform extracts of FD1 and FD2 also showed promising GI50 values (lower 
than 30 µg/mL) and therefore should also be considered for further mechanistic 
studies. The chloroform extract of FD3 will not be considered for further studies 
as the GI50 values for PC3 is more than 30 µg/mL. 
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4.1.3.2 Effects of plant extracts on cells viability using MTT (3-(4,5-
dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) assay 
 In this study, the MTT assay was used to determine the effects of the 
plant extracts on the viability of two prostate cancer cell lines: DU145 and 
LNCaP cells. All cell lines were treated with n-hexane, chloroform and aqueous 
extracts over a range of concentrations for 72 hours. The cytotoxic effects of all 
plant extracts were investigated and their G150 values were determined. 
 
As shown in table 4.3, the most cytotoxic extract against the two prostate 
cancer cell lines (DU145 and LNCaP) was the chloroform extract of Marantodes 
pumilum with a GI50 value less than 15 µg/mL. The same pattern of cytotoxicity 
was observed with the MTT assay for the chloroform extracts of MP, FD1 and 
FD2 as their GI50 values were recorded to be below than 30 µg/mL when 
compared to the results collected from the SRB assay. Therefore, these results 
further validated the decision to choose the chloroform extracts of MP, FD1 and 
FD2 for further mechanistic studies 
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Table 4.3  GI50 concentrations (µg/mL) of the n-hexane, chloroform and aqueous plant extracts determined for PC3, DU145, and 
LNCaP cells as assessed by the MTT and SRB assays at 72 hours. Paclitaxel (0.01µM) was used as a reference drug. Each 
result was obtained in three independent experiments and run in triplicate. *(P<0.05) as determined by un-paired t-test. 
 
Plant Name and 
part 
Extract Sample 
Code 
GI50 (µg/ml) based on SRB assay GI50 (µg/ml) based on 
MTT assay 
   PC3 DU145 LNCaP DU145 LNCaP 
Paclitaxel  Pac 0.01*± 0.05 
µM 
0.01*± 0.06 
µM 
0.01*± 0.05 
µM 
0.01*± 0.04 
µM 
0.01*± 0.05 
µM 
Marantodes 
pumilum 
(Aerial) 
n-hexane 
Chloroform 
Aqueous 
MP (H) 
MP (C) 
MP(A) 
20.2*± 0.5 
14.3*± 0.3 
>200 
25.3*± 0.6 
14.6*± 0.4 
>200 
26.7*± 0.8 
13.2*± 0.2 
>200 
24.3*± 0.5 
13.3*± 0.3 
150.2*± 0.3 
23.8*± 0.7 
13.1*± 0.6 
135.8*± 0.6 
Ficus deltoidea 
1 (FD1) 
(Aerial) 
n-hexane 
Chloroform 
Aqueous 
FD1 (H) 
FD1 (C) 
FD1 (A) 
>200 
23.2*± 0.2 
>200 
100*± 1.5 
20.1*± 0.6 
>200 
>200 
21.4*± 0.4 
>200 
96*± 1.3 
19.3*± 0.3 
>200 
95*± 2.1 
19.2*± 0.6 
>200 
Ficus deltoidea 
2 (FD2) 
(Aerial) 
n-hexane 
Chloroform 
Aqueous 
FD2 (H) 
FD2 (C) 
FD2 (A) 
58.4*± 1.2 
29*± 0.3 
>200 
74.3*± 2.1 
15*± 0.4 
>200 
>200 
27*± 0.5 
>200 
52.1*± 1.5 
14*± 0.6 
>200 
150.2*± 2.5 
23*± 0.3 
>200 
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Table 4.3 (Continues)  
Plant Name 
 
Extract Sample 
Code 
GI50 (µg/ml) based on SRB assay GI50 (µg/ml) based on 
MTT assay 
   PC3 DU145 LNCaP DU145 LNCaP 
Ficus deltoidea 
3 (FD3) 
(Root) 
n-hexane 
Chloroform 
Aqueous 
FD3 (H) 
FD3 (C) 
FD3 (A) 
>200 
34.2 ± 3.4 
>200 
>200 
30.3 ± 4.3 
>200 
175 ± 6  
28.7 ± 5.2 
51.3± 4.2 
>200 
28.3 ± 4.1 
>200 
175.2 ± 7.4 
26.1 ± 4.1 
48.3 ± 3.9 
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4.1.4 Morphological changes of LNCaP and PC3 cell lines after treated 
with active extracts of the plant extracts 
Cell death could occur via two distinct forms known as apoptosis and 
necrosis. Therefore, it is very important to determine the mode of cell death 
induced by the active extracts of the plants. Apoptosis is a programmed cell 
death characterized by the initial detachment and shrinkage of the cells, 
followed by the extensive plasma membrane blebbing, and the formation of 
apoptotic bodies that consist of cytoplasm with tightly packed cellular 
organelles with or without nuclear fragments (Elmore 2007). In vivo, these 
bodies will be subsequently phagocytosed by macrophages or adjacent cells 
such as parenchymal cells and neoplastic cells thus preventing them from 
going through lysis. However, when this process occurs in an in vitro 
environment, these apoptotic bodies will ultimately swell and lyses due to the 
absence of phagocytes and undergo secondary necrosis (Ho, Yazan et al. 
2009). In this study, the morphology of the prostate cancer cell lines (LNCaP 
and PC3) untreated and treated with the active extracts of Marantodes 
pumilum and Ficus deltoidea was analysed using an EVOS® FL Imaging 
System at 24, 48 and 72 hours. The characteristics of apoptosis such as cells 
detachment from the substratum, cell shrinkage, nuclear condensation, 
membrane blebbing and the formation of apoptotic bodies were detected in 
the treated cells (Figure 4.19 to Figure 4.22). Reduction in the cell population 
was very obvious when comparing between the untreated and the treated 
cells (Figure 4.13 to Figure 4.18).  
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Sample/Hour 24 48 72 
Control 
(untreated) 
Paclitaxel 
Figure 4.13.  Morphological changes of PC3 cells treated with the GI50 of Paclitaxel (positive control) for 24, 48, and 72 hours viewed under the 
EVOS®  FL Imaging System (100x magnification). Steady decline of the cell population was noted at all endpoints as compared to the control 
(Untreated cells).length of the white scale is 400 um 
400 um
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Sample/Hour 24 48 72 
MPc 
MPh 
Figure 4.14.  Morphological changes of PC3 cells treated with the GI50 of MPc and MPh for 24, 48, and 72 hours viewed under the EVOS®  FL 
Imaging System (100x magnification). Steady decline of the cell population was noted at all endpoints as compared to the control (Untreated cells). 
400um 
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Sample/Hour 24 48 72 
FD1c 
FD2c 
Figure 4.15.  Morphological changes of PC3 cells treated with the GI50 of FD1c and FD2c for 24, 48, and 72 hours viewed under the EVOS®  FL 
Imaging System (100x magnification). Steady decline of the cell population was noted at all endpoints as compared to the control (Untreated cells). 
400um 
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Sample/Hour 24 48 72 
Control 
(untreated) 
   
Paclitaxel 
   
 
Figure 4.16.  Morphological changes of LNCaP cells treated with the GI50 of Paclitaxel for 24, 48, and 72 hours viewed under the EVOS®  FL 
Imaging System (100x magnification). Steady decline of the cell population was noted at all endpoints as compared to the control (Untreated cells). 
400um 
161	
Sample/Hour 24 48 72 
MPc 
MPh 
Figure 4.17.  Morphological changes of LNCaP cells treated with the GI50 of MPc and MPh for 24, 48, and 72 hours viewed under the EVOS®  FL 
Imaging System (100x magnification). Steady decline of the cell population was noted at all endpoints as compared to the control (Untreated cells). 
400um 
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Sample/Hour 24 48 72 
FD1c 
   
FD2c 
   
 
Figure 4.18.  Morphological changes of LNCaP cells treated with the GI50 of FD1c and FD2c for 24, 48, and 72 hours viewed under the EVOS®  FL 
Imaging System (100x magnification). Steady decline of the cell population was noted at all endpoints as compared to the control (Untreated cells) 
400um 
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         (A) (B) (C)     (D) 
Figure 4.19.  PC3 cells viewed under the EVOS®  FL Imaging System (200x magnification) after 72 hours of treatment with the GI50 concentration 
of Paclitaxel (B), Marantodes pumilum (Chloroform) (C), and Marantodes pumilum (n-Hexane) (D) extracts. (A) represents the Control (Untreated 
PC3 cells). The cells showed characteristics of apoptosis such as the formation of apoptotic bodies (AB), membrane blebbing (MB) and nuclear 
compaction (NC).  
400um 
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                     (A)                                                (B)                                                (C)                                                 (D) 
 
Figure 4.20.  LNCaP cells viewed under the EVOS®  FL Imaging System (200x magnification) after 72 hours of treatment with the GI50 
concentration of Paclitaxel (B), Marantodes pumilum (Chloroform) (C), and Marantodes pumilum (n-Hexane) (D) extracts. (A) represented the 
Control (Untreated LNCaP cells). The cells showed characteristics of apoptosis such as the formation of apoptotic bodies (AB), membrane 
blebbing (MB) and nuclear compaction (NC). 
 
400um 
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                     (A)                                                (B)                                                   (C)                                                 (D) 
 
Figure 4.21.  PC3 cells viewed under the EVOS®  FL Imaging System (200x magnification) after 72 hours of treatment with the GI50 concentration 
of Paclitaxel (B), FD1 (Chloroform) (C), and FD2 (Chloroform) (D) extracts. (A) represents the Control (Untreated PC3 cells). The cells showed 
characteristics of apoptosis such as the formation of apoptotic bodies (AB), membrane blebbing (MB) and nuclear compaction (NC).  
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   (A) (B)  (C)  (D) 
Figure 4.22.  LNCaP cells viewed under the EVOS®  FL Imaging System (200x magnification) after 72 hours of treatment with the GI50 
concentration of Paclitaxel (B), FD1 (Chloroform) (C), and FD2 (Chloroform) (D) extracts. (A) represents the Control (Untreated PC3 cells). The cells 
showed characteristics of apoptosis such as the formation of apoptotic bodies (AB), membrane blebbing (MB) and nuclear compaction (NC).  
400um 
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4.1.5 Effect of the active extracts of the plants on apoptosis of prostate 
cancer cell lines 
 
4.1.5.1 DAPI staining 
4’-6-Diamidino-2-phenylindole or DAPI is a dye that can be used as a 
tool to visualize the nuclear changes that occur during apoptosis (Wang, 
Martindale et al. 2000). During apoptosis, the condensation and fragmentation 
of nuclei allow the apoptotic cells to be visualized using the fluorescence 
microscopy technique - as DAPI is able to bind strongly and selectively to the 
minor groove of adenine-thymine regions of the DNA, producing a fluorescent 
blue colour that is directly proportional to the amount of DNA present. The 
compromised apoptotic cell membrane will allow more DAPI to enter the cells 
and stains a stronger blue colour. This study indicates that the number of 
apoptotic cells were higher in the treated cells than the untreated cells (Figure 
4.23 to Figure 4.26).  
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Samples Images Samples Images 
Control 
(untreated) 
MPc 
Paclitaxel MPh 
Figure 4.23.  Fluorescence image of PC3 cells stained with DAPI after 72 hours incubation with the active extracts of Marantodes pumilum and 
Paclitaxel (Positive control). Apoptotic cells were represented by the blue fluorescence colour seen in the images. More apoptotic cells can be 
seen in the cells treated with Paclitaxel and the active extracts of Marantodes pumilum. 
400 um
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Samples Images Samples Images 
Control 
(untreated) 
MPc 
Paclitaxel MPh 
Figure 4.24.  Fluorescence image of LNCaP cells stained with DAPI after 72 hours incubation with the active extracts of Marantodes pumilum and 
Paclitaxel (Positive control). Apoptotic cells were represented by the blue fluorescence colour seen in the images. More apoptotic cells can be 
seen in the cells treated with Paclitaxel and the active extracts of Marantodes pumilum. 
400um 
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Samples Images Samples Images 
Control 
(untreated) 
FD1c 
Paclitaxel FD2c 
Figure 4.25.  Fluorescence image of PC3 cells stained with DAPI after 72 hours incubation with the active extracts of Ficus deltoidea and Paclitaxel 
(Positive control). Apoptotic cells were represented by the blue fluorescence colour seen in the images. More apoptotic cells can be seen in the 
cells treated with Paclitaxel and the active extracts of Ficus deltoidea. 
400um 
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Samples Images Samples Images 
Control 
(untreated) 
FD1c 
Paclitaxel FD2c 
Figure 4.26.  Fluorescence image of LNCaP cells stained with DAPI after 72 hours incubation with the active extracts of Ficus deltoidea and 
Paclitaxel (Positive control). Apoptotic cells were represented by the blue fluorescence colour seen in the images. More apoptotic cells can be 
seen in the cells treated with Paclitaxel and the active extracts of Ficus deltoidea. 
400um 
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4.1.5.2 Annexin V-FITC  and Propidium Iodide staining 
Up-regulation of anti-apoptotic protein expression and the inactivation 
of pro-apoptotic proteins in most type of cancers have led to the unchecked 
cellular growth of tumor, inability to respond to cellular stress, harmful 
mutations and DNA damage. These cellular irregularities enable cells to 
evade programmed cell death or commonly known as apoptosis and this has 
been recognized as one of the six essentials alterations in cell physiology that 
dictate the growth of tumor cells (Fesik 2005). Therefore, in cancer research it 
is a favorable characteristic to have plant extracts or compound/s that could 
induce cancer cell death through apoptosis rather than necrosis due to the 
inflammatory response induced by the necrotic cells leading to the release of 
chemoatractants to the surrounding tissues (Nicholson 2000). 
 
 In this study, the Annexin V-FITC Apoptosis detection kit is used to 
evaluate the mode of cell death induced by the active plant extracts. The kit is 
a combination of conjugated fluorescein isothiocynate (FITC) to Annexin V 
and Propidium Iodide that can detect and discriminate apoptotic, necrotic and 
dead cells.  Annexin V has a high affinity to phosphatidylerine (PS) which is a 
negatively charged phospholipid normally located in the cytosolic leaflet of the 
plasma membrane lipid bilayer (Koopman, Reutelingsperger et al. 1994). 
During early apoptosis, the redistribution of PS from the inner leaflet to the 
outer leaflet will enable Annexin V to bind to it in the presence of physiological 
concentration of Calcium ions (Ca2+) whereas the dead cells will be detected 
by the binding of Propidium Iodide to the cellular DNA inside the cell (Moss, 
Edwards et al. 1991). 
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 The results showed that there was a significant increase (p<0.05) in 
the population of LNCaP cells in the early apoptosis phase after the treatment 
with Marantodes pumilum (27%) (Figure 4.27 & Figure 4.28) and Ficus 
deltoidea (Figure 4.31 & Figure 4.32) (FD1: 35%, FD2: 16%) chloroform 
extract when compared to the untreated cells (11%). LNCaP cells treated with 
Marantodes pumilum n-Hexane extract also demonstrated a significant 
increase (p<0.05) in the early apoptosis (20%), late apoptosis (or secondary 
necrosis) and necrosis phases when compared to the untreated cells.  
 
 PC3 cells treated with Marantodes pumilum (Figure 4.29 & Figure 4.30) 
(20%) and Ficus deltoidea (Figure 4.33 & Figure 4.34) (FD1: 29%, FD2:13%) 
chloroform extract show a similar increasing trend (p<0.05) in the cell’s 
population in the early apoptosis phase when compared to the untreated cells 
(7%). Treatment with Marantodes pumilum n-Hexane (21%) extract caused a 
significant increase (p<0.05) of the cell population in the early apoptosis 
phase when compared to the untreated cells (7%). This shows an evasion of 
apoptosis and is recognized to be one of the six hallmarks of cancer, failure to 
activate apoptosis is regarded as one of the major obstacles to the successful 
treatment of cancers with drugs (Kaufmann and Vaux 2003, Cummings, Ward 
et al. 2004).  
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                           Control                                              Campthotecin 
 
          
    Marantodes Pumilum chloroform                 Marantodes pumilum n-hexane  
Figure 4.27.  The dot plots of LNCaP cells after 6 hours treatment with the active 
extracts of Marantodes pumilum as determined by Annexin V-FITC and PI staining. The 
cells were treated with different active extracts for 6 hours. Results shown are 
representative of three independent experiments. 
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Figure 4.28.  The percentage (%) of cell distribution of LNCaP cells after 6 hours 
treatment with the active extracts of Marantodes pumilum as determined by Annexin V-
FITC and PI staining. The cells were treated with different active extracts for 6 hours. * 
p< 0.05 as compared to the untreated cells. Results shown are representative of three 
independent experiments. 
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                           Control                                            Campthotecin 
     
    Marantodes Pumilum chloroform            Marantodes Pumilum n-Hexane   
Figure 4.29.  The dot plots of PC3 cells after 6 hours treatment with the active extracts 
of Marantodes pumilum as determined by Annexin V-FITC and PI staining. The cells 
were treated with different active extracts for 6 hours. Results shown are 
representative of three independent experiments. 
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Figure 4.30.  The percentage (%) of cell distribution of PC3 cells after 6 hours treatment 
with the active extracts of Marantodes pumilum as determined by Annexin V-FITC and 
PI staining. The cells were treated with different active extracts for 6 hours. * p< 0.05 as 
compared to the untreated cells. Results shown are representative of three 
independent experiments. 
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                            Control                                             Campthotecin 
      
                    FD1 chloroform                                     FD2 chloroform                     
Figure 4.31.  The dot plots of LNCaP cells after 6 hours treatment with the active 
extracts of Ficus deltoidea as determined by Annexin V-FITC and PI staining. The cells 
were treated with different active extracts for 6 hours. Results shown are 
representative of three independent experiments. 
 
 
 
 
179	
Figure 4.32.  The percentage (%) of cell distribution of LNCaP cells after 6 hours 
treatment with the active extracts of Ficus deltoidea as determined by Annexin V-FITC 
and PI staining. The cells were treated with different active extracts for 6 hours. * p< 
0.05 as compared to the untreated cells. Results shown are representative of three 
independent experiments. 
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                           Control                                             Campthotecin 
     
                    FD1 chloroform                                     FD2 chloroform                     
Figure 4.33.  The dot plots of PC3 cells after 6 hours treatment with the active extracts 
of Ficus deltoidea as determined by Annexin V-FITC and PI staining. The cells were 
treated with different active extracts for 6 hours. Results shown are representative of 
three independent experiments. 
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Figure 4.34.  The percentage (%) of cell distribution of PC3 cells after 6 hours treatment 
with the active extracts of Ficus deltoidea as determined by Annexin V-FITC and PI 
staining. The cells were treated with different active extracts for 6 hours. * p< 0.05 as 
compared to the untreated cells. Results shown are representative of three 
independent experiments. 
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4.1.5.3 Caspase 3 and 7 activity 
 Apoptosis is a programmed cell death coordinated by members of the 
caspase family (Walsh, Cullen et al. 2008). These caspases can be divided 
into two distinct types, the initiator caspases (caspase-8, caspase-9, and 
caspase-10). Initiator caspases are highly specific proteases that cleave and 
activate proteins including the downstream caspases also known as the 
effector caspases (caspase-3, caspase-6, and caspase-7). Effector caspases 
are responsible for most of the proteolysis taking place during apoptosis 
causing the cleavage of Poly ADP Ribose Polymerase 1 (PARP-1) and other 
cellular proteins (Slee, Harte et al. 1999). In normal conditions, the primary 
function of PARP-1 is to detect and repair DNA damage. However, in 
caspase-mediated apoptotic cell death, the cleavage of several key proteins 
that is required for cellular functioning and survival - including PARP-1 - is 
very important. In fact, the cleavage of PARP-1 by caspases especially 
caspase-3 is considered to be one of the important hallmarks of apoptosis 
(Kaufmann, Desnoyers et al. 1993). The cleavage of PARP-1 by the caspases 
will result in the formation of two specific fragments; an 89-kD catalytic 
fragment and a 24-kD DBD (Lazebnik, Kaufmann et al. 1994). The formation 
of these two fragments will irreversibly inhibit its function to detect and repair 
DNA damage (Chaitanya, Alexander et al. 2010). 
 
 Both LNCaP (Figure 4.35 & 4.37) and PC3 (Figure 4.36 & 4.38) cells 
treated with Marantodes pumilum and Ficus deltoidea chloroform extract 
displayed a significant increase (p<0.01) in the activity of caspases 3 and 7 
when compared to the untreated cells. LNCaP and PC3 cells treated with 
Marantodes pumilum n-Hexane extract also showed a similar effect (p<0.05). 
These findings further indicate that both plant extracts stimulate prostate 
cancer cell death via apoptosis and that this process is mediated, at least in 
part of the activation of caspases 3 and 7. 
 
183	
Figure 4.35.  Caspase 3/7 activity in LNCaP cells treated with the active extracts of 
Marantodes pumilum for 72 hours. The y-axis shows the luminescent signal subtracted 
from a blank, which is proportional to the caspase activity. The error bars display the 
standard error of mean (SEM) obtained from 3 independent experiments. Significance 
compared to control, *(P<0.05),**(P<0.01) as determined by un-paired t-test. 
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Figure 4.36.  Caspase 3/7 activity in PC3 cells treated with the active extracts of 
Marantodes pumilum for 72 hours. The y-axis shows the luminescent signal subtracted 
from a blank, which is proportional to the caspase activity. The error bars display the 
standard error of mean (SEM) obtained from 3 independent experiments. Significance 
compared to control, *(P<0.05),**(P<0.01) as determined by un-paired t-test. 
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Figure 4.37.  Caspase 3/7 activity in LNCaP cells treated with the active extracts of 
Ficus deltoidea for 72 hours. The y-axis shows the luminescent signal subtracted from 
a blank, which is proportional to the caspase activity. The error bars display the 
standard error of mean (SEM) obtained from 3 independent experiments. Significance 
compared to control, *(P<0.05),**(P<0.01) as determined by un-paired t-test. 
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Figure 4.38.  Caspase 3/7 activity in PC3 cells treated with the active extracts of Ficus 
deltoidea for 72 hours. The y-axis shows the luminescent signal subtracted from a 
blank, which is proportional to the caspase activity. The error bars display the 
standard error of mean (SEM) obtained from 3 independent experiments. Significance 
compared to control, *(P<0.05),**(P<0.01) as determined by un-paired t-test. 
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4.1.5.4 MMP depolarization in active plant extracts treated PC3 cell line 
In addition to its metabolic functions, mitochondria play a major role in 
the management of other cellular functions like cell survival and death 
(Galluzzi, Kepp et al. 2012). Mitochondrial changes, including variations in 
mitochondrial membrane potential (Δψm), are the key events during drug-
mediated apoptosis (Zamzami, Marchetti et al. 1995). One of the distinctive 
features of the early stage of apoptosis is the disruption of active 
mitochondria, which includes changes in the mitochondrial membrane 
potential and alterations to the oxidation-reduction potential of the 
mitochondria. These changes are believed to be caused by the opening of the 
mitochondrial permeability transition pore (PTP) that leads to the passage of 
ions and small molecules (Ly, Grubb et al. 2003). Hence, to assess the effect 
of the active plant extracts on mitochondrial activity, the mitochondrial 
membrane potential (MMP) was studied using the cationic fluorescent probe 
JC-1. This compound can selectively enter into the mitochondrion of cells, and 
reversibly changes from red to green fluorescence as the mitochondrial 
membrane potential decreases. By measuring such a shift in the fluorescence 
emission by flow cytometry, MMP can be readily detected. As shown in Figure 
4.39 to Figure 4.41, the active extracts of the plants increased the percentage 
of mitochondrial membrane potential (MMP) depolarization significantly 
(*p<0.05 and **p<0.01) in PC3 cell lines which indicate that the active extracts 
of the plants induce cell death in human prostate cancer cells with the 
involvement of mitochondrial membrane depolarization. These findings further 
support previous results shown in section 4.1.5.3, which showed the 
activation of caspases 3 and 7. 
		 188	
    
                             Control                                          Campthotecin 
         
  Marantodes Pumilum (Chloroform)        Marantodes Pumilum (n-Hexane) 
Figure 4.39.  Representative MMP profiles of flow cytometry for active plant extracts-
treated PC3 cells. Depolarization of mitochondrial membrane potential (MMP) of PC3 
prostate cancer cell lines was induced by the active extracts of Marantodes pumilum 
.PC3 cell lines were treated with the GI50 of the plant extracts for 6 hours. Results 
shown are representative of three independent experiments. 
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FD1 (Choloroform)  FD2 (Chloroform) 
Figure 4.40.  Representative MMP profiles of flow cytometry for active plant extracts-
treated PC3 cells. Depolarization of mitochondrial membrane potential (MMP) of PC3 
prostate cancer cell lines was induced by the active extracts of Ficus deltoidea.PC3 
cell lines were treated with the GI50 of the plant extracts for 6 hours. Results shown are 
representative of three independent experiments. 
Figure 4.41.  Quantification analysis of percentage MMP intensity in Figure 4.39 & 
Figure 4.40. Data represented as means ± SEMs (n=3). *p<0.05 and **p<0.01 and 
against control. 
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4.1.5.5 Nuclear DNA fragmentation 
Nuclear DNA fragmentation is one of the important hallmarks of 
apoptosis. This process involves the double-strand cleavage of nuclear DNA 
at the linker regions between nucleosomes, which leads to the production of 
oligonucleosomal fragments (Kerr, Winterford et al. 1994). The degradation of 
the double-stranded nuclear DNA into oligonucleosomal fragments or 
nucleosomal units is one of the best characterized biochemical features of 
apoptotic cell death (Nagata 2000), as it enables the detection of apoptotic 
cells by using the in-situ assays of DNA fragmentation called the Terminal 
deoxynucleotidyl tranferase mediated biotin dUTP Nick End Labelling assay 
(TUNEL).  However, the interpretation of this assay must be carefully 
assessed together with other morphological features of apoptotic cells 
because single-strand DNA ends in cell nuclei are also present in necrotic 
cells (Collins, Schandl et al. 1997).  
 
In order to prevent the possible experimental bias, the results from this 
study must be supported by other hallmarks of apoptosis such as the 
activation of caspases and the up-regulation of pro-apoptotic proteins as well 
as the down-regulation of anti-apoptotic proteins. In this study the TUNEL 
assay was used to assess the effects of the active plant extracts on prostate 
cancer cells’ nuclear DNA fragmentation. Figure 4.42 to Figure 4.44 show that 
after 72 hours of treatment with active plant extracts, a more localized green 
fluorescent (fluorescein-12-dUTP) colour can be detected, in the treated cells 
as compared to the control. The localized green fluorescent label can only be 
detected in apoptotic cells while the red Propidium Iodide stain will label both 
apoptotic and non-apoptotic cells. These findings provide more evidence that 
both Marantodes pumilum and Ficus deltoidea plant extracts induce prostate 
cancer cell death via apoptosis. 
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Control 
 
DNAse (Positive Control) 
Figure 4.42.  PC3 cells treated DNAse (positive control) and stained with DeadEnd™ 
Flurometric TUNEL system after 72 hours. Red fluorescence indicates healthy cells 
while green fluorescence shows fragmented nuclear DNA. Results shown are 
representative of three independent experiments. 
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MPc 
 
MPh 
Figure 4.43.  PC3 cells treated with Marantodes pumilum plant extracts and stained 
with DeadEnd™ Flurometric TUNEL system after 72 hours. Red fluorescence indicates 
healthy cells while green fluorescence shows fragmented nuclear DNA. 
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FD1c 
FD2c 
Figure 4.44.  PC3 cells treated with Ficus deltoidea plant extracts and stained with 
DeadEnd™ Flurometric TUNEL system after 72 hours. Red fluorescence indicates 
healthy cells while green fluorescence shows fragmented nuclear DNA. 
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4.1.5.6 PC3 cell death via apoptosis (instrinsic pathway) based on Bax, 
Bcl-2 and Smac/DIABLO mRNA gene expression 
Apoptosis is a programmed cell death that occurs through a highly 
complex and sophisticated mechanism involving an energy dependent 
cascade of molecular event. Research has indicated that there are two major 
pathways for apoptosis: (1) extrinsic, also called ‘the death receptor pathway’; 
and (2) intrinsic, otherwise known as the ‘mitochondrial-driven pathway’. 
However, new findings by Igney and Krammer (2002) suggest that the two 
pathways are linked and molecules in one pathway can influence the other. In 
addition, new evidence suggests that there is an additional pathway that 
involves T-cell mediated cytotoxicity and perforin-granzyme-dependent killing 
of the cells (Martinvalet, Zhu et al. 2005). However all of these pathways show 
important similarities in which they converge into the same terminal (or 
execution) pathways and are initiated by the activation of caspase-3. This 
results in DNA fragmentation, degradation of cytoskeletal and nuclear 
proteins, cross-linking of proteins, formation of apoptotic bodies, expression of 
ligands for phagocytic cells receptors and finally uptake by phagocytic cells 
(Hengartner 2000). 
 
The intrinsic signaling pathways involve a diverse array of non-
receptor-mediated stimuli that produce intracellular signals, which act directly 
on targets within the cells and are driven by mitochondria. These stimuli may 
act in either a positive or negative fashion; where negative signals involve the 
absence of certain growth factors, hormones and cytokines without which will 
trigger apoptosis and on the other hand positive signals include exposure to 
radiation, toxins, hypoxia, hyperthermia, viral infections and free radicals 
(Elmore 2007). All of these stimuli will cause disruption to the inner 
mitochondrial membrane that lead to the opening of the mitochondrial 
permeability transition (MPT) pore, loss of the mitochondrial transmembrane 
potential and release of two main groups of pro-apoptotic proteins from the 
intermembrane space to the cytosol (Saelens, Festjens et al. 2004). The first 
group - which consists of cytochrome c, Smac/DIABLO and the serine 
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protease HtrA2/OMI - are responsible in the activation of the caspase-
dependent mitochondrial pathway (Du, Fang et al. 2000, Garrido, Galluzzi et 
al. 2006), while the second group - consisting of the apoptosis-inducing factor 
(AIF), endonuclease G and caspase-activated DNAse (CAD) -  are 
responsible for DNA fragmentation and condensation of peripheral nuclear 
chromatin, which is a late event that occurs after the cell has committed to die 
(Joza, Susin et al. 2001).  
 
All these apoptotic mitochondrial events are controlled and regulated 
by members of the Bcl-2 family of proteins (Cory and Adams 2002). The Bcl-2 
family of proteins is responsible in maintaining the mitochondrial membrane 
permeability and can either be pro-apoptotic (Bcl-10, Bax, Bak, Bid, Bad, Bim, 
Bik and Blk) or anti-apoptotic (Bcl-2, Bcl-x, Bcl-XL, Bcl-XS, Bcl-w and BAG). 
These proteins are very important and their balance (usually measured as the 
ratio Bax/Bcl-2) will determine if the cell commits to apoptosis or aborts this 
process. Therefore, in this study, we will look at the effects of the active plant 
extracts on the expression of 3 different genes (Bax, Bcl-2, and 
Smac/DIABLO), which play vital roles in the production of proteins that are 
actively involved in the intrinsic pathway of apoptosis.  
 
Figure 4.45 (summary in Table 4.4) shows that MPc is able to increase 
the expression of Bax and Smac/DIABLO by 9-fold and 4-fold respectively, 
while reducing the expression of Bcl-2 by more than 20-fold in a significant 
manner. MPh also significantly stimulates the expression of both Bax and 
Smac/DIABLO by 12-fold and 3-fold respectively, while inhibiting Bcl-2 
expression by 7-fold. A similar trend was observed for both FD1c and FD2c 
extracts as they significantly up-regulate the expression of Bax (FD1c: 2-fold, 
FD2c: 2-fold) and Smac/Diablo (FD1c: 4-fold, FD2c: 2-fold) even though the 
extent of gene expression stimulation was not as much as both MPc and 
MPh. Both FD1c and FD2c also significantly down-regulated the expression of 
Bcl-2 by 7 and 12-fold respectively. These findings suggest that all active 
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extracts of the plants increase the expression of pro-apoptotic genes and 
reduce the expression of anti-apoptotic genes, which commit PC3 cells into 
apoptosis by an increased production of pro-apoptotic proteins and reduced 
production of anti-apoptotic proteins. Table 4.5 shows the summary of all the 
investigations being carried out in order to determine the mode of cells death 
induced by the active extracts of both Marantodes pumilum and Ficus 
deltoidea plants and their respective results. Evidences from these studies 
suggest that all active plant extracts induce prostate cancer cell death via 
apoptosis. 
Figure 4.45.  Bcl-2, Bax and Smac/DIABLO mRNA gene expressions in PC3 cells 
treated with MNTC of the active plant extracts of Marantodes pumilum and Ficus 
deltoidea after 96 hours. The genes expressions were determined as described in RT-
qPCR Conditions and Analysis. Data are mean ±  SD; n=4 experiments. * P < 0.05, *** P< 
0.001. 
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Table 4.4  mRNA gene expression analysis (Bax, Bcl-2 & Smac/DIABLO) in PC3 cells 
treated with MNTC of the active plant extracts of Marantodes pumilum and Ficus 
deltoidea after 96 hours. The genes expressions were determined as described in RT-
qPCR Conditions and Analysis where Control = 1. Data are mean ±  SD; n=4 
experiments. * P < 0.05, *** P< 0.001. 
Sample Gene Fold expressions relative to Control in PC3 cells 
MPc Bax 9*** 
Bcl-2 0.02***(> 20-Fold) 
Smac/DIABLO 4*** 
MPh Bax 12*** 
Bcl-2 0.15*(7-Fold) 
Smac/DIABLO 3* 
FD1c Bax 2 
Bcl-2 0.13*(7-Fold) 
Smac/DIABLO 4*** 
FD2c Bax 2* 
Bcl-2 0.09***(12-Fold) 
Smac/DIABLO 2* 
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Table 4.5  Summary list of all the investigation carried out to determine the mode of death induced by the active extracts of both Marantodes 
pumilum and Ficus deltoidea plants and their respective results. 
Assay/Sample MPc MPh FD1c FD2c 
Morphological 
observation 
(Characteristics of 
apoptosis or necrosis) 
Apoptosis (+) 
Necrosis (−) 
Apoptosis (+) 
Necrosis (−) 
Apoptosis (+) 
Necrosis (−) 
Apoptosis (+) 
Necrosis (−) 
DAPI staining Apoptotic cells visible Apoptotic cells visible Apoptotic cells visible Apoptotic cells visible 
Annexin V-FITC 
fluorocytometric 
analysis 
é Number of cells in
early apoptosis
compared to control 
(untreated cells) 
é Number of cells in
early apoptosis
compared to control 
(untreated cells) 
é Number of cells in
early apoptosis
compared to control 
(untreated cells) 
é Number of cells in
early apoptosis
compared to control 
(untreated cells) 
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Table 4.5 (Continues) 
Assay/Sample MPc MPh FD1c FD2c 
Mitochondrial membrane 
potential (MMP) 
depolarization analysis 
é MMP depolarization é MMP depolarization é MMP depolarization é MMP depolarization 
Detection of Caspase 3/7 é Caspases 3/7 
production  
é Caspases 3/7 
production 
é Caspases 3/7 
production 
é Caspases 3/7 
production 
Nuclear DNA 
fragmentation analysis 
Nuclear DNA 
fragmentation (+) 
Nuclear DNA 
fragmentation (+) 
Nuclear DNA 
fragmentation (+) 
Nuclear DNA 
fragmentation (+) 
mRNA gene expression 
analysis 
é Pro-apoptotic genes 
êAnti-apoptotic genes 
é Pro-apoptotic genes 
êAnti-apoptotic genes 
é Pro-apoptotic genes 
êAnti-apoptotic genes 
é Pro-apoptotic genes 
êAnti-apoptotic genes 
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4.1.6 Effect of the active extracts of the plants on the cell cycle of 
prostate cancer cell lines 
The effects of the active extracts of Marantodes pumilum and Ficus 
deltoidea on the cell cycle of LNCaP and PC3 cell lines were evaluated using 
a flow cytometer. As shown in Figure 4.46 & Figure 4.48, there was a 
significant increase (p<0.05) in the population of LNCaP cells at the G2M 
phase as compared to the untreated cells when treated with the GI50 of both 
Marantodes pumilum chloroform and n-Hexane extracts and Ficus deltoidea 
extracts. The same trend was observed (Figure 4.47 & Figure 4.49) when the 
PC3 cells were treated with the GI50 of both plant extracts. In addition, 
treatment with the GI50 of both plant extracts also caused a significant 
decrease in the population of both LNCaP and PC3 cells at G0/G1 phase 
(p<0.05) while the percentages of cell population at the S phase remains 
almost the same for both cell lines. 
 
 Cell cycle arrest enables DNA repair to occur thus preventing 
replication of the damaged templates (Murray 2004). Cell cycle arrests 
specifically at the G2M phase and it serves to prevent the cells from entering 
the mitosis (M) phase with damaged genomic DNA. The transition of G2-
phase into M-phase is regulated by the activity of Cyclin B-cdc2 (CDK1) 
complex (Al-Ejeh, Kumar et al. 2010). Cell cycle arrest at G2M phase 
ultimately inactivates the Cyclin B-cdc2 complex via two parallel cascades. 
The first cascade involves the phosphorylation of Chk kinases that inactivates 
cdc25 - which prevents the activation of cdc2 - while the second cascade 
involves the up-regulation of p53 proteins - which binds to and dissociates the 
Cyclin B-cdc2 complex (Lukas, Lukas et al. 2004, Foster 2008). Nevertheless, 
further studies need to be carried out in order to understand the actual 
mechanisms on how the active extracts of Marantodes pumilum and Ficus 
deltoidea induces cell cycle arrest at G2M phase. Apart from that, further 
studies should be done in order to identify the phytochemicals responsible for 
the activity.  
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  Control Campthotecin 
 Marantodes Pumilum chloroform   Marantodes Pumilum n-Hexane             
Figure 4.46.  Effect of the active extracts of Marantodes pumilum on the cell cycle of 
LNCaP cells analysed by measuring DNA content using flow cytometer. The cells were 
treated with the GI50 of the active extracts. *p<0.05 as compared to the untreated cells. 
Paclitaxel treatment was used as positive control. Results shown are representatives 
of three independent experiments. 
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                                 Control                              Campthotecin 
                  
      Marantodes Pumilum chloroform   Marantodes Pumilum n-Hexane              
Figure 4.47.  Effect of the active extracts of Marantodes pumilum on the cell cycle of 
PC3 cells analysed by measuring DNA content using flow cytometer. The cells were 
treated with the GI50 of the active extracts. *p<0.05 as compared to the untreated cells. 
Paclitaxel treatment was used as positive control. Results shown are representatives 
of three independent experiments. 
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                                Control                                Campthotecin 
               
                         FD1 chloroform                       FD2 chloroform 
Figure 4.48.  Effect of the active extracts of Ficus deltoidea on the cell cycle of LNCaP 
cells analysed by measuring DNA content using flow cytometer. The cells were treated 
with the GI50 of the active extracts. *p<0.05 as compared to the untreated cells. 
Paclitaxel treatment was used as positive control. Results shown are representatives 
of three independent experiments. 
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                                 Control                             Campthotecin 
               
                          FD1 chloroform                       FD2 chloroform 
Figure 4.49.  Effect of the active extracts of Ficus deltoidea on the cell cycle of PC3 
cells analysed by measuring DNA content using flow cytometer. The cells were treated 
with the GI50 of the active extracts. *p<0.05 as compared to the untreated cells. 
Paclitaxel treatment was used as positive control. Results shown are representatives 
of three independent experiments. 
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4.1.7 Effect of the plant extracts on Arachidonic metabolism (ALOX-5) 
As mentioned in section 2.1.4.4, the production of the 5-LOX enzyme 
could also contribute to the growth of prostate cancer cells. This enzyme is 
known to be encoded by the ALOX-5 gene. Ghosh and Myers (1997) reported 
that the inhibition of 5-LOX would block the production of its metabolites and 
triggers apoptosis in prostate cancer cells. This study was conducted to 
investigate the effects of the active plant extracts of the mRNA gene 
expression of the ALOX-5 gene. Figure 4.50 shows that only MPc was able to 
inhibit the expression of ALOX-5 gene in a significant manner. The other 3 
plant extracts were not able to have any significant effect on the expression of 
the gene. This data is very interesting as it suggests that MPc was also able 
to trigger PC3 cell death via apoptosis by inhibiting ALOX-5 gene expression 
apart from activating the intrinsic pathway of apoptosis. 
Figure 4.50.  ALOX-5 mRNA gene expressions in PC3 cells treated with MNTC of the 
active plant extracts of Marantodes pumilum and Ficus deltoidea after 96 hours. The 
genes expressions were determined as described in RT-qPCR Conditions and 
Analysis. Data are mean ±  SD; n=4 experiments. * P < 0.05, *** P< 0.001. 
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4.1.8 Inhibition of PC3 cells migration and invasion 
 Metastasis is responsible for 90% of cancer mortality rates. It 
represents the major problem in the treatment of cancer, is indicative for poor 
prognosis, and has dramatic effects on the survival of patients. Metastasis 
involves multiple processes such as infiltrative growth through the 
extracellular matrix (ECM), cell migration through blood or lymph vessels and 
rise of distant colonies (Gupta and Massagué 2006) Migration is described as 
any directed cell movement in the body. The ability to migrate allows cells to 
change their position within tissues or different organs. Invasion on the other 
hand, is defined as the penetration of tissue barriers, such as passing through 
the basement membrane and infiltration into the underlying interstitial tissues 
by malignant tumor cells.  
 
Migration and invasion are clearly separated terms in experimental 
biology as migration only involves the directed movement of cells on a 
substrate such as basal membranes, ECM fibers, or plastic plates (2D 
surfaces); whereas, invasion involves cell movement through a 3D matrix, 
which is accompanied by a restructuring of the 3D environment (Friedl and 
Wolf 2010). Despite the difficulties in defining different modes of migration, it 
is a fact that the ability to migrate is a prerequisite to invade; a cell cannot 
invade without migration but can move without invasion (Fackler and Grosse 
2008).  
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4.1.8.1 Active extracts of the plants suppressed Migration of PC3 cells 
in Vitro 
To investigate the effects of the active extracts of the plants on the 
migration of PC3 cells, cells were treated with the maximum non-toxic 
concentration (MNTC) for 72 hours and seeded in the 96 well plate (cell 
exclusion zone assay). After 24, 48 and 72 hours of incubation, the migratory 
activity of the cells were examined and the results are shown in Figure 4.36. 
Throughout this study, the morphology of PC3 cells were monitored frequently 
in order to make sure that the cells did not show any significant signs of cell 
death as these will influence the outcome of this study. If a drug or an extract 
has the ability to inhibit cancer cells migration, it could be detected by using 
MNTC. 
 
Figure 4.51 to Figure 4.53 show the inhibitory activity of the active 
extracts of Marantodes pumilum, Ficus deltoidea plants and Paclitaxel 
(positive control) on the migration of PC3 cells as viewed under EVOS® FL 
Imaging System. Figure 4.54 indicates that, the active extracts of both plants - 
Marantodes pumilum and Ficus deltoidea - at MNTC significantly inhibited the 
migration of PC3 cells. This observation also indicates that the active extracts 
of the plant suppressed the migration of PC3 cells in a time-dependent 
manner. Both MPc and FD1c reduced the number of migrated cells by 50% at 
every time point. To further validate the results of this study, another migration 
study was conducted by using the transwell migration assay method (Boyden 
Chamber). Results obtained from this experiment are shown in Figure 4.55.  
 
After 24 hours of treatment with the active extracts of the plant, we can 
clearly see that all active extracts of both plants showed significant inhibition 
to the migration of the PC3 cells with MPc and FD1c reducing the number of 
migrated cells by almost 60%. These results are in agreement with the 
previous data obtained previously when conducting the cell migration study by 
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using the cell exclusion zone assay method. Thus, it seems quite likely that 
MPc, MPh, FD1c and FD2c could inhibit PC3 cell migration.  
 
In section 2.2.2, we have mentioned that chemokines such as CXCL12 
can act as major regulators of cells trafficking and adhesion (Kyriakou, Rabin 
et al. 2008). The binding of CXCL12 to its receptor, CXCR4, is said to initiate 
divergent signalling pathways that lead to multiple responses including the 
phosphorylation of MEK/ERK signalling cascade and the activation of NF-κB, 
which is important for tumor cell progression and survival. Therefore, further 
study needs to be conducted to get a better understanding on how the active 
plant extracts suppress the migration of PC3 cells. 
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Sample/Hour 24 48 72 
Control 
Paclitaxel 
Figure 4.51.  Migration of PC3 cells treated with the MNTC of Paclitaxel for 24, 48, and 72 hours viewed under the EVOS®  FL Imaging System. 
Inhibition of migration can be clearly seen after treatment with Paclitaxel compared to the untreated cells. Results shown are representative of 
three independent experiments. 
1000 um
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Sample/Hour 24 48 72 
MPc 
MPh 
Figure 4.52.  Migration of PC3 cells treated with the MNTC of the active extracts of Marantodes pumilum for 24, 48, and 72 hours viewed under the 
EVOS®  FL Imaging System. Inhibition of migration can be clearly seen after treatment with MPc and MPh compared to the untreated cells. Results 
shown are representative of three independent experiments. 
1000um 
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Figure 4.53.  Migration of PC3 cells treated with the MNTC of the active extracts of Ficus deltoidea for 24, 48, and 72 hours viewed under the 
EVOS®  FL Imaging System. Inhibition of migration can be clearly seen after treatment with FD1c and FD2c compared to the untreated cells. 
Results shown are representative of three independent experiments. 
1000um 
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Figure 4.54.  Oris™Cell Migration analysis: 5 x 104 of PC3 cells were seeded per well 
and allowed to adhere. Stoppers were then removed and the active extracts of both 
Marantodes pumilum (MPc and MPh) and Ficus deltoidea  (FD1c and FD2c) were added 
to te wells, and the plate was incubated to permit cell migration. The cells were labelled 
with CellTracker™  Green and the fluorescence quantified in the detection zone using a 
Synergy HT BioTek plate reader. Results shown are representatives of three 
independent experiments, *p<0.05 and **p<0.01 and against control as analysed by the 
Student’s t test. 
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Figure 4.55.  CytoSelect Cell Migration analysis: Effects of the active extract of both 
Marantodes pumilum (MPc and MPh) and Ficus deltoidea (FD1c and FD2c) plants on 
the migration of the PC3 cells. PC3 cells were treated with the MNTC concentration of 
MPc, MPh, FD1c and FD2c for 24 hours. Results shown are representatives of three 
independent experiments, *p<0.05 and **p<0.01 and against control as analysed by the 
Student’s t test. 
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4.1.8.2 Active extracts of the plants suppressed invasion of PC3 cells in 
vitro 
Figure 4.56 shows the effect of the active extracts of the plants on PC3 
cell invasion after 48 hours of treatment. All active extracts exhibited 
significant inhibition on the invasion of the prostate cancer cells after 48 hours 
of treatment. Both MPc and FD1c extracts reduced the number of invading 
cells by more than two-fold when compared to control. These results indicate 
that the active extracts of both plants are not only capable of inhibiting or 
delaying PC3 cell migration but could also prevent cell invasion in a significant 
way. As mentioned previously, the inhibition of both cell migration and 
invasion could occur through MMP modulation. It is well known that: (1) the 
derangement of ECM by MMPs play an initial key role in cell movement via 
the alteration of cell-ECM interactions; and (2) MMPs breakdown the 
basement membrane allowing cancer cells to migrate and invade.  
Among MMPs, MMP-2 and MMP-9 play the most important role in 
basement membrane type IV collagen degradation (Stetler-Stevenson 1990, 
Giancotti and Ruoslahti 1999, Zeng, Cohen et al. 1999). In particular, MMP-2 
expression is associated with tumor invasion, angiogenesis, metastasis and 
recurrence (Wang, Wang et al. 2003, Komatsu, Nakanishi et al. 2004). It was 
reposted that MMP-2 and MMP-9 are correlated with an aggressive, invasive 
or metastatic tumor phenotype (Cockett, Murphy et al. 1997, Papathoma, 
Zoumpourlis et al. 2001). It is well known that MMP inhibitors block 
endothelial cell activities which are essential for new vessel development 
leading to proliferation and invasion (Benelli, Adatia et al. 1993, Murphy, 
Unsworth et al. 1993). Therefore, MMP-2 and MMP-9 are thought to be 
therapeutic targets of anticancer drugs based on the degrading action of both 
enzymes on gelatins, which are major components of the basement 
membrane. As this is the first time that these active extracts are reported to 
inhibit both the migration and invasion of prostate cancer cells (PC3), more 
studies should be conducted in order to understand the actual mechanism 
that led to this activity. 
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Figure 4.56.  CytoSelect Cell Invasion analysis: Effects of the active extract of both 
Marantodes pumilum (MPc and MPh) and Ficus deltoidea (FD1c and FD2c) plants on 
the invasion of the PC3 cells. PC3 cells were treated with the MNTC concentration of 
MPc, MPh, FD1c and FD2c for 48 hours. Results shown are representatives of three 
independent experiments, *p<0.05 and **p<0.01 and against control as analysed by the 
Student’s t test. 
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4.1.8.3 VEGF-A, CXCR4 and CXCL12 mRNA Gene expression 
This study was conducted to investigate the effects of the active plant 
extracts on the mRNA gene expression of VEGF-A, CXCL12 and CXCR4. 
Figure 4.57 shows that only FD1c was able to increase the expression of 
CXCR4 by 2-fold significantly. However, for CXCL12 mRNA gene expression, 
all plant extracts inhibit its expression in a significant manner. MPh reduced 
the expression of CXCL12 by 16-fold while MPc, FD1c and FD2c reduced the 
expression of the gene by more than 20-fold. Figure 4.57 also show that MPh 
and FD1c were able to down-regulate the expression of VEGF-A by 7-fold 
and 9-fold respectively in a significant manner. MPc inhibited the expression 
of VEGF-A significantly by 20-fold. However, FD2c did not show any 
significant effect on the mRNA gene expression. The significant inhibition of 
the mRNA gene expression of both CXCL12 and VEGF-A by the active plant 
extracts suggests an explanation on how these plant extracts were able to 
suppress both migration and invasion as reported earlier. Table 4.6 
summarizes the activity of the active extracts of both Marantodes pumilum 
and Ficus deltoidea plant on the mRNA gene expression of CXCR4, CXCL12 
and VEGF-A 
 
 
 
 
 
 
 
 
 
		 217	
 
 
Figure 4.57.  CXCR4, CXCL12 and VEGF-A mRNA genes expression in PC3 cells 
treated with MNTC of the active plant extracts of Marantodes pumilum and Ficus 
deltoidea after 96 hours. The genes expressions were determined as described in RT-
qPCR Conditions and Analysis. Data are mean ±  SD; n=4 experiments. * P < 0.05, *** P< 
0.001 
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Table 4.6  mRNA gene expression analysis (CXCR4, CXCL12 & VEGF-A) in PC3 cells 
treated with MNTC of the active plant extracts of Marantodes pumilum and Ficus 
deltoidea after 96 hours. The genes expressions were determined as described in RT-
qPCR Conditions and Analysis where Control = 1. Data are mean ±  SD; n=4 
experiments. * P < 0.05, *** P< 0.001. 
Sample Gene Fold expressions relative to Control in PC3 cells 
MPc CXCR4 1 
CXCL12 0.003***(>20-Fold) 
VEGF 0.05***(2-Fold) 
MPh CXCR4 1 
CXCL12 0.07*** (16-Fold) 
VEGF 0.1*(7-Fold) 
FD1c CXCR4 2* 
CXCL12 0.01*** (>20-Fold) 
VEGF 0.1*** (9-Fold) 
FD2c CXCR4 1 
CXCL12 0.003***(>20-Fold) 
VEGF 1 
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4.1.9 Identification of the active fractions from the plant extracts 
 
4.1.9.1 Fractionation of the plant extracts 
Three plant extracts namely Marantodes pumilum choloroform extract 
(MPc), Ficus deltoidea var. angustifolia (Miq) corner chloroform extract 
(FD1c), and Ficus deltoidea Jack var. deltoidea chloroform extract (FD2c) 
were chosen to be further fractionated using the method explained in 3.1.2 
based on the GI50 values of each plant extracts obtained from cytotoxicity 
studies with all 3 prostate cancer cell lines (PC3, DU145 and LNCaP). 140 
fractions were collected for each plant extract and each fraction was 
examined by a thin layer chromatography (TLC) (section 3.1.3). TLC is a 
common analytical chromatography technique used to separate non-volatile 
mixtures. In this study, this method is used to ascertain the presence of 
different materials/compounds in fractions from column chromatography 
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Figure 4.58  TLC analysis of SEPHADEX of the MPc extract (fraction 4 to 68) viewed 
under white light. T stands for total crude extract (crude extract of MPc). 
 
Figure 4.59  TLC analysis of SEPHADEX of the MPc extract (fraction 4 to 68), viewed 
under 254 nm wavelength. T stands for total crude extract (crude extract of MPc). 
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Figure 4.60  TLC analysis of SEPHADEX of the MPc extract (fraction 4 to 68), viewed 
under 366 nm wavelength. T stands for total crude extract (crude extract of MPc). 
 
 
Figure 4.61  TLC analysis of SEPHADEX of the MPc extract after derivatisation with 
anisaldegyde (fraction 4 to 68), viewed under white light. T stands for total crude 
extract (crude extract of MPc). 
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Figure 4.62  TLC analysis of SEPHADEX of the MPc extract (fraction 1 to 18), viewed 
under 254 nm wavelength. T stands for total crude extract (crude extract of MPc). 
 
 
Figure 4.63  TLC analysis of SEPHADEX of the MPc extract (fraction 1 to 18), viewed 
under 366 nm wavelength. T stands for total crude extract (crude extract of MPc). 
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Figure 4.64  TLC analysis of SEPHADEX of the MPc extract after derivatisation with 
anisaldegyde (fraction 1 to 18), viewed under white light. T stands for total crude 
extract (crude extract of MPc). 
 
 
Figure 4.65  TLC analysis of SEPHADEX of the MPc extract (fraction 19 to 36), viewed 
under 254 nm wavelength. T stands for total crude extract (crude extract of MPc). 
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Figure 4.66  TLC analysis of SEPHADEX of the MPc extract (fraction 19 to 36), viewed 
under 366 nm wavelength. T stands for total crude extract (crude extract of MPc). 
 
 
Figure 4.67  TLC analysis of SEPHADEX of the MPc extract after derivatisation with 
anisaldegyde (fraction 19 to 36), viewed under white light. T stands for total crude 
extract (crude extract of MPc). 
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Based on the TLC profiles of MPc shown in Figures 4.58 to 4.67 the 
eluates were then pooled into 7 major fractions (fraction 1, fraction 2-8, 
fraction 10-13, fraction 15-17, fraction 21-24, fraction 27-29, fraction 30-33). 
These fractions were subjected to another cytotoxicity study with PC3 cell 
lines to determine their activity. 
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Figure 4.68  TLC analysis of SEPHADEX of the FD1c extract (fraction 16 to 33), viewed 
under 254 nm wavelength. T stands for total crude extract (crude extract of FD1c). 
Figure 4.69  TLC analysis of SEPHADEX of the FD1c extract (fraction 16 to 33), viewed 
under 366 nm wavelength. T stands for total crude extract (crude extract of FD1c). 
		 227	
 
Figure 4.70  TLC analysis of SEPHADEX of the FD1c extract after derivatisation with 
anisaldegyde (fraction 16 to 33), viewed under white light. T stands for total crude 
extract (crude extract of FD1c). 
 
 
Figure 4.71  TLC analysis of SEPHADEX of the FD1c extract (fraction 34 to 51), viewed 
under 254 nm wavelength. T stands for total crude extract (crude extract of FD1c). 
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Figure 4.72  TLC analysis of SEPHADEX of the FD1c extract (fraction 34 to 51), viewed 
under 366 nm wavelength. T stands for total crude extract (crude extract of FD1c). 
 
 
Figure 4.73  TLC analysis of SEPHADEX of the FD1c extract after derivatisation with 
anisaldegyde (fraction 34 to 51), viewed under white light. T stands for total crude 
extract (crude extract of FD1c). 
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Based on the TLC profiles of FD1c shown in Figures 4.68 to 4.73 the 
eluates were then pooled into 5 major fractions (fraction 20-23, fraction 24-30, 
fraction 31-36, fraction 37-42, fraction 43-51). These fractions were subjected 
to another cytotoxicity study with PC3 cell lines to determine their activity. 
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Figure 4.74  TLC analysis of SEPHADEX of the FD2c extract (fraction 16 to 33), viewed 
under 254 nm wavelength. T stands for total crude extract (crude extract of FD2c). 
 
 
Figure 4.75  TLC analysis of SEPHADEX of the FD2c extract (fraction 16 to 33), viewed 
under 366 nm wavelength. T stands for total crude extract (crude extract of FD2c). 
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Figure 4.76  TLC analysis of SEPHADEX of the FD2c extract after derivatisation with 
anisaldegyde (fraction 16 to 33), viewed under white light. T stands for total crude 
extract (crude extract of FD2c). 
 
 
Figure 4.77  TLC analysis of SEPHADEX of the FD2c extract (fraction 34 to 51), viewed 
under 254 nm wavelength. T stands for total crude extract (crude extract of FD2c). 
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Figure 4.78  TLC analysis of SEPHADEX of the FD2c extract (fraction 34 to 51), viewed 
under 366 nm wavelength. T stands for total crude extract (crude extract of FD2c). 
 
 
Figure 4.79  TLC analysis of SEPHADEX of the FD2c extract after derivatisation with 
anisaldegyde (fraction 34 to 51), viewed under white light. T stands for total crude 
extract (crude extract of FD2c). 
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 Based on the TLC profiles of FD2c shown in Figures 4.74 to 4.79 the 
eluates were then pooled into 8 major fractions (fraction 16, fraction 17-22, 
fraction 23-26, fraction 27-28, fraction 29-33, fraction 34-36, fraction 37-39, 
fraction 40-45). These fractions were subjected to another cytotoxicity study 
with PC3 cell lines to determine their activity. 
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4.1.9.2 Identification of the active fractions using SRB staining assay 
Even though the main objective of this research is to produce 
standardized extracts with chemopreventive properties, further extraction and 
fractionation of the plant extracts is important in order to identify active 
compounds that could be used for their standardization.  
 
Size exclusion chromatography of the active plant extracts yielded 140 
fractions. Based on the TLC profiles, the eluates were then pooled into 20 
major fractions. These fractions were then tested for their cytotoxic activity 
(SRB staining assay on PC3 cells) and their GI50 determined.  
 
Figure 4.80 shows that out of the 20 major fractions being tested, only 4 
fractions were observed to have better efficacy than their respective plant 
extracts. These fractions were FD1c F30-33, FD1c F43-51, FD2c F29-33 and 
FD2c F34-36. Table 4.7 shows the GI50 of each active fraction. The GI50 
values for each fraction were significantly lower than their respective plant 
extracts before further fractionation process was carried out (P< 0.05). 
Therefore, these findings suggest that further extraction and fractionation 
processes implied on the active plant extracts were able to increase their 
efficacy. 
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Table 4.7  GI50 concentrations (µg/mL) of the active fractions from Marantodes 
pumilum and Ficus deltoidea plant extracts determined for PC3 cells as assessed by 
SRB assays after 72 hours. Each result was obtained in three independent 
experiments, which was run in triplicate. 
 
Plant name Fraction 
(Chloroform) 
Sample Code GI50 (µg/ml) 
with PC3 
Marantodes pumilum  
(Blume) Kuntze (synonym 
Labisia pumila var. pumila) 
Fraction 30-33 MPc F30-33 4.1 ± 0.3 
Ficus deltoidea var. 
angustifolia (Miq.) Corner 
Fraction 43-51 FD1c F43-51 12.3 ± 0.4 
Ficus deltoidea Jack var. 
deltoidea 
Fraction 29-33 FD2c F29-33 28.2 ± 0.2 
Fraction 34-36 FD2c F34-36 24.2 ± 0.1 
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a) 
 
b) 
 
Figure 4.80.  Dose-response curves of the effect of the extracts against PC3 cell line. a) 
Effect of MPc fractions, b) Effect of FD1c and FD2c fractions on the viability of PC3 cell 
line after 72 hours of exposure. All data represent the mean values and standard error 
of mean (SEM) for the cytotoxic extracts after 72 hours of exposure. Each point was 
obtained from three independent experiments, which was run in triplicate. 
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4.1.10 Effects of the active fractions of the plant extracts on mRNA 
genes expression 
 
4.1.10.1 Apoptosis-related Gene expression (Bcl-2, Bax, Smac-
Diablo, ALOX-5) 
The 4 active fractions were further tested to investigate their mode of 
action on PC3 prostate cancer cell lines. Table 4.8 shows that MPc F30-33 
has significantly inhibited both Bcl-2 and ALOX-5 mRNA gene expression by 
more than 20-fold and 3-fold respectively. MPc F30-33 also increased the 
expression of Bax by 20-fold in a significant manner. Smac/DIABLO mRNA 
gene expression was significantly stimulated by MPc F30-33 (50-fold), FD2c 
F29-33 (5-fold), and FD2c F34-36 (4-fold). However, FD1c F43-51 did not 
show any significant effect on the expression of Smac/DIABLO. This is 
contradictory to the previous data in section 4.1.5.6, which show that the 
active extract of FD1c significantly increased the expression of the gene by 4-
fold. This could happen due to the loss of active metabolite/s during the 
fractionation process. Even though FD1c F43-51 showed better efficacy than 
its active extracts, the loss of some bioactive component/s might lead to PC3 
cell death through a different mode of action. Other active fractions showed a 
similar trend in activity when compared to their active extracts but with better 
efficacy. Therefore, these data suggest that the active fraction of the plant 
extracts (MPc F30-33, FD2c F29-33, and FD2c F34-36) also induced PC3 
prostate cancer cells death via apoptosis as observed with their active 
extracts.  
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Table 4.8  mRNA gene expression analysis (Bax, Bcl-2 & Smac/DIABLO) in PC3 cells 
treated with MNTC of the active fractions of Marantodes pumilum and Ficus deltoidea 
after 96 hours (Apoptosis-related genes). The genes expressions were determined as 
described in RT-qPCR Conditions and Analysis where Control = 1.  Data are mean ±  
SD; n=4 experiments. * P < 0.05, *** P< 0.001. 
Sample Gene Fold expressions relative to Control in PC3 
cells 
MPc F30-33 Bax 20*** 
Bcl-2 0.02*** (20-Fold) 
ALOX-5 0.3* (3-Fold) 
Smac/DIABLO 54*** 
FD1c F43-51 Smac/DIABLO 1 
FD2c F29-33 Smac/DIABLO 5*** 
FD2c F34-36 Smac/DIABLO 4* 
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4.1.10.2 Migration-related Gene expression (VEGF, CXCR4, CXCL12) 
In this study we will investigate the effect of the active fractions of 
mRNA gene expression related to cell migration and invasion. Table 4.9 
shows that both MPc F30-33 and FD1c F43-51 have significantly down-
regulated the mRNA gene expression of VEGF by 22-fold and 4-fold 
respectively, whereas both active fractions of the FD2c extract did not cause 
any significant changes to the expression of VEGF. Even though none of the 
active fractions significantly caused any changes to the expression of CXCR4, 
all 4 of them had caused significant inhibition to the expression of CXCL12 by 
more than 20-fold. These findings are similar to the previous results observed 
with the active extracts of the plants but with greater efficacy. Therefore, the 
active fractions of the plant extracts also inhibit PC3 prostate cancer cells 
migration and invasion through similar mode of action.  
Table 4.9  mRNA gene expression analysis (VEGF-A, CXCR4 & CXCL12) in PC3 cells 
treated with MNTC of the active fractions of Marantodes pumilum and Ficus deltoidea 
after 96 hours (Migration-related genes). The genes expressions were determined as 
described in RT-qPCR Conditions and Analysis where Control = 1. Data are mean ±  
SD; n=4 experiments. * P < 0.05, *** P< 0.001. 
Sample Gene Fold expressions relative to Control in PC3 cells 
MPc F30-33 VEGF-A 0.04***(22-Fold) 
CXCR4 1 
CXCL12 0.009***(>20-Fold) 
FD1c F43-51 VEGF-A 0.3***(4-Fold) 
CXCR4 1 
CXCL12 0.02*(>20-Fold) 
FD2c F29-33 VEGF-A 1 
CXCR4 1 
CXCL12 0.005***(>20-Fold) 
FD2c F34-36 VEGF-A 1 
CXCR4 2 
CXCL12 0.005***(>20-Fold) 
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4.1.11 Specificity study using normal Human Dermal Fibroblast cells 
This study is carried out in order to investigate the effect of the active 
plant extracts on normal human cells. The results presented in this thesis 
indicate that the active extracts of both Marantodes pumilum (MPc and MPh) 
and Ficus deltoidea (FD1c and FD2c) and their active fractions (MPc F30-33, 
FD1c F43-51, FD2c F29-33, and FD2c F34-36) show great potential in 
prostate cancer cell inhibition by inducing cell death via apoptosis, causing 
cellular arrest at G2M phase and significantly inhibiting both prostate cancer 
cells migration and invasion. 
 
However, all these activities would be useless if the active extracts also 
exert toxic effect on normal human cells. Normal human dermal fibroblast 
cells (HDFa) were used to ascertain the differential toxicity of the active 
extracts. The results of this study are shown in Figure 4.81. We established 
the Maximum Non-Toxic Concentrations of the extracts (MNTC) as the 
concentration allowing 80% of the cell population to grow. The MNTC of both 
MPc and MPh are about 200 µg/mL and the MNTC values for both FD1c and 
FD2c are more than 200 µg/mL. All fractions but MPc F30-33 (≥ 100 µg/mL) 
were observed to have MNTC values of more than 200 µg/mL. However, 
considering the very low GI50 value of MPc F30-33 (4 µg/mL), this fraction is 
still considered to show selective cytotoxicity. The remaining 3 active 
fractions, FD1c F43-51, FD2c F29-33, and FD2c F34-36 were observed to 
have MNTC value of more than 200 µg/mL. This information indicates that all 
the active extracts of the plant as well as the active fractions show selectivity 
and is specifically inhibiting PC3 cells line growth. 
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a) 
 
b) 
 
Figure 4.81.  Effects of a) MPc, MPh, FD1c and FD2c, and b) MPc F30-33, FD1c F43-51, 
FD2c F29-33, and FD2c F34-36 plants on the growth of HDFa cells as assessed by SRB 
assays after 72 hours. Each result was obtained in three independent experiments, 
which was run in triplicate. 
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4.1.12 Identification of the active principles from the plant extracts 
4.1.12.1 Bioguided isolation of monounsaturated Alkyl Resorcinol 
from MPc F30-33 fraction 
4.1.12.1.1 HPLC microfractionation of MPc F30-33 
A high performance liquid chromatography (HPLC) microfractionation 
was carried out for MPc F30-33 in order to investigate the separation of the 
compounds and identify which fraction/s are responsible for the cytotoxic 
activity against PC3 prostate cancer cell lines. Figure 4.82 shows HPLC 
chromatogram of MPc F30-33. 4 different wavelengths were used in this study 
including 254, 210, 270 and 330nm. The peaks distribution looks almost 
similar in all investigated wavelengths, however the intensity of each peak is 
different. Therefore, the scale on the Y-axis is different for each wavelength 
due to different signal intensities.  Based on the chromatograph shown in 
Figure 4.82, 8 microfractions were collected from MPC F30-33 and all of 
these microfractions were subjected to a cytotoxicity assay on PC3 cells using 
SRB. The GI50 of each microfractions were calculated and Figure 4.83 shows 
that only microfraction 5 was significantly cytotoxic (P <0.05) against PC3 
cells with a GI50 value of 4 µg/mL. Therefore, microfraction 5 was analyzed 
further in order to identify its bioactive compound that might be responsible for 
the cytotoxic activity against prostate cancer cell lines. 
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Figure 4.82.  HPLC chromatogram of MPc F30-33. 4 different wavelengths were used in this study including 254, 210, 270 and 330nm. The peaks 
distribution looks almost similar in all investigated wavelengths, however the intensity of each peak is different. Therefore, the scale on the Y-axis 
is different for each wavelength due to different signal intensities. 
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Figure 4.83.  Overlay of the HPLC chromatogram of MPc F30-33 with their respective GI50. The GI50 concentrations (µg/mL) of the microfractions 
determined for PC3 cells as assessed by the SRB assays at 72 hours. Paclitaxel (0.01µM) was used as a reference drug. Each result was obtained 
in three independent experiments and run in triplicate. 
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4.1.12.1.2 Elucidation of microfraction no. 5 
Compound MP-1, as shown in Figure 4.84, was isolated as a colorless 
oil. In the IR spectrum shown in Figure 4.94, absorption bands for hydroxyl 
was observed at 3380.75 cm-1, and for alkenyl at 1600.16 cm-1. The HRESI-
MS (Figure 4.86) of compound MP-1 exhibited a protonated molecular ion 
[M+H]+ peak at m/z 402.2 (calcd. for C27H45O2+H, 401) which corresponded to 
the molecular formula C27H45O2. The 1HNMR (Figure 4.87) spectrum gave 
signals that are characteristic of resorcinol with unsaturated alkyl substituents 
at the 5th position, 5-alkylresorcinol (AR). A singlet at δ5.87 ppm and 
overlapped signals at δ6.02 ppm, form the aromatic part of the compound. 
The 1HNMR spectrum exhibited resonances for the alkenyl side chain at 
δ2.37 ppm (m), δ1.53 ppm (m), δ2.07 ppm (q, J=26.5, 13.5, 7), and δ5.45 ppm 
(m), overlapped signals from δ1.21 ppm to δ2.37 ppm, and at δ0.87 ppm (m). 
The 13CNMR spectrum (Figure 4.88) showed 6 resonances in the aromatic 
region (δ100.8-δ157.9ppm). Inspection of key HMQC (Figure 4.90) 
correlations showed two bond correlation between H at position 2 to C-1 and 
C-3, H at position 4 to C-3, H at position 6 to C-1 and H at position 1’ to C-2 
and C-5. HMBC (Figure 4.91) data showed three bond correlation between H 
at position 4 to C-2, H at position 6 to C-2, and H at position 1’ to C-4; and 
four bond correlation between H at position 4 to C-1’, H at position 6 to C-1’, 
and H at position 1’ to C-6. The aliphatic chain has a double bond due to the 
signals at δ5.45-δ5.53 ppm, which is a multiplet and integrated for 2H 
revealed the presence of a double bond in the aliphatic chain. We did not 
determine the position of the double bond in the aliphatic chain. Since the 
structure of MP-1 is not yet fully elucidated, in an effort to validate the 
structure of MP-1, a comparison is made to another 5-alkylresorcinol 
compound namely 1-O-methyl-6-acetoxy-5-(pentadec-10Z-enyl)resorcinol 
(Figure 4.85) isolated by Al-Mekhlafi, Shaari et al. (2012). Table 4.10 shows 
1H and 13C NMR spectroscopic data for 1-O-methyl-6-acetoxy-5-(pentadec-
10Z-enyl)resorcinol measured in CDCL3. The spectroscopic data in Table 
4.10 display similar peaks positioning for both C and H spectra especially in 
the aromatic region and the location of the alkenyl side chain when compared 
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to the spectroscopic data of MP-1 in the same table with slight differences in 
chemical shifts. The slight different in chemical shift is expected as different 
solvents were used for NMR analysis. However, the C at position 6 in 1-O-
methyl-6-acetoxy-5-(pentadec-10Z-enyl)resorcinol corresponds to δ131.7 ppm 
whereas the same C in MP-1 corresponds to δ108.4 indicating a huge 
different in the chemical shift. This phenomenon can be explained due to the 
fact that C at position 6 in 1-O-methyl-6-acetoxy-5-(pentadec-10Z-
enyl)resorcinol is attached to a stronger electron-withdrawing group thus 
making it more deshielded. This comparison has further validated the 
elucidated structure of MP-1. 
 
 
Figure 4.84  Structure of MP-1 
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Table 4.10  1H and 13C NMR spectroscopic data for compound MP-1 measured in benzene-d6 and 1H and 13C NMR spectroscopic data for 1-O-
methyl-6-acetoxy-5-(pentadec-10Z-enyl)resorcinol measured in CDCL3. The spectroscopic data is put side by side so that the structure can be 
easily compared, thus validating the structure of MP-1. The spectroscopic data for 1-O-methyl-6-acetoxy-5-(pentadec-10Z-enyl)resorcinol is 
adapted from “Alkylresorcinols and cytotoxic activity of the constituents isolated from Labisia pumila” by N. A. Al-Mekhlafi, K. Shaari, F. Abas, R. 
Kneer, E. J. Jeyaraj, J. Stanslas, N. Yamamoto, T. Honda, and N. H. Lajis, 2012, Phytochemistry (2012) 80, 42-49. Copyright 2012 by Elsevier. 
Adapted with permission. 
 
MP-1 1-O-methyl-6-acetoxy-5-(pentadec-10Z-enyl)resorcinol 
Position 1H 13C 2J 3J / 4J Position δH (J in Hz) δC 
1  157.9   1  151.8 
2 5.87 (s) 100.8 C-3, C-1  2 6.24 (d, J = 2.5 Hz) 98.4 
3  157.9   3  154.3 
4 6.02 (overlapped) 108.4 C-3 C-1’, C-2 4 6.18 (d, J = 2.5 Hz) 107.9 
5  146.1   5  136.7 
6 6.02 (overlapped) 108.4 C-1 C-1’, C-2 6  131.7 
1’ 2.37 (m) 36.6 C-5, C-2’ C-4, C-6 1’ 2.39 (t, J = 7.5 Hz) 32.2 
2’ 1.53 (m) 31.9   2’ 150 (m) 30.3 
 2.07 (q, J = 26.5, 13.5, 7) 28.0   3’-8’ 1.32-1.27 (m) 29.6-30.2 
 5.45 (m) 130.6   9’ 2.01 (m) 27.2 
 5.45 (m) 130.6   10’ 5.35 (m) 130.0 
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Table  4.10 (Continues) 
MP-1 1-O-methyl-6-acetoxy-5-(pentadec-10Z-enyl)resorcinol 
Position 1H 13C 2J 3J / 4J Position δH (J in Hz) δC 
 2.07 (q, J = 26.5, 13.5, 7) 27.7   11’ 5.35 (m) 130.0 
 1.21-2.37 (overlapped) 23.1-
30.6 
  12’ 2.01 (m) 27.2 
21 0.87 (m) 14.6   13’-14’ 1.32-1.27 (m) 22.6 
     15’ 0.89 (t, J = 7.0 Hz) 14.3 
     2-OCH3 3.71 (s) 56.1 
     1-OCOCH3 2.32 (s) 170.3 
     1-OCOCH3  20.7 
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Figure 4.85  Structure of 1-O-methyl-6-acetoxy-5-(pentadec-10Z-enyl)resorcinol 
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Figure 4.86  MP-1 ESI-MS result 
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Figure 4.87  1HNMR of MP-1 dissolved in benzene-d6 at 500MHz. The 1HNMR spectrum gave signals that are characteristic of resorcinol with unsaturated 
alkyl substituents at the 5th position, 5-alkylresorcinol (AR). A singlet at δ5.87 ppm and overlapped signals at δ6.02 ppm, form the aromatic part of the compound. 
The alkenyl side chain is identified at δ2.37 ppm (m), δ1.53 ppm (m), δ2.07 ppm (q, J=26.5, 13.5, 7), and δ5.45 ppm (m), overlapped signals from δ1.21 ppm to δ2.37 
ppm, and at δ0.87 ppm (m). 
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Figure 4.88  13CNMR of MP-1 dissolved in benzene-d6 at 500MHz 
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Figure 4.89  DEPT of MP-1 dissolved in benzene-d6 at 500MHz 
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Figure 4.90  HMQC correlations of MP-1 dissolved in benzene-d6 at 500MHz. Correlations between H and C are shown in the figure 
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Figure 4.91  HMBC correlations of MP-1 dissolved in benzene-d6 at 500MHz. Correlations between H and C are shown in the figure. 
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Figure 4.92  COSY of MP-1 dissolved in benzene-d6 at 500MHz 
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Figure 4.93  NOESY of MP-1 dissolved in benzene-d6 at 500MHz 
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Figure 4.94  Infrared spectra for MP-1  
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4.1.12.2 Dereplication of Isovitexin from FD1c F43-51, Lupeol, 
Moretenol from FD2c F29-33 and Oleanolic acid from FD2c F34-
36 fractions 
Previously, researchers have used the conventional methods, which 
rely heavily on bioactivity-directed fractionation methodology in order to 
identify, isolate and elucidate the bioactive lead compound from the crude 
extracts. This process, which depends on the results of the bioassay to guide 
the isolation, is often tedious, expensive, time consuming - and quite 
frequently we may end up with disappointing outputs when isolating a 
previously known and well characterized compound (Ghisalberti 1993, Alali 
and Tawaha 2009). In order to tackle these issues, a procedure known as 
dereplication has been used in natural products and phytochemistry research. 
This procedure is able to discriminate between previously known compounds 
and potential novel entities in a more efficient and rapid way while only 
working at the level of crude extracts (Alali and Tawaha 2009).  
 
Dereplication will prevent us from wasting important resources, as this 
procedure will be oriented towards targeted isolation of compounds 
presenting novel spectroscopic features. dereplication could also be a very 
useful procedure that can be used to investigate the presence of known 
compounds in a crude extracts or fractions in a quick and efficient way, thus 
making it essential for natural product research (Constant and Beecher 1995, 
Ackermann, Regg et al. 1996). In the dereplication method, hyphenated 
techniques using UV spectroscopy and mass spectrometry coupled with the 
use of natural products database are very important in order to determine the 
identity of the active compound at the earliest possible stage of the discovery 
process (Sedlock, Sun et al. 1992, Su, Rowley et al. 2002, Sarker and Nahar 
2012). In this study, the Ultra High Performance Liquid Chromatography–
Electro Spray Ionization-Mass Spectrometry (UHPLC–ESI-MS) and Liquid 
Chromatography-Photodiode Array Detection (LC-PDA) was used in order to 
analyse the secondary metabolite constituents of the active fractions from 
both FD1 and FD2 plants. 
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4.1.12.2.1 UHPLC-MS analysis of FD1c F43-51  
FD1c F43-51 was active against PC3 cancer cell lines with a GI50 
value of 12 µg/mL. The UHPLC-MS-ELSD-PDA profiles are shown in Figure 
4.95. The shifts for the retention time (tR) of the 12 peaks in this 
chromatogram (Figure 4.95) are due to the sequential four-channel detection 
system. The universal ELSD detection method provides accurate data in 
accessing the relative content of individual compounds in a mixture that may 
not be UV active (Yang, Liang et al. 2014). Peaks 3a and 3b with tR 5.72 min 
were present in the highest concentration, which accounts for 75.27% of the 
total mass. The positive and negative-ion ESIMS detection procedures 
showed different sensitivities (Table 4.11), with the positive mode producing a 
strong total ion chromatogram (TIC) for all the compounds. Therefore, the 
positive ESIMS and UV data were used to determine the structural 
information of the compounds present. Peaks 3a and 3b gave the same 
accurate mass of 433 and were dereplicated as Vitexin and Isovitexin 
respectively (Figure 4.96). These two compounds are known constituents of 
Ficus deltoidea (Bunawan, Amin et al. 2014). Peak 5 with tR 9.46 min was 
also detected with a good concentration with 8.22% of total mass and it was 
dereplicated as Brosimacutin (Figure 4.96). The other 10 compounds 
(Compounds 1,2,4 and 6-12) were present in a very small concentration and 
thus not considered to play a major role in the cytotoxic activity of FD1c F43-
51 fraction. 
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Figure 4.95  Overlay of ELSD, UV and MS (base peak monitoring) chromatograms for sample FD1c F43-51. 
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Table 4.11  MSI dereplication of FD1c F43-51 sample. 
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Vitexin 
 
Brosimacutin A 
 
Figure 4.96  The chemical structure of isovitexin, vitexin and brosimacutin A. 
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4.1.12.2.2 UHPLC-MS analysis of FD2c F29-33 and FD2c F34-36 
fractions 
FD2c F29-33 and FD2c F34-36 were active against PC3 cancer cell 
lines with GI50 values of 28 µg/mL and 24 µg/mL respectively. The UHPLC-
MS-ELSD-PDA chromatogram in Figure 4.97 shows 6 peaks. For FD2c F29-
33, 4 major peaks were detected - peak 1 is similar to peak 3 - at tR 24.15 
(peak 2), tR 24.42 (peak 3), tR 25.87 (peak 4) and tR 31.59 (peak 6). These 
peaks correspond to 21.07% (peak 3 + peak 1), 20.09% (peak 2), 34.40% 
(peak 4), and 31.59% (peak 6) of total mass respectively. ESIMS data shows 
that these peaks gave accurate masses of 457, 425, 427 and 443 respectively 
and were dereplicated as Oleanolic acid, Lupenone, Lupeol, Moretenol, and 
Betulin (Figure 4.98).  
For FD2c F34-36 fraction, 2 major compounds were dereplicated as 
Oleanolic acid - at tR 24.42, which correspond to 73.33% (peak 1 + peak 3) of 
total mass - and Lupenone at tR 24.15, and tR 27.77 - which correspond to 
18.65% of total mass. Both Oleanolic acid and Lupenone gave accurate 
masses of 457 and 425 respectively according to the ESIMS data (Table 
4.12). 
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Figure 4.97  Overlay of ELSD, UV and MS (base peaks monitoring) chromatograms for samples FD2c F29-33 and FD2c F34-36.  
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Table 4.12  MSI dereplication of FD2c F29-33 and FD2c F34-36 samples. 
 
		 267	
 
 
Oleanolic acid 
           
Lupenone                               Lupeol 
           
Moretenol                             Betulin 
 
Figure 4.98  The chemical structure of Oleanolic acid, Lupenone, Lupeol, Moretenol 
and Betulin 
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4.1.12.3 Anti-proliferative activity of dereplicated compounds 
Previously, LC-MS dereplication has identified isovitexin in the active 
fraction of FD1c and oleanolic acid, betulin, and lupeol in the active fractions 
of FD2c. This study was conducted to evaluate the cytotoxic activity of the 
individual compounds identified through LC-MS dereplication method. SRB 
staining assay was used for the purpose of this study. 
 
 Table 4.13 shows the GI50 of each compound. LC-MS dereplication 
has identified isovitexin as one of the major compound in the active fraction of 
FD1c, however the GI50 value for isovitexin is significantly (P< 0.05) higher 
than its respective active fraction (GI50 = 12 µg/ml). Similar findings were 
observed with the GI50 values for oleanolic acid, betulin and lupeol, which 
were identified through LC-MS dereplication of the active fractions of FD2c. 
The GI50 values for each of these compounds were significantly (P< 0.05) 
higher than their respective active fractions (FD2c F29-33 = 28 µg/ml, FD2c 
F34-36 = 24 µg/ml). These results indicated that the active fractions of both 
FD1c and FD2c were more cytotoxic against PC3 cells than each of these 
individual compounds.  
 
 In the case of FD1c, even though isovitexin was identified as the major 
compounds in the active fraction, lower cytotoxic activity of the compound 
against PC3 cells might suggest that the other minor compounds such as 
brosimacutin and aurone flavonoids might have contributed to the more potent 
cytotoxic activity of the active fraction. In the active fractions of FD2c, 
oleanolic acid, betulin, and lupeol were dereplicated as the major compounds 
in the active fraction. However, as mentioned earlier, none of these individual 
compounds were shown to have better cytotoxic activity than their respective 
active fractions. Once again, this could suggest that the more potent cytotoxic 
activity of the active fractions of FD2c might be due to the additives or 
synergistic effects of the compounds identified in the plant.  
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Table 4.13  GI50 concentrations (µg/mL) of the compounds identified through LC-MS 
dereplication determined for PC3 cells as assessed by SRB assays after 72 hours. 
Each result was obtained in three independent experiments, which was run in 
triplicate. 
Compound Source of Identification GI50 (µg/ml) with PC3 cells 
Isovitexin FD1c 43 
Oleanolic Acid FD2c 34 
Betulin FD2c 47 
Lupeol FD2c 36 
 
 Table 4.14 and Table 4.15 below summarize all the investigations that 
have been carried out for both the active extracts and the active fractions of 
both Marantodes pumilum and Ficus deltoidea plants in this project. 
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Table 4.14  Summary of all the investigations carried out using the active extracts of Marantodes pumilum (n-hexane and chloroform) and Ficus 
deltoidea  (chloroform) plants. ‘é ’ Increased, ‘ê ’ Decreased ‘+’ characteristic detected, and ‘−‘ characteristic not detected  
Assay/Sample MPc MPh FD1c FD2c 
Morphological observation 
(Characteristics of 
apoptosis or necrosis) 
Apoptosis (+) 
Necrosis (−) 
Apoptosis (+) 
Necrosis (−) 
 Apoptosis (+) 
Necrosis (−) 
Apoptosis (+) 
Necrosis (−) 
DAPI staining Apoptotic cells visible Apoptotic cells visible Apoptotic cells visible Apoptotic cells visible 
Annexin V-FITC 
fluorocytometric analysis 
é Number of cells in
early apoptosis
é Number of cells in
early apoptosis
é Number of cells in
early apoptosis
é Number of cells in
early apoptosis
Mitochondrial membrane 
potential (MMP) 
depolarization analysis 
é MMP
depolarization 
é MMP
depolarization 
é MMP
depolarization 
é MMP
depolarization 
Detection of Caspase 3/7 é production of
Caspases 3/7
é production of
Caspases 3/7
éproduction of 
Caspases 3/7 
é production of
Caspases 3/7
Nuclear DNA 
fragmentation analysis 
+ + + + 
’ 
Ap
op
to
si
s 
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Table 4.14 (Continues) 
Assay/Sample MPc MPh FD1c FD2c 
 mRNA gene 
expression analysis 
Bcl-2 ê Expression ê Expression ê Expression ê Expression 
Bax é Expression é Expression é Expression é Expression 
Smac/DIABLO é Expression é Expression é Expression é Expression 
Cell cycle analysis Cell cycle arrest 
at G2M phase 
Cell cycle arrest at 
G2M phase 
Cell cycle arrest 
at G2M phase 
Cell cycle arrest at 
G2M phase 
mRNA gene expression (ALOX-5) êExpression No Changes No changes No changes 
 2D Migration study using Platypus cells 
migration kit 
êNumber of 
migrated cells 
êNumber of 
migrated cells 
êNumber of 
migrated cells 
êNumber of 
migrated cells 
3D Migration study using modified 
Boyden Chamber 
 êNumber of 
migrated cells 
êNumber of 
migrated cells 
êNumber of 
migrated cells 
êNumber of 
migrated cells 
3D Invasion study using modified Boyden 
Chamber 
êNumber of 
invading cells 
êNumber of 
invading cells 
êNumber of 
invading cells 
êNumber of 
invading cells 
mRNA gene expression 
analysis 
CXCR4 No Changes No Changes é Expression No Changes 
CXCL12 êExpression êExpression êExpression êExpression 
VEGF-A êExpression êExpression êExpression No Changes 
Specificity study using HDFa  G150 >200µg/ml G150 >200µg/ml G150 >200µg/ml G150 >200µg/ml 
M
ig
ra
tio
n 
& 
In
va
si
on
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Table 4.15  Summary of all the investigations carried out using the active fractions of Marantodes pumilum and Ficus deltoidea plants. ‘é ’ 
Increased, ‘ê ’ Decreased and ‘NA’ Not Available 
. 
Assay/Samples MPc F30-33 FD1c F43-51 FD2c F29-33 FD2c F34-36 
mRNA gene 
expression analysis 
Bcl-2 êExpression NA NA NA 
Bax é Expression NA NA NA 
Smac/DIABLO é Expression é Expression é Expression é Expression
ALOX-5 êExpression 
mRNA gene 
expression analysis 
CXCR4 No Changes No Changes No Changes No Changes 
CXCL12 êExpression êExpression êExpression êExpression 
VEGF-A êExpression êExpression No Changes No Changes 
Specificity study using HDFa G150 >100µg/ml G150 >200µg/ml G150 >200µg/ml G150 >200µg/ml 
M
ig
ra
tio
n 
& 
In
va
si
on
 
Ap
op
to
si
s 
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4.2 Discussions 
Approximately 90% of androgen-dependent prostate cancer is detected 
in the local and regional stages, therefore the cure rate is very high as nearly 
100% of men diagnosed and treated at this stage will be disease free after 5 
years. However, many men die as therapy eventually fails when the disease 
progresses to androgen-independent stage (Feldman and Feldman 2001). 
This stage of prostate cancer is lethal and has the ability to progress and 
metastasize. At present, there is no effective therapy that can be used for 
men diagnosed with androgen-independent prostate cancer. There is a need 
for chemopreventive products targeting middle-aged men in my country. This 
is because treatment results are not sustainable for the local health system, 
which does not cover all the population. Developing such a product from 
traditional Malay medicinal plants would facilitate better compliance among 
Malaysian patients as the use of traditional plants and herbs are culturally 
embedded into the local lifestyle. 
The three plants chosen for this study - namely Marantodes pumilum 
(Blume) Kuntze (synonym Labisia pumila var. pumila), Ficus deltoidea var. 
angustifolia (Miq.) Corner and Ficus deltoidea Jack var. deltoidea - have 
shown promising cytotoxicity in a preliminary screening conducted at the start 
of this study. In natural product research, crude extracts showing a GI50 value
of less than 100 µg/mL can be considered to be cytotoxic and selected for 
further studies, with the most promising ones are those with a GI50 lower than 
30 µg/mL (Ab Shukor, Merrina et al. 2008). In the preliminary screenings, 
three different cell lines have been used (PC3, DU145 and LNCaP) - each 
representing a different stage of prostate cancer: LNCaP cancer cell line 
represents the androgen-dependent prostate cancer whereas PC3 and 
DU145 cancer cell lines represent the androgen-independent prostate cancer 
(Shafi, Yen et al. 2013). For mechanistic studies, our main focus turns onto 
PC3 cells, which is a type of androgen-independent prostate cancer cell 
overexpressing ALOX-5, thus allowing for the measurement of a wider array 
of potential targets. 
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 From my investigations, the data collected has shown that all of the 
active plant extracts and their respective fractions were cytotoxic against all 
three types of prostate cancer cell lines - including PC3 with a very low GI50 
value. Al-Mekhlafi, Shaari et al. (2012) described the anti-proliferative 
properties of Marantodes pumilum extracts against prostate cancer cells lines. 
Here, the mechanistic details of such property are characterised in detail: the 
active plant extracts induce apoptosis in PC3 cells via the intrinsic pathway, 
as evidenced by the significant activation of caspases 3 and 7. This activation 
is mediated –at least in part- by their ability to affect the mRNA gene 
expression of Bax, Bcl-2, and Smac/DIABLO. These genes are responsible 
for the production of their respective proteins, which play an important role in 
the intrinsic pathway of apoptosis as depicted in Figure 4.99. 
 
 
Figure 4.99  Effects of active plant extracts on the intrinsic pathway of apoptosis 
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 However, MPc is also able to induce PC3 cell death via apoptosis in an 
alternative way, namely the inhibition of mRNA gene expression of ALOX-5, 
which is responsible for the production of LOX-5 enzyme. According to Ghosh 
and Myers (1997), the inhibition of 5-LOX would block the production of its 
metabolites triggering apoptosis in this prostate cancer cell line. In PC3 cells 
treated with the active extracts of the plants, the cell population in the G0/G1 
phase was reduced, whereas cell population in the G2/M phase was 
increased significantly when compared to the untreated PC3 cells. These data 
implied that the active plant extracts induced cell cycle arrest at G2/M phase. 
Many other studies using compounds isolated from plants have reported a 
similar activity in other types of cancer cell lines including prostate cancer, 
where they exhibited an anti-proliferative activity such as: 8-O-β-
glucopyranoside isolated from Rumex japonicus Houtt against A549, (human 
lung cancer cells) (Xie and Yang 2014); Scrophularia striata against Jurkat 
tumor cells (T cell leukaemia) (Azadmehr, Hajiaghaee et al. 2013); and 
Solanum nigrum against PC3 (prostate cancer cells) (Nawab, Thakur et al. 
2012). Cell cycle arrest enables DNA repair to occur, thus preventing 
replication of the damaged templates (Murray 2004) and cell cycle arrest 
specifically at the G2M phase serves to prevent the cells from entering the 
mitosis (M) phase with damaged genomic DNA. 
 
 In this study, all anti-proliferative plant extracts (MPc, FD1c and FD2c) 
were observed to have significant inhibitory effect on the migration and 
invasion of PC3 cancer cell lines. Further mechanistic studies showed that the 
active plant extracts and their respective fractions (MPc F30-33, FD1c F43-
51, FD2c F29-33 and FD2c F34-36) were able to inhibit both PC3 cells 
migration and invasion by modulating the CXCR4, CXCL12 and VEGF mRNA 
gene expression. Recently, increasing evidence indicate that tumor 
microenvironment including tumor-stromal cells interactions have a crucial 
role in tumor initiation and progression (Guo, Wang et al. 2015). Singh, Singh 
et al. (2004) reported that CXCL12-CXCR4 interactions were able to modulate 
prostate cancer cell migration and invasion. CXCL12 is a type of chemokines 
that bind to and activate a family of chemokine receptors (Vindrieux, Escobar 
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et al. 2009). CXCR4 is a type of chemokine receptor that consists of seven-
transmembrane receptors coupled to G protein (Ransohoff 2009). CXCL12 
and chemokine receptors CXCR4 and CXCR7, are the key factors that link 
between cancer cells and their microenvironment. Functional CXCR4 was 
reported to be expressed by prostate cancer cell lines PC3 and LNCaP, as 
well as normal prostate epithelial cells (PrEC). However, significantly higher 
levels of CXCR4 were observed in the malignant cell lines such as PC3 and 
LNCaP compared to the normal prostatic epithelial cells. Previous studies 
conducted by Singh, Singh et al. (2004) shows that the number of malignant 
prostate cancer cell lines that migrated in response to CXCL12 was 
significantly higher than for cells not exposed to CXCL12 as chemoattractant. 
Therefore, interruption to the level of CXCL12 and disruption to CXCL12-
CXCR4 litigation could possibly lead to the inhibition of prostate cancer cells 
migration and invasion. All the active extract of the plants and their respective 
fractions were able to down-regulate the CXCL12 mRNA gene expression 
significantly. This might lead to the fall of the production of CXCL12 
chemokines and thus inhibiting both PC3 cells migration and inhibition. 
However, none of them were able to have any significant effect on the 
expression of CXCR4.  
 
Even though not all of the active extracts of the plants show any 
significant effects on the mRNA gene expression of VEGF, two of the active 
fractions namely MPc F30-33 and FD1c F43-51 had shown significant 
inhibition to the expression of the gene. Vascular endothelial growth factor 
(VEGF) is known to be a critical regulator of endothelial cell migration by 
increasing endothelial cell permeability, stimulating proliferation, and 
promoting migration of phosphatidylinositol-3-kinase and the small GTPase 
Rac-1 (Soga, Connolly et al. 2009). Apart from that, VEGF also play a very 
important role in the formation of new blood vessels from pre-existing 
capillaries and venules - a process called angiogenesis. Overexpression of 
VEGF is normally seen in cancer cells, as it is vital to help create the 
microenvironment that would promote the growth of the cells. Therefore, by 
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reducing the expression of VEGF, the production of its protein will be 
decreased and thus creating a microenvironment that is not suitable for the 
cancer cells to migrate or invade.  
 
Despite the cytotoxic effects of all the active plant extracts and their 
respective fractions on prostate cancer cell lines, they showed specific 
selectivity when tested with normal human dermal fibroblast cells (HDFa). 
Extracts from these plants have been reported to be cytotoxic towards other 
cancer cell lines but we cannot surmise from the available reports if these 
extracts show any specific potency to one of them. 
 
Bioguided isolation of MPc F30-33 revealed that the 5-alkylresorcinol 
MP-1 was responsible for the cytotoxicity against PC3 prostate cancer cell 
lines. Al-Mekhlafi, Shaari et al. (2012) isolated two similar cytotoxic 
compounds against the same cell lines. They were identified as 1-O-methyl-6-
acetoxy-5-(pentadec-10Z-enyl)resorcinol and 1-O-methyl-6-acetoxy-5-
pentadecylresorcinol (see Figure 2). However, they did not study their 
mechanism of action (Al-Mekhlafi, Shaari et al. (2012). Thus, this is the first 
time a report on the mechanisms of the cytotoxic activity against prostate 
cancer cell line (PC3) of an alkenylresorcinol isolated from Marantodes 
pumilum. The activity of alkylresorcinol was first described by Anderson, 
David et al. (1931), after extracting and isolating them from Ginkgo biloba. 
More alkylresorcinols were subsequently isolated from higher plants and also 
from bacteria, fungi, algae and mosses (Kozubek and Tyman 1999, 
Zarnowski, Suzuki et al. 2000).  
 
Alkylresorcinol compounds have been reported to show anti-parasitic, 
anti-fungal, anti-microbial, anti-oxidants, and anti-cancer effects. Their various 
biological activities have been reviewed comprehensively by Kozubek and 
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Tyman (1999). The cytotoxic activity of 5-alkylresorcinol compounds on 
cancer cell lines have been reported on several studies previously such as 
breast (Chuang and Wu 2007), colon (Al-Mekhlafi, Shaari et al. 2012), 
leukemia (Arisawa, Ohmura et al. 1989), prostate (Chuang and Wu 2007, Al-
Mekhlafi, Shaari et al. 2012), liver (Filip, Anke et al. 2002) and human 
squamous carcinoma (Buonanno, Quassinti et al. 2008). In this study we have 
shown that MP-1 induced prostate cancer cell death via apoptosis instead of 
necrosis.  
 
In 2008, a resorcinolic lipid known as Climacostol, which is a natural 
toxin isolated from the freshwater ciliated protozoan Climacostomum virens. It 
effectively inhibits the growth of two tumor cell lines, human squamous 
carcinoma (A431 cells) and human promyelocytic leukaemia (HL60 cells), in a 
dose-dependent manner by inducing apoptosis (Buonanno, Quassinti et al. 
2008). Another study conducted by Barbini, Lopez et al. (2006) showed that 
after 24 hours of treatment with 5-alkylresorcinol, the hepatocellular 
carcinoma cell lines showed the typical morphological characteristics of 
apoptosis, DNA fragmentation and condensed and fragmented nuclei. 
Arisawa, Ohmura et al. (1989) has reported the relationship between the 
cytotoxicity to KB cells and the number of carbon of the side chain of an 5-
alkylresorcinol and according to this report, the cytotoxic activity was 
positively correlated with the number of carbons of the side chain - increasing 
from 5 to 13; longer side chains becoming detrimental to the effect. The same 
report also concluded that hydroxylation at C1 and C3 carbons was a 
structural requirement to enhance the cytotoxicity towards cancer cell lines. 
Both C1 and C3 in MP-1 are hydroxylated. Of note, we have also 
demonstrated that MP-1 inhibits both prostate cancer cell migration and 
invasion. No similar report has been found after extensive literature search. 
Therefore, this is the first time such activity has been documented for this 
class of compound.  MP-1 maybe used as marker for future standardization of 
the extract and developed as nutraceuticals. However, before the 
standardized active extracts could reach the market for human consumption, 
		 279	
they will have to go through different phases of development depending on 
the regulatory requirements as mentioned in section 2.3.2. The development 
of MP-1 as a chemoteraphy drug for prostate cancer would have to follow the 
multiple phases set for drug development. 
 
The LC-MS dereplication of active fractions of Ficus spp. identified 
isovitexin in FD1c F43-51; oleanolic acid, moretenol, betulin, lupenone, and 
lupeol in FD2c F29-33; and oleanolic acid, and lupenone in FD2c F34-36. 
Both isovitexin and moretenol have been previously reported to be isolated 
from Ficus deltoidea (Bunawan, Amin et al. 2014). However, this is the first 
time that oleanolic acid, betulin, lupenone, and lupeol are identified in this 
species. Oleanolic acid has been identified in Ficus microcarpa (Ao, Li et al. 
2008), Ficus hispida Linn (Joseph and Raj 2011), and Ficus nervosa (Chen, 
Cheng et al. 2010). Betulin was identified in Ficus foveolata (Somwong, 
Suttisri et al. 2013), Ficus racemosa (Bopage), and Ficus carica L. (Oliveira, 
Baptista et al. 2012). Lupenone was identified in Ficus pseudopalma (Ragasa, 
Tsai et al. 2009), Ficus microcarpa (Kuo and Lin 2004), and Ficus sycomorus 
(Ahmadu, Agunu et al. 2007). While, lupeol has been previously identified in 
Ficus pseudopalma Blanco (Santiago and Mayor 2014), Ficus odorata (Tsai, 
De Castro-Cruz et al. 2012), and Ficus polita Vahl (Kuete, Kamga et al. 2011).  
 
All compounds have been reported to show cytotoxic activity against 
cancer cell lines (Hwang, Chai et al. 2003, Peng, Fan et al. 2006, Jung, Kim 
et al. 2007, Chaturvedi, Bhui et al. 2008, Yan, Huang et al. 2010). Despite 
this, only lupeol (Saleem 2009), oleanolic acid (Deeb, Gao et al. 2010) and 
betulin (Chintharlapalli, Papineni et al. 2007) were reported to have cytotoxic 
activity against prostate cancer cell lines. We added to this list for the first 
time, isovitexin, as one of the compound that play an important role in the 
cytotoxic activity of Ficus deltoidea var. augustifolia against prostate cancer 
cell line. This study also suggests that, moretenol and lupenone showed 
cytotoxic activity against prostate cancer cell lines. Deeb, Gao et al. (2010) 
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also claimed that oleanolic acid was able to inhibit growth and induce 
apoptosis in prostate cancer cells. Apart from that, another report by Saleem, 
Kweon et al. (2005) stated that lupeol induced cell death via apoptosis in 
androgen-sensitive prostate cancer cells. A study conducted by Liu, Bi et al. 
(2016) demonstrated that lupeol inhibited gallbladder carcinoma cell invasion 
by suppressing the EGFR/MMP-9 signaling pathway. However this study 
showed that FD1c and FD2c were able to inhibit both prostate cancer cell 
migration and invasion by modulating the VEGF-CXCR4-CXCL12 axis. None 
of the compounds identified through the dereplication of FD1c and FD2c were 
reported previously to show similar activity. However in this study only 
differential mRNA gene expression of CXCR4, CXCL12 and VEGF-A was 
carried out. Further investigations are needed to validate the findings. These 
include western blotting and proteomic studies. Western blot study for 
example will give information about the expression of the proteins linked with 
CXCR4, CXCL12 and VEGF-A genes (Mahmood and Yang 2012).  
 
The findings reported in this study establish a pharmacological 
rationale and inform standardization methods to develop active extracts from 
the two selected Malaysian Ficus deltoidea varieties into nutraceutical 
applications that may be used as chemopreventives for prostate cancer. Here 
the complexity and lack of novelty in chemical terms preclude any drug 
development efforts. 
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5 Conclusions and Future Work 
 
5.1 Conclusion 
This study was conducted to investigate the potential of two species of 
plants from Malaysia namely Marantodes pumilum (Blume) Kuntze (synonym 
Labisia pumila var. pumila) and Ficus deltoidea L. against the growth of 
prostate cancer cells. In order to achieve this objective, this study has been 
divided into 3 major parts; 1) In vitro mechanistic studies using PC3 prostate 
cancer cell lines, 2) Characterisation of the active extracts, bioguided isolation 
and identification of bioactive compounds from the plants and 3) Effects of 
cytotoxic fractions and principles on 2D migration and 3D invasion. 
 
Firstly, this work has thoroughly characterized the in vitro mechanisms 
by which the selected plants have a potential chemopreventative effect 
against prostate cancer. The in vitro cytotoxic activity against both androgen 
dependent (LNCaP), and non-androgen dependent (DU145 and PC3) human 
prostate cancer cell lines. This activity is concentrated in the chloroform 
extracts. The cytotoxic activity was 5 to 10 times more selective towards 
prostate cancer cells when compared to normal human fibroblasts. Because 
the non-androgen dependent prostate cancer is nowadays lacking efficient 
clinical management we decided to carry out mechanistic studies using the 
highly malignant PC3 cell line. It is now evident that all act by inducing 
mitochondria-driven (intrinsic pathway) apoptosis characterized by Annexin V 
expression, MMP depolarization, activation of caspases 3 and 7, and cell 
cycle arrest at G2/M phase, thus leading to nuclear DNA fragmentation and 
cell death. The extracts specifically modulate the expression of Bax, Bcl-2, 
and Smac/Diablo genes, which encode the respective proteins, which 
together will cause mitochondrial membrane permeabilization, thus 
compromising cell viability. Additionally, MPc is able to down-regulate the 
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Alox-5 mRNA gene expression. It is known that PC3 cells are highly 
dependent on Alox-5 activity (biosynthesis of leukotrienes) for survival.  
 
Secondly, this study has revealed that the PC3 prostate cancer cells 
inhibitory activity of Marantodes pumilum (Blume) Kuntze (MP) is mainly due 
to the presence of a 5-alkenyl resorcinol. Therefore, this is the first time a 
report on the mechanism of the cytotoxic activity against prostate cancer cell 
lines (PC3) of an alkenylresorcinol isolated from Marantodes pumilum.has 
been produced.  
 
In the case of Ficus deltoidea var. angustifolia (FD1) the active fraction 
is rich in flavonoids such as isovitexin. In the case of Ficus deltoidea var. 
deltoidea (FD2), the active fraction consists of a mixture of terpenes including 
oleanolic acid, moretenol, betulin, lupenone and lupeol. This is the first time 
that oleanolic acid, betulin, lupenone, and lupeol were identified in this plant 
species. In addition, no other report has demonstrated the important role 
played by isovitexin in the cytotoxic activity of Ficus deltoidea var. augustifolia 
against prostate cancer cell line. Regardless the phytochemical differences, 
both active fractions are able to modulate the expression of Bax, Bcl-2, and 
Smac/Diablo genes, thus mirroring the crude extracts mechanism of action. 
However, we cannot rule out that other fractions may also contribute to the 
overall pro-apoptotic effect of the crude and/or chloroform extract without 
being endowed with significant direct cytotoxic activity.  
 
In the last part of this study, the effects of cytotoxic extracts on 2D 
migration and 3D invasion were tested by exclusion assays and modified 
Boyden chamber, respectively. All active plant extracts inhibited both 
migration and invasion of PC3 cells (MPc; P<0.01, FD1c and FD2c; P<0.05). 
These effects were accompanied by a very significant down-regulation of both 
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VEGF-A and CXCL-12 gene expressions but not CXCR4 by 2 of the active 
plant extracts (MPc, and FD1c) and all of their active fractions (MPc F30-33 
and FD1c F43-51) respectively. These results, for the first time, have 
demonstrated that MP-1, FD1c and FD2c were able to inhibit both prostate 
cancer cells migration and invasion. For the case of MP-1, this is the first time 
such activity has been documented for this class of compound. The 
modulation of the CXCL12-CXCR4 axis plays important role in cancer cells 
metastasis whilst inhibition of the VEGF-A gene expression could eventually 
impair cancer cells angiogenesis. However, since only differential mRNA 
genes expression study was conducted that lead to these findings, more 
investigations including western blotting and proteomic studies need to be 
carried out in order to validate and confirm the findings. 
 
In summary, evidence gathered in this study suggests a role for 
interaction of MPc, FD1c and FD2c in three of the Hallmarks of Cancer in PC3 
cells; apoptosis by activating of the intrinsic pathway, inhibition of both 
migration and invasion by modulating the CXCL12-CXCR4 axis, and inhibiting 
angiogenesis by modulating VEGF-A expression. The promising results seen 
in this study warrant further investigation of these plants for a role in the 
treatment of prostate cancer. 
 
5.2 Future Work 
The findings from this study shows promising potential for the 
development of herbal preparations for prostate health. To this end no further 
work would be needed because food supplements are not regulated as 
medicines and only reasonable safety data needs to be provided. However 
from a manufacturing point of view more work needs to be done to 
understand if the plants are consistently synthesizing the phytochemicals 
profile that is involved in the cytotoxic activity year after year and if their 
geographical precedence is influencing it.  
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Second, from an academic point of view, it would be highly interesting to 
see if our in vitro data would translate into in vivo effects as it is by no means 
a good representative of how complex the cells in the human body worked. In 
vitro models do not take into account the interactions that occur when cells go 
through the oncogenic and metastatic process. Therefore, the use of in vivo 
model is very important as cancer cell lines do not and cannot recapitulate the 
disease processes that occur in living tissues. Mouse and mice models are 
often used for prostate cancer research. Significant reduction of the tumor 
size is expected after the treatment with the bioactive compounds from 
Marantodes pumilum (Blume) Kuntze (synonym Labisia pumila var. pumila) 
and Ficus deltoidea L. plants.  
 
Third, the use of Next Generation Sequencing-based approaches have 
become very popular recently in the field of medicine. NGS-based 
approaches have been used in genetic diagnosis, building disease network, 
pharmacogenomics and drug discovery. One of the predominant use of NGS 
is by using its RNA-sequencing platform to profile gene expression levels in 
normal or mutant cells and identify differentially expressed transcripts among 
group of samples. NGS could also be used to investigate the effect of plant 
extracts or their active principle on the gene expression profile in specific cells 
or tissues.  
 
Lastly, it is not yet known whether the identified/dereplicated active 
principles do directly interact with the therapeutic targets described in this 
thesis as being the basis of the pro-apoptotic effects of the extracts and 
fractions. 
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5.2.1 Future Phytochemical studies of the plants 
 The plant materials used in this study were mostly collected from farms 
in southern Malaysia. Since these plants also grow wildly in different parts of 
the country, it is also interesting to conduct a study, which involves the 
collection of similar plant materials that grow in the wild or in farms from 
different part of Malaysia. This study is important as we can develop complete 
phytochemical profiles, make comparison of these profiles and gain better 
understanding on the distribution of the phytochemicals available in these 
plants and whether they are affected by external factors such as locations, 
weather conditions or the way they are planted. 
 
 In Malaysia, Marantodes pumilum and Ficus deltoidea plants can be 
found growing wildly in the lowland and hill forests at an altitude of 300 to 700 
meters in several states such as Kedah, Perak, Negeri Sembilan, Johor, 
Pahang, Terengganu and Kelantan. In the last 5 years, some local 
biotechnology companies have started to do contract farming for several well-
known plant species in Malaysia including Marantodes pumilum and Ficus 
deltoidea. These agricultural lands or farms are located in different part of 
peninsular Malaysia including Desaru, Kota Tinggi, Parit Raja, and Dungun. In 
this study, plant samples will be collected from different part of Malaysia for 
both farmed and wildly growing plants. These plant samples will be dried and 
extracted using the same method before phytochemical profiles analysis is 
carried out using HPLC and mass spectrometry. This analysis will provide 
vital information regarding the distribution of phytochemicals available in the 
plant and whether the ways they are planted or geographical location affect 
the profiles. In addition, this study would also tell us whether the plants are 
consistently synthesizing the phytochemicals involved in the cytotoxic activity 
year after year and if their geographical precedence is influencing it. 
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5.2.2 In vivo study using Prostate cancer xenograft model 
As mentioned earlier, in vivo study is a very important step in drug 
discovery. Data from this thesis shows the promising in vitro activity of the 
plant extracts, therefore in vivo study using a suitable model must be carried 
out to see the effect of the active plant extracts on a more complicated 
organism model such as mice. Non-obese diabetic severe combined 
immunodeficiency (NOD-SCID) mice (males; 6–8 weeks old; body weight, 
23–25 g) will be chosen and are bred in the animal facility at Universiti Sains 
Malaysia, housed in sterile micro-isolator cages under specific pathogen-free 
conditions with controlled temperature (20–21 °C) and humidity (50–60%). 
Daily light cycles will be regulated with 12 hours light and 12 hours dark. 
Cages will be completely changed once or twice a week. Animals are handled 
under sterile conditions. The maximum tolerated dose of the plant extracts will 
be determined using conventional methodology. Animal care and experiments 
will be carried out in accordance with the guidelines of the Universiti Sains 
Malaysia ethical and animal care council. 
The mice used in this experiment will be transplanted with the LTL-
313H, PTEN-deficient, metastatic and PSA-secreting, patient-derived prostate 
cancer tissue line (Choi, Gout et al. 2012) and maintained as grafts under 
renal capsules of male NOD-SCID mice supplemented with testosterone 
(Watahiki, Wang et al. 2011). Tumors will be harvested 10 weeks after 
grafting and pieces of tumor tissue (2.5 × 2.5 × 1.25 mm3) are grafted under 
the renal capsules of 36 testosterone-supplemented male mice (6 groups; 6 
mice/group; 4 grafts/mouse). The grafts are expected to have 100% 
engraftment rate with an average tumor volume doubling time of 13–15 days. 
The rise in the plasma PSA levels of the mice will be used as an indicator for 
tumor growth. When the level of plasma PSA reaches 12 ng PSA/ml, i.e. 
equivalent to tumor volumes of 30–50 mm3, the mice will be randomly 
distributed into 6 groups and treated with the active plant extracts orally. The 
mice will be euthanized after 3 weeks and tumor volumes will be measured 
using callipers and tissue sections prepared for histopathological analysis. 
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Tumor growth of treated animals relative to untreated animals will be used as 
a measure of antitumor activity using the following formula; 
T/C = (treated tumor volume3wks − treated tumor volume0wks):(control tumor 
volume3wks – control tumor volume0wks) × 100%, with T/C > 0 indicating tumor 
growth and T/C < 0 indicating tumor shrinkage. Tumor growth 
inhibition = 100% − T/C. 
 
5.2.3 Transcriptomics using Next Generation Sequencing (NGS) 
Next generation sequencing-based transcriptome analysis (RNA 
sequencing) has enabled the profiling of global patterns of expression of 
distinct RNA species including mRNA, miRNA, IncRNA and tRNA. These 
RNA species are important as they perform unique functions in a cell or tissue 
during the development of disease or pathogenesis (Chaitankar, Karakülah et 
al. 2016). A process called temporal transcriptome, which involved the 
profiling of normal and mutant cells, could help in identifying genetic changes 
that lead to cellular dysfunction and elucidate gene networks associated with 
homeostasis and disease (Lander 2011). Dramatic reduction in cost and 
increased throughput of screening has led to the widespread use of NGS in 
genomic analysis.  
 
 The use of NGS technology to profile gene expression level and 
identify differentially expressed transcripts among group of samples could 
provide important information about the effect of a certain drug or plant 
extracts on the gene expression in normal or mutant cells. The genomic data 
collected from NGS will lead to systemic level approaches for quantitative 
analysis of the dynamic interplay of molecules within a specific cells or 
tissues. With this in mind, we have collaborated with UCL Genomic to use the 
Illumina MiSeq facility available at their disposal to investigate the effect of the 
active plant extracts on the gene expression profile in PC3 cells. Table 5.2 
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below showed the results for the differential gene expression in PC3 cells 
when cells treated with MPc was compared with untreated cells (Control). 
Figure 5.1 showed the MA plot where Robust Multiarray Average (RMA) 
normalized data of all the possible comparisons between the pairwise log2 
intensities of the samples. This study will be completed once the effect of the 
active principles, which are isolated and identified in the plant, on the gene 
expression profile in PC3 has been done in the future. This study will be 
carried out in collaboration with Malaysia Genome Institute and once the 
study is completed the results will be published as soon as possible. 
Table 5.1  Differential gene expression in PC3 cells analysed using Illumina MiSeq RNA 
sequencing 
Annotation Gene Count 26,364 
Assessed Gene Count 12,710 
Differentially Expressed Gene Count 9,238 
 
 
Figure 5.1  MA plot showing the RMA normalised data of all the possible comparisons 
between the pairwise log2 intensities of the samples 
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5.2.4 In silico studies of selected phytochemicals 
 We have characterised for the first time, the mechanism of actions that 
lead to PC3 cancer cells death and inhibition of PC3 cells migration, invasion 
and angiogenesis by the bioactive compounds isolated and identified from 
MP, FD1 and FD2 plants through in vitro mechanistic studies. However, we 
have yet to characterize the interactions between the active compounds with 
the therapeutic targets. The effects of these compounds are normally initiated 
by direct interactions with target proteins. In silico docking techniques can be 
used to generate a three-dimensional (3D) structure of the protein and 
investigate their interactions at molecular level. Docking software such as 
Autodock, GOLD and Glide can be used for this study (Verdonk, Cole et al. 
2003, Friesner, Murphy et al. 2006, Morris, Huey et al. 2009). This will enable 
us to understand the complementarity at the molecular level of a ligand 
(bioactive compound) and a protein target.  
 
These are some of the studies that need to be conducted before the 
output of this study can be used for human application. Data collected from 
these studies will provide more information and contribute towards future 
development of these active plant extracts. 
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